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Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer in the world. 
Although curative treatments such as liver transplantation, surgical resection and local 
ablation are available, these treatments are not always possible due to the sizes, position of the 
tumor or if the cancer has spread beyond the liver. In addition, 70% - 80% of recurrence rate 
is observed in patients undergo surgical resection and local ablation due to multicentric 
carcinogenesis and regrowth of remaining microscopic intrahepatic metastatic foci. Therefore, 
the prognosis for HCC is very poor where the incident rate is almost equal to mortality rate.  
 
Viral gene therapy may hold an important role to improve HCC prognosis and has emerged as 
a potential candidate to efficiently treat these non-resectable HCC. Therefore, the main 
objective of the current study is to generate a safe and effective gene-virotherapy vector for 
treatment of HCC. The active proliferation feature of tumor cells as a “regulator” to turn on a 
cascade of therapeutic gene expression mediated by the vector of choice was exploited. This 
is achieved using a two-step transcriptional activation system whereby the transcriptional 
activator proteins produced under hepatocyte-specific promoter activity will bind to DNA 
target sequences located upstream from a second promoter. The second promoter is activated 
in the proliferation-phase of the cell-cycle; therefore transgene expression is activated only in 
actively proliferating hepatocytes. The newly generated vector is denoted as AH-6CC-L2C 
and used for expressing yeast cytosine deaminase (yCD) suicide gene to demonstrate the 
functionality, effectiveness and versatility of the designed vector. In order to develop an 
efficient viral vector for clinical application, strategy to indirectly monitor the gene delivery 
in term of distribution, levels and kinetics of suicide gene expression via non-invasive 
imaging in pre-clinical models is also incorporated with bicistronic co-expression of 
luciferase reporter gene and yCD suicide gene as mediated by foot-and-mouth disease virus 
(FMDV) 2A peptide. Such monitoring system is in fact a general missing link in clinical trials 
conducted with viral vectors.  
 
The results in this thesis demonstrated that, AH-6CC-L2C viral vectors could induce strong 
bystander cell killing efficiency in proliferating HCC versus non-proliferating HCC in the 
presence of 5-fluorocytosine (5-FC; prodrug) in vitro. By contrast, minimal cell kill was 
observed in non-proliferating HCC and proliferating but non-HCC cells. In addition, AH-
6CC-L2C could confer liver-specific and proliferation-dependent gene expression in HCC 
cell line-derived PLC/PRF/5-DsRed2 tumors and HCC patient-derived tumor implants HCC 
26-1004 in immunodeficient mice. After normalizing for differential vector infectivities, the 
same was not observed when similar amount of viruses were intratumorally administered into 
animals bearing human renal cell carcinoma. The functionality of these viruses was further 
challenged in animals bearing orthotopic HCC patient-derived tumors. The amount of viruses 
administered was adjusted based on the luciferase readout, which indirectly correlated to the 
levels of yCD protein expression. The result showed a rapid suppression of tumor 
volume/weight to about one third of the control animals that corresponded to a significant 
decrease in Ki-67 cell proliferation index and an increase in active caspase-3 expression. Most 
importantly, these vectors could also confer significantly elevated luciferase activities (3 - 5-
fold) at a low multiplicity of infection equivalent to one in short-term cultures of patient-
derived HCC versus primary cells derived from adjacent matched normal liver tissues. 
 
In conclusion, a safe and efficient HSV-1 amplicon viral vector that could potentially be used 
to treat patients with non-resectable HCC was generated. Targeting the proliferating human 
HCC cells through the transcriptional control of the therapeutic gene could be a feasible 
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1.1 Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) or liver cancer is the fifth most common cancer in men and 
seventh most common cancer in women (El-Serag, 2011), but the third leading cause of 
cancer death (El-Serag and Rudolph, 2007; Parkin, 2002), in the world. The incident rate of 
HCC is almost equal to mortality rate. Therefore, the prognosis of HCC is very poor. 
According to Cancer Facts and Figure 2012 (published online by American Cancer Society), 
the overall relative 5-year survival rate of patients with HCC is about 14%. For HCC patients 
who are diagnosed in early stage, their 5-year survival rate can be increased to 27%. 
Unfortunately, if the HCC patients are diagnosed with regional (spread to lymph nodes in the 
area of the liver) or distant (spread to other organs or parts of the body) stage of disease, the 5-
year survival rate further reduces to 9% and 4%, respectively. 
 
Major risk factor for HCC in Asia is due to the chronic infection of hepatitis B virus (HBV). 
Other major risk factors include alcohol related cirrhosis, non-alcoholic fatty liver disease and 
hepatitis C virus (HCV) infection. In some developing countries, risk factors for HCC may 
include parasitic infection like schistosomiasis (Habib et al., 2006), liver fluke (Srivatanakul, 
2001; Suksumek et al., 2008) and consumption of food contaminated with mold toxin, i.e., 
aflatoxin (Wogan, 1992). 
 
1.1.1 Carcinogenesis of HCC 
HCC is a heterogeneous disease generated from complex hepatocarcinogenesis processes (El-
Serag and Rudolph, 2007). Figure 1.1 summarizes the suspected mechanism of 
hepatocarcinogenesis from various risk factors (Farazi and DePinho, 2006). Among all the 
mechanisms of hepatocarcinogenesis, most of these risk factors will eventually lead to the 
progression and formation of cirrhosis in about 80 to 90% of HCC patients. Different 
subpopulation of HCC cells may be derived from different multiple mutations during the 
progression and formation of cirrhosis. Thus, due to the heterogeneity of this disease, HCC is 





























Figure 1.1 Mechanisms of hepatocarcinogenesis. The suspected mechanisms of 
hepatocarcinogenesis for the various risk factors are shown. Adapted from Farazi and 
DePinho (2006). 
 
1.1.2 Current treatment of HCC 
The current available treatments for HCC include surgical resection, liver transplantation, 
local ablation and chemotherapy. In general, Barcelona Clinic Liver Cancer (BCLC) staging 
system and Milan criteria are commonly used to access the prognosis for HCC and help the 
clinicians in deciding the appropriate treatment for HCC patients. BCLC staging system is 
accessed based on patient’s performance status, cancer symptoms, number of nodules, size of 
nodules, and liver function. For the liver function, it is further accessed using the Child-Pugh 
classification system based on another 5 clinical measures including total bilirubin level, 
serum albumin level, international normalized ratio (INR), ascites state and hepatic 
encephalopathy grades (Forner et al., 2010). Each measure is given a score from 1 to 3 
depends on its severity. The scores are then summed up to determine the overall severity 
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where 5 to 6 points is categorized as Child-Pugh A, 7 to 9 points is Child-Pugh B and 10 to 15 
points is Child-Pugh C. Based on the BCLC staging system, HCC patient could be staged into 
very early stage (single HCC <2 cm; Child-Pugh A, Performance status 0), early stage (Single 
or 3 nodules <3 cm; Child-Pugh A or B; Performance status 0), intermediate stage (Large 
multinodular; Child-Pugh A or B; Performance status 0; No portal vein thrombosis), 
advanced stage (Portal vein invasion; Extrahepatic spread/metastasis; Child-Pugh A-B; 
Performance status 1 or 2) and terminal stage (Child-Pugh C; Performance status 3 or 4). 
Milan criteria are more specific in deciding the eligibility of patient subjected for liver 
transplant. According to the guidelines the patients that are eligible for liver transplant are 
those who have a solitary tumor nodule that is less than 5 cm or 3 nodules that each of the 
nodules is less than 3 cm (Mazzaferro et al., 1996). 
 
Among all the available treatments for HCC, surgical resection remains the treatment of 
choice for patients with solitary HCC at a very early stage without cirrhosis and no portal 
hypertension (overall survival of 90%). For patients with cirrhosis, surgical resection is still 
recommended with 70% 5-year survival rate provided that the tumor is less than 3 cm in 
diameter, no portal hypertension and has normal total bilirubin level at less than 17.1 µmol/L 
(Llovet et al., 1999; Llovet et al., 2005). If these patients have portal hypertension, the 5-year 
survival rate is further reduced to about 50% (Ishizawa et al., 2008). Unfortunately, the 
recurrent rate after surgical resection is as high as 70% due to progression and formation of 
cirrhosis continue to risk the patient for developing new HCC nodule. Therefore, an 
alternative and most appropriate treatment for HCC patients with cirrhosis is liver transplant 
which has lower risk of tumor recurrence and 5-year survival rate of up to 75%. If the patients 
fulfill the Milan criteria, the 4-year survival rate is estimated to be 85% with only 8% of 
patients having tumor recurrence after liver transplantation (Mazzaferro et al., 1996).  
 
For patients who usually have larger or multifocal HCC lesion (less than 5 cm) that are not 
eligible for surgical resection and liver transplantation, the next best treatment option is local 
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ablation. There are basically 2 categories of the local ablation techniques that could induce 
tumor necrosis which involves injection of chemical (e.g., ethanol, acetic acid) or temperature 
modification. (e.g., radiofrequency, microwave, laser or cryoablation). When comparing 
across different ablation techniques, radiofrequency ablation (RFA) is currently the first-line 
technique for HCC local ablation due the reason that it could also effectively treat a relatively 
large tumor (3 to 5 cm). The 5-year survival rate of RFA is about 50% to 75% in Child-Pugh 
A HCC patients (Lencioni, 2010). In fact, the local ablation has recently challenged the 
surgical resection as first-line treatment of very early state HCC due to the similar 5-year 
survival rate (Forner et al., 2012). Several other novel ablation techniques like microwave and 
electroporation are also currently being evaluated (Lencioni, 2010). Nevertheless, the 5-year 
recurrence rate for the RFA local ablation technique is also as high as 80% (Lencioni et al., 
2005). 
 
Intermediate-stage HCC patients, who have compensated cirrhosis, no symptom related to 
HCC and no vascular invasion but large or multifocal HCC lesion, is usually treated by local 
ablation with trans-arterial chemoembolization (TACE). However, TACE is only a palliative 
treatment but not longer curative as in surgical resection, liver transplantation and RFA. The 
overall 2-year survival rate for these intermediate-stage HCC patient is about 20 to 25% (El-
Serag, 2011). 
 
For advanced-stage HCC patients (those with vascular invasion, extrahepatic spread and have 
HCC cancer related symptoms), the current main treatment option is the oral systemic 
chemotherapeutic agent sorafenib. Sorafenib is an active small molecule multikinase inhibitor 
that targets the vascular endothelial growth factor receptors, platelet-derived growth factor 
receptor β, FMS-like tyrosine kinase 3 (Flt-3), c-kit protein and RET receptor tyrosine kinases 
with anti-proliferative and anti-angiogenic properties (Carlomagno et al., 2006). The 1-year 
survival rate for advanced HCC patient treated with sorafenib is less than 10% (El-Serag et 
al., 2008). Currently, due to the success of the sorafenib as a first effective systemic 
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chemotherapy drug for HCC, researchers are trying to evaluate its use alone or in combination 
with other treatments or small molecular drugs (i.e., erlotinib, doxorubicin, CS-1008, 
mapatumumab, BIBF-1120, bevacizumab, oxaliplatin and capecitabine) to further improve 
the effectiveness of sorafenib in treating the advanced HCC (Gomez-Martin et al., 2012; 
Ibrahim et al., 2012; Schmid et al., 2012). 
 
1.1.3 Current problem of HCC treatment 
As clearly indicated above, one of the current major problems of HCC treatment is the high 
recurrence rate after surgery resection or local ablation due to the presence of liver cirrhosis 
that may lead to the formation of new HCC tumor. Besides that, recurrence may also happen 
due to the ability of HCC to undergo intrahepatic metastasis (Li et al., 2008). While the most 
effective curative treatments of HCC are liver transplantation, surgical resection and radio-
frequency ablation, these treatment regimens are not always possible due to the size, position 
of the tumor or if the cancer has spread beyond the liver (Bruix and Sherman, 2011). In 
addition, due to the reason that HCC patients usually do not show any symptoms of disease at 
early stages, they are often diagnosed with HCC at advance stages with large tumor burden. 
Thus, treatment for these patients may be more challenging due to the big size of tumor, 
multifocality of their tumors, deteriorating liver function and increasing portal hypertension 
(Donckier et al., 2003). 
 
In such conditions, chemotherapy is usually used to treat these advanced HCC patients who 
are not eligible for radio-frequency ablation, surgical resection and liver transplantation. 
Unfortunately, HCC is frequently resistant to chemotherapeutic drug treatment (Yang et al., 
2002). Currently, the most effective drug for HCC treatment is sorafenib (Cheng et al., 2008). 
Recently, long-term results of using sorafenib in treating advanced HCC in routine clinical 
practice have also confirmed the ability of sorafenib to reduce the progression of patients with 
advanced HCC (Sacco et al., 2012). Although sorafenib could significantly increase the 
overall median patient survival by an additional 3 months compared to patients receiving the 
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placebo, the prognosis for a patient with HCC remains poor. Only about 2% objective 
response rates were observed in HCC patients receiving sorafenib therapy, and the primary 
benefit of sorafenib treatment was restricted to disease stabilization (Ikeda et al., 2008). 
 
1.1.4 Viral gene therapy of HCC 
In order to efficiently treat these non-resectable HCC as well as prevent the recurrence of 
cancer, viral gene therapy has emerged as a potential candidate. Various viral vectors are 
being developed for cancer gene therapy including adenovirus, measles virus, herpes simplex 
virus type I (HSV-1), lentivirus, retrovirus, adeno associate virus (AAV) etc. (summarized in 
Table 1.1). 
 
Specifically in treatment of the HCC, a lentivirus expressing the siRNA targeting to the 
HBsAg gene was shown to suppress the HCC growth via inhibition of HBV replication in an 
animal model (Xiangji et al., 2011). AAV viral vector expressing the antisense hypoxia-
inducible factor-1α (HIF-1α) was also generated and successfully enhanced the efficacy of 
transcatheter arterial embolization (TAE) in treating the HCC model in rats (Sun et al., 2009). 
In addition, Semliki Forest Virus (SFV) which is a member of the alphavirus was also shown 
to confer anti-tumor responses in cell lines-derived HCC and primary HCC tumor induced by 
chronic infection with woodchuck hepatitis virus (WHV) by expressing high levels of 
interleukin-12 (Rodriguez-Madoz et al., 2009). Unfortunately, these vectors lack the gene 
regulation systems for limiting the therapeutic genes expression in target cells which are 
crucial for safety application of the vector of choice and may become a major limitation for 
further clinical trial or when systemic delivery of the vector is needed.  
 
The idea of targeting rapidly dividing tumor cells is an interesting concept for potential cancer 
gene therapy. However, most of the current viral vectors are unable to accommodate the 
relatively large transcriptional regulatory cassettes. For example, the recombinant adeno-
associated virus-derived vectors (rAAV) has limited transgene packaging capacity of only 
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~4.5 kb. Although the transgene capacity of such rAAV can be further increased by exploiting 
the fact that rAAV genomes concatemerize after transduction (Nakai et al., 2000) to encode 
the regulatory and therapeutic gene cassette in reconstituting a functional gene in two 
independent rAAV vectors (Le Bec and Douar, 2006), the administration of a higher ratio of 
the two rAAV vectors in an attempt to achieve a higher therapeutic expression level could 
cause a greater potential for adverse immune response.  
 
Moreover, inserting multiple gene regulation systems for safe and efficient gene delivery for 
these vector systems mentioned above may be a challenge due to the limited transgene 
capacity of these vector, i.e., lentivirus (~8 kb), AAV (~4.5 kb) and alphavirus (~5 kb). While 
it is possible to use a single tumor-specific promoter to regulate the therapeutic gene, these 
promoters are always weak in gene expression (Cao et al., 2000; Nettelbeck et al., 2000; 
Papadakis et al., 2004). In general, an idle safe and efficient gene vector for expressing high 
level of therapeutic genes may consist of tumor/tissue specific promoter such as ApoE/hAAT 
(~2.2 kb) or AFP/AFP (2.1 kb) promoter; cell cycle-dependent regulation system such as 
Gal4/NF-YA (~1.6 kb) and 8× Gal/cyclin A2 promoter (0.3 kb); reporter genes to monitor the 
therapeutic gene expression such as luciferase (~1.6 kb) and GFP (~0.8 kb) gene; multiple 
therapeutic genes such as yCD (~0.5 kb), TRAIL (~0.8 kb), FasL (~0.9 kb) and p53 (~1.2 
kb); element to co-express the therapeutic gene such as IRES (~0.5 kb) and FMDV 2A (~0.07 
kb); strong promoter such as CAG (~1.6 kb); elements to maintain the stability of transgene 
such as EBNA-1 (~1.2 kb) and oriP (~2 kb) and so on. The total size of these regulation 
elements is easily more than 10 kb even when the crucial elements to package the viral vector 
to infectious virion are excluded. Thus, most of the current available gene therapy vectors are 
limited by their transgene capacity and unable to accommodate these regulation elements. 
 
On the other hand, this would not be an issue in HSV-1 amplicon viral vector with a large 150 
kb transgene capacity (Cuchet et al., 2007; Marconi et al., 2010). Recently, successful 
packaging and intact delivery of genomic inserts of >100 kb with efficiencies of up to 100% 
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has been demonstrated in the HSV-1 amplicon viral vectors platform (Hibbitt and Wade-
Martins, 2006; Senior and Wade-Martins, 2005; Wade-Martins et al., 2003). In another study, 
Krisky and colleagues have also previously demonstrated the potential of engineering the 
large transgene capacity of HSV-1 for simultaneously expressing 5 transgenes (hIL-2, hGM-
CSF, hB7.1, HSV-tk and hIFNγ) with independently regulated expression cassettes (Krisky et 
al., 1998a). Thus, the large DNA insert capacity enable the possibility of engineering vector 
carrying multiple reporter and therapeutic transgene cassettes simultaneously, including 
endogenous controlling elements that may prove critical to ensure prolonged, regulated and 
tissue-specific expression as well as monitoring the therapeutic gene expression. Therefore, 
the replication-defective HSV-1 amplicon viral vector was selected as our gene vector of 
choice in this thesis. 
 
With regard to clinical trials, recombinant HSV-1 viruses have been used against a wide range 
of cancers as summarized in Table 1.2. Among these, oncolytic NV1020 has shown 
promising results in that delivery of the vector in twelve patients with hepatic metastases from 
colorectal cancer resulted in a median survival of 25 months; seven patients with stable 
disease, and two patients with partial response (Fong et al., 2009). In a separate trial involving 
twenty-two patients, NV1020 was combined with conventional chemotherapy. Of these 
patients, fourteen patients had stable disease, one had partial response and the median survival 
was 11.8 months (Geevarghese et al., 2010). 
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Table 1.1 Advantages and disadvantages of various vectors for gene therapy. 
 




• Safer than viral transduction in general 
• Easy to produce 
• Low production yield 
• High cost 
• Low gene transfer efficiency 






• Broad host range 
• Infect dividing and non-dividing cells 
• Long-term gene expression 
• Limited transgene capacity (~4.5 kb)
• Difficult to obtain high titer of pure 
virus 




• Infect dividing and non-dividing cells 
• Relatively large insert capacity (~37 kb)
• Non-oncogenic 
• High titers production yield 
• Host immune response 
• Transient gene expression 
Alphavirus 
 
• Broad host range 
• High gene expression levels 
• Transient gene expression  
• Limited transgene capacity (~5 kb) 
• Requires cotransfection of cells with 
vector and helper RNAs providing 
viral structural proteins in trans 
Baculovirus 
• Broad host range 
• Do not replicate in mammalian host 
cells 
• No preexisting host immunity 
• Relatively large insert capacity (~38 kb)
• Rapid clearance by the complement 
system 
• Low level of viral gene expression in 
mammalian cells 
• Host immune response 
Herpes 
simplex 
virus type I 
(HSV-1) 
• Virtually unlimited transgene capacity 
(~150 kb) 
• Infect dividing and non-dividing cells 
• Low toxicity and low immunogenic 
• Transient gene expression  
• Vector production depends on 
transfection of cells 
Lentivirus 
• Stable gene expression 
• Infect dividing cells and non-dividing 
cells 
• Broad host range 
• Random integration of viral genome, 
may possibly cause mutagenesis 
• Limited transgene capacity (~8 kb) 
Measles 
virus 
• Tumor selectivity  
• Broad tumor host range 
• Low toxicity and low immunogenic 
• Preexisting host immunity 
• Limited transgene capacity (~5 kb) 
 
Poxvirus 
• Generate potent antibody and T-cells 
responses for vaccine against cancer 
• Do not replicate in mammalian host 
cells 
• Broad host range 
• Relatively large insert capacity (~25 kb)
• Host immune response 
• Transient gene expression 
Retrovirus 
• Stable gene expression 
• Only infect dividing cells 
• Low immunogenic 
• Random integration of viral genome, 
may possibly cause mutagenesis 
• Limited transgene capacity (~8 kb) 





• Replication in the cytoplasm         
(avoid integration into host DNA) 
• High level of transgene expression 
• Limited preexisting host immunity 
• Host immune response 
• Limited transgene capacity               
(~0.5 – 2 kb) 
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Table 1.2 Clinical trials involving recombinant HSV-1 viruses for cancers treatment. 
 
Vector Indication Phase Delivery Dose Ref. 
G207 recurrent GBM Ib 
intratumoral 
injection 
2 doses 2 or 5 days as 
follow:           
1.5×108, 1×109 pfu/ml 
(Markert et al., 
2009) 
G207 GBM I 
intratumoral 
injection 
Single dose ranging 
from 1×106 to 3×109 
pfu/ml 









Dose:                      
104, 105 or 5 × 105 pfu 
in 0.5 ml saline 








Injected at 10 sites 
with 0.1-0.2 ml per 
site.                     
Total: 105 pfu in 1 ml 








105 pfu in 1 ml 
(Papanastassiou 








Up to 105 pfu in 1 ml 











4 fixed doses weekly 
as follow:           
3×106, 1×107, 3×107 












4 doses weekly as 
follow:              
3×106, 1×107, 3×107 
and 1×108 pfu/ml 











4 doses on days 1, 22, 
43 and 64 
Cohort I: 106, 
106,106,106 pfu/ml 
Cohort II: 106, 
107,107,107 pfu/ml 















Single dose as follow: 
106, 107,108 pfu/ml 
Three doses as 
follow: 106, 107,107 
pfu/ml or 106, 108,108 
pfu/ml or 108, 108,108 
pfu/ml 
(Hu et al., 2006)
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1.2 Herpes Simplex Virus Type 1 
Herpes Simplex Virus Type 1 (HSV-1) is a 152.26 kb double stranded DNA virus under the 
family of herpesviridae, subfamily of alphaherpesvirinae and genus of simplexvirus 
(McGeoch, 1989). According to the NCBI genome database for HSV-1 genome 
(NC_001806.1; sequenced by the McGeoch laboratory), the viral DNA encoded for 77 genes 
for 77 proteins with 68.3% of GC contents (see Figure 1.2 for HSV-1 genetic map). The 
virion consists of 4 structural components which include lipid envelope, tegument, 
icosadeltahedral capsid and glycoprotein spikes (Figure 1.3). The glycoprotein spikes 
attached on the lipid envelope are responsible for receptor-mediated entry of HSV-1 (Burton 
et al., 2001). The tegument is responsible for the induction of viral gene functions (Batterson 
and Roizman, 1983) which contains viral regulatory protein and transcription activator such 
as virion host shut-off (vhs) and VP16, respectively. For icosadeltahedral capsid located near 
surrounding of the core, it is composed by 162 capsomers that arranged in a T = 16 
icosahedral symmetry which contains channels that control by the tegument proteins to 
transport the DNA through these channels (Zhou et al., 1999). 
 
Figure 1.2 Genetic map of herpes simplex virus type I (HSV-1). (Ward and Roizman, 1994) 
See Appendix I for permission to reproduce. 
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Figure 1.3 Structure of Herpes Simplex Virus Type I (HSV-1).  
 
HSV-1 viral genome will only get circularized upon infection in host cells. The HSV genome 
is divided into 6 important regions; (1) the "a" or pac sequences at the end of linear molecules 
that are responsible for circularization and packaging of viral DNA into virions. (2) RL 
encodes the immediate early regulatory protein (ICP0 or α0) and the gene for the latency 
associated transcript, known as LAT. (3) UL or the long unique sequence that encodes at least 
56 distinct proteins, most of these proteins have functions related to DNA replication 
enzymes and capsid proteins. (4) RS short repeats that encode a very important immediate 
early protein, ICP4 that acts along with early viral proteins such as ICP0 and ICP27. These 
proteins are essential for viral DNA replication. (5) The origins of replication. The oriL is 
located in the middle of the UL region while the oriS is in the RS region. (6) US short unique 
region that encodes 12 ORFs. Many of these ORFs encode for glycoproteins important in 










From all the encoded genes in HSV-1, it is estimated about half of the genes are non-essential 
for in vivo viral replication. These genes usually are encoded for functions that are involved in 
virus-host interaction and can be deleted to reduce the cytotoxicity effect (due to the 
expression of viral proteins) in the construction of gene delivery vectors (Krisky et al., 
1998b). In addition, this also allows us to insert the desired exogenous DNA into the HSV-1 
genome for various gene therapy purposes.  
 
1.2.1 Life cycle of HSV 
HSV-1 is a known human pathogen that infects neurons and may cause life-threatening 
disease like encephalitis. The life cycle of HSV starts when it infects a cell. The HSV could 
enter the cell when its envelope fuses with cell membrane heparan sulphate through the 
glycoprotein spikes, notably glycoprotein C and B (Campadelli-Fiume et al., 2007; Herold et 
al., 1994). This open the cell membrane and allow the tegument proteins and capsid with 
HSV genome in its core to enter the cytoplasm. Immediately, the viral DNA and the VP16 
tegument protein are transported into the nucleus in order to start the expression of gene 
encoded for proteins that are required for lytic circle in a sequential expression manner started 
with immediate early (IE), early (E), and late (L) gene products. Figure 1.4 illustrates initial 

























Figure 1.4 Initial HSV step in infection to enter the host cell nucleus.  
 
UL19 with associated 
scaffolding protein UL26 

















Figure 1.5 HSV virus particle assembly step in capsid. (Adapted from image obtained from 
Dr. Edward K. Wagner’s website: http://darwin.bio.uci.edu/~faculty/wagner/hsv4f.html) 
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In nucleus, VP16 tegument protein is important to induce the expression of IE gene product 
such as ICP0, ICP4, ICP22, ICP27 and ICP47. These genes are important for replication and 
encapsulation of the virus (Wysocka and Herr, 2003). The expression of ICP4 and ICP27 IE 
genes are then required for starting the expression of E and L genes including UL18, UL19, 
UL26, UL38 etc. that play an important role in the virus assembly steps in capsid (Thomsen 
et al., 1995) as illustrated in Figure 1.5. The assembled capsid is then surrounded by primary 
tegument protein, UL31 that helps the capsid to bud through the inner nucleus membrane 
containing viral glycoproteins followed by budding through the outer nuclear membrane. The 
cytoplasmic capsid then assembles various tegument proteins including vhs and α-TIF to form 
a matured capsid and helps in final envelopment process. Final envelopment takes place when 
the mature capsids and associated tegument proteins bud into exocytotic vesicles containing 
all the glycoproteins associated with the mature virions. The mature infectious virion could 
now bud out the cell membrane and start a new HSV infection cycle. The HSV envelopment 























Figure 1.6 HSV virus envelopment and release process. (Adapted from image obtained from 
Dr. Edward K. Wagner’s website: http://darwin.bio.uci.edu/~faculty/wagner/hsv4f.html) 
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1.2.2 Types of recombinant HSV-1 vectors 
HSV-1 has been extensively modified for the past 30 years so that it could be a safe and 
versatile recombinant HSV-1 vector for use in the field of gene therapy. There are 2 types of 
the recombinant HSV-1 viral vectors which include replication-competent HSV-1 vector and 
replication-defective HSV-1 vector. 
 
1.2.2.1 Replication-competent HSV-1 vectors 
Replication-competent HSV-1 vectors (also known as recombinant attenuated HSV-1 viruses) 
are usually a conditionally replicating oncolytic HSV-1 that have the tumor selective 
replication properties. These viral vectors only replicate in cancer cells but not in the normal 
cells. This is possible by deleting the critical genes that are required for virus to efficiently 
replicate in normal cells but are dispensable in tumor cells. These genes include thymidine 
kinase (TK), ribonucleotide reductase (ICP6) and γ34.5 (ICP34.5) (Lou, 2003). Some of the 
commonly known HSV-1 oncolytic viruses include G207 (disruption of ICP6 and 1000 bp 
deletion in both copies of γ34.5) (Chou and Roizman, 1992; Kooby et al., 1999), hrR3 
(disruption of ICP6) (Kasuya et al., 1999), dlsptk (TK gene deleted) (Martuza et al., 1991) 
and HSV1716 (759 bp deletion in both copies of γ34.5) (Papanastassiou et al., 2002). 
 
1.2.2.2 Replication-defective HSV-1 vectors 
Replication-defective HSV-1 vectors could be generated simply by disruption of 1 or several 
essential IE gene, such as ICP4, ICP22 and ICP27 (Sacks et al., 1985; Samaniego et al., 1998; 
Wu et al., 1996). These vectors only replicate in cell lines that stably expressing the deleted 
IE gene which provides the helper function. In addition, the vectors still retain many of its 
wild-type HSV-1 desirable features such as the ability to express transgenes in central and 
peripheral neurons after establishing latent infections. However, due to the reason that these 
vectors are expressing the viral proteins, the vectors may also induce some innate immune 
responses and cause toxicity (Bowers et al., 2003). Another type of the replication-defective 
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HSV-1 vector type is HSV-1 amplicon viral vector that contains the HSV-1 genome which is 
mostly deleted and do not encoded for any viral protein.  
 
1.2.3 HSV-1 amplicon viral vector 
The HSV-1 amplicon viral vectors are replication-defective and non-integrating vectors. This 
viral vector was first developed by Richard FL Spaete and Niza Frenkel about 30 years ago in 
1982 to serve as a potentially useful reagent for the cloning and amplifying of large foreign 
genes that are more than 5 kb (Spaete and Frenkel, 1982). Later, they found that this defective 
viral vector could also be a useful vector to transfer the desired gene into a wide variety of 
host-cell species that are susceptible to HSV infection. However, since the normal host for 
HSV-1 is neuron, most of current studies using HSV-1 are focusing on gene delivery to 
neuron in order to treat brain diseases such as Parkinson disease (Sun et al., 2003), 
neuropathic pain (Zou et al., 2011), Friedreich's ataxia disease (Lim et al., 2007) and brain 
tumor (Ho et al., 2010; Saydam et al., 2007). Besides neuron, several other groups have also 
shown that HSV-1 amplicon viral vector could infect different cell types including skeletal 
muscle cells (Bujold et al., 2002; Wang, 2006; Wang et al., 2000), retina cells (Fraefel et al., 
2005), cardiomyocytes (Ferrera et al., 2005), osteoblasts (Xing et al., 2004) and pancreatic β-
cells (Liu et al., 1996). Moreover, it is interesting to note that glypican-3 (GPC3) containing 
heparan-sulfate proteoglycan that is required for efficient entry of HSV-1 into the host cells 
(see Figure 1.4) is upregulated in cell surface of HCC (Li et al., 2012a; Midorikawa et al., 
2003). Therefore, HSV-1 amplicon viral vector may efficiently infect HCC cells and 
potentially be used to deliver the therapeutic genes into HCC.  
 
HSV-1 amplicon viral vector is exactly identical with its wild-type HSV-1 virion except for 
the packaged genome. For wild-type HSV-1, whole complete viral genome will be packaged 
into the virus particle. Whereas for HSV-1 amplicon viral vector, only two essential elements 
(pac sequences and oriS; Figure 1.7a) together with other desired transgenes are packaged 
into the viral particle. These 2 essential elements are only important to provide a signal to the 
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packaging machinery to package the amplicon plasmid DNA using a rolling circle mechanism 
into the virus particle and more importantly, they do not encode for any viral protein (Spaete 
and Frenkel, 1985). The generated viral particle will contain a genome with concatemer gene 
cassette as in amplicon plasmid up to about 150 kb as illustrated in Figure 1.7b.  
 
 
Figure 1.7 Packaging mechanism of HSV-1 amplicon viral vectors. (a) Basic pHGCX 
amplicon plasmid construct with HSV-1 oriS and HSV-1 pac signal. (b) Rolling circle 
mechanism of HSV-1 virus DNA packaging into the virion. The concatemer number DNA 
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1.2.4 Generation of HSV-1 amplicon viral vector 
HSV-1 amplicon viral vector could be packaged using the helper virus-based or helper virus-
free packaging system. For helper virus-based method, cells are first transfected with the 
amplicon plasmid followed by superinfection with helper HSV-1 virus to package the 
amplicon plasmid into the infectious HSV-1 amplicon viral vector. However, the resulting 
virus stock is contaminated with the helper virus particles which induce strong cytotoxicity 
upon infection of the target cells due to the presence of immune response elicited against the 
IE genes encoded by the helper HSV-1 virus. Thus, a better way to produce the HSV-1 
amplicon viral vector is through the helper virus-free method (Fraefel et al., 1996).  
 
In helper virus-free packaging system, amplicon plasmid and a set of 5 overlapping cosmids 
(cos6Δa, cos14, cos28, cos48Δa and cos56) are co-transfected into the packaging cell line to 
allow the production of helper virus-free HSV-1 amplicon viral vector. These 5 overlapping 
cosmids contain the entire HSV-1 genome, except the pac sequences, in separate cosmid 
which could provide the helper functions in trans. The pac sequences are deleted to prevent 
the homologous recombination of cosmid sequences that may generate the infectious 
replication-competent virion (Cunningham and Davison, 1993). In such condition, six 
recombination events are needed to generate the replication-competent HSV-1 and it is 
therefore considered a rare event. 
 
In order to simplify the packaging procedure, an attempt to construct the entire HSV-1 
genome with pac sequences deleted in an F-plasmid-based bacterial artificial chromosome 
(BAC) was proposed (Saeki et al., 1998). Unfortunately, recombination rate between the 
BAC and amplicon plasmid also increases with this strategy leading to the generation of 
replication-competent helper viruses at a frequency of 10-4 to 10-6. Saeki and colleagues were 
then able to produce the amplicon stocks that were virtually free of replication-competent 
helper virus contamination by deleting the ICP27 gene and adding a “stuffer” sequence from 
ICP 0 to BAC (Saeki et al., 2001). The improved BAC (fHSVΔpacΔ27 0+) could efficiently 
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package the helper virus-free HSV-1 amplicon viral vector at the titer of up to 3 – 10 × 108 
transduction unit (TU)/ml. An illustration on the helper virus-free packaging system is 

















Figure 1.8 Helper virus-free packaging system. 
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1.2.5 Advantages of HSV-1 amplicon viral vector 
HSV-1 amplicon viral vector is an attractive gene therapy vehicle for delivering the DNA into 
the mammalian cells because the vector has a large transgene capacity of almost 150 kb that 
no other vector could compete (Inoue et al., 2004). In addition, HSV-1 amplicon viral vector 
is also able to transduce wide range of host cells in the dividing or non-dividing stages. These 
capabilities make this viral vector quite versatile for broad range of applications with virtually 
unlimited potential gene regulation strategies or other desired elements to be applied in 
various target cells types. For example, multiple therapeutic genes together with reporter 
gene; cell- or tumor-type-specific promoter regulation system; therapeutic gene amplification 
system; inducible system and large transgenes or therapeutic genes and so on could be 
packaged into HSV-1 viral particle with 150 kb transgene capacity. 
 
1.2.6 Disadvantages of HSV-1 amplicon viral vector 
HSV-1 amplicon viral vector is known to confer transient expression of transgene due to its 
episomal existence in cells. There are at least two mechanisms that could suppress the 
transgene expression of HSV-1 amplicon viral vector. First, amplicon-mediated transgene 
expression is partially transcriptional silenced in the host cells due to the presence of bacterial 
DNA sequences in amplicon plasmid that are also packaged into the infectious virion (Suzuki 
et al., 2006). Further analyses by Suzuki and colleagues reveal that immediately after 
infection with HSV-1 amplicon viral vector, the bacterial sequences existed in amplicon 
plasmid DNA are associated with an inactive form of histone molecules in cells leading to the 
silencing of the transgene expression (Suzuki et al., 2006). Secondly, amplicon infection also 
induces the expression of type I interferons which initiate the innate immune responses (via 
STAT1 activation) and resulted in transient transgene expression in a tissue-dependent 
manner (Suzuki et al., 2007, 2008). Further work aiming to improve transgene stability of 
amplicons therefore has to be pursued in order to overcome this limitation. 
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1.3 Effective gene regulation system for HSV-1 amplicon viral vector in cancer gene 
therapy 
For a successful cancer gene therapy utilizing the viral vectors for clinical application, high 
stringency in restricting the therapeutic effect to cancer cells is a must. This is important to 
minimize any potential unwanted side effects from excessive levels of therapeutic protein 
because unregulated therapeutic gene expression may indiscriminately affect both cancer and 
normal cells. Therefore, tumor-specific expression of therapeutic gene may help in this 
context and is important for providing a balance between therapeutic efficacy and non-
specific toxicity resulting from overexpression of the therapeutic gene. 
 
The characteristics of a good gene regulation system may include (1) low basal level of gene 
expression in non-targeted cells; (2) positively induced in targeted cells or with the presence 
of inducer but repressed when treatment is no longer required; (3) high expression level of 
therapeutic gene at physiological levels that enable a therapeutics outcome; (4) ability to fine 
tune the therapeutics effect to an optimal therapeutic level; (5) therapeutic genes that would 
only confer the desired effect only on its targeted cells sparing the normal cells; (6) the 
regulatory elements from human origin to reduce the risk of immunogenicity; (7) the 
regulatory elements that do not affect the endogenous gene expression; (8) ability to limit the 
therapeutic genes expression only in specific cells; and (9) ability to induce and repress the 
therapeutic effect in shortest time if the treatment is no longer required or discontinue the 
treatment in a timely manner if adverse effects are observed.  
 
While it is possible to regulate the therapeutic gene expressions using exogenously regulated 
inducible systems like tetracycline regulated system (Gossen and Bujard, 1992), rapamycin 
dimerizer-regulated system (Rivera et al., 1996) and RU486 regulated system (Oligino et al., 
1998); however, when its inducer is administrated, the unexpected therapeutic gene 
expressions in non-targeted normal cells may be hard to control in vivo if the viral vectors are 
accidentally delivered or spread systemically. Therefore, the endogenous regulation systems 
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that only allow the activation of therapeutic gene expression in only selected cancer cells is 
more favorable. The endogenous regulation systems may include various tissue/tumor-
specific promoters (i.e., hAAT (Van Linthout et al., 2002a), AFP (Dai et al., 2012), CEA (Qiu 
et al., 2012), GFAP (Ho et al., 2004) etc.) and promoters that are induced according to the 
physiological states of the cells such as cell cycle-regulated promoter (such as cyclin A2 
(Nettelbeck et al., 1999), PCNA (Jackson and Pereira-Smith, 2006), PLK1 (Martin and 
Strebhardt, 2006) etc.) or hypoxia inducible systems (Chen et al., 2007; Kim et al., 2012; 
Longo et al., 2011) that are only activated in the region with low oxygen tension. Recently, 
Foka and colleagues have also identified several HCC-specific promoters using the 
microarray analysis by comparing of differential expression of regulated genes in HCC and 
normal liver (Foka et al., 2010). These genes includes Angiopoietin-like-3, Cytochrome P450, 
family 2, subfamily C, polypeptide 8, Vitronectin, Alcohol dehydrogenase 6-class V, 
Apolipoprotein B, Fibrinogen beta chain, Inter-alpha-globulin-inhibitor H3 and Inter-alpha-
globulin-inhibitor H1. The strategy of combining the the microRNAs that are specifically 
downregulated in HCC with liver-specific apolipoprotein E (apoE)-AAT promoter is also 
described as one of the endogenously regulated system to precisely target the HCC in an 
oncolytic HSV-1 vector (Fu et al., 2012).  
 
1.3.1 Rational of using cell cycle-dependent regulation system 
Among all the endogenous regulation systems, cell cycle-dependent regulation system that 
controls the expression of therapeutic gene specifically in proliferating cells has drawn our 
attention. One of the hallmarks of the cancer is that the cancer cells need to sustain its 
proliferative signaling (Hanahan and Weinberg, 2011). Therefore, proliferation-dependent 
transcriptional activation that is endogenously triggered could provide a means of improving 
the efficiency of cancer gene therapy.  
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Transcription of cell cycle genes are dependent on the binding of cell-cycle-dependent factor 
1 (CDF-1) and cyclin A CHR binding factor (CHF) repressor proteins that have been 
observed to bind to the CDE and/or CHR elements within the cell cycle promoters (Liu et al., 
1997; Philips et al., 1999). Such property has been exploited to generate a proliferation-
dependent two-step transcriptional activation (TSTA) system with endogenously available 
cyclin A2 promoter (Nettelbeck et al., 1999). The strategy is based on the interaction of 
transcriptional repressor proteins, CDF-1 and CHF which are specifically expressed during 
the G0/G1 phase, with CDE and/or CHR elements. In resting or non-dividing cells, these 
repressor proteins on the CDE/CHR binding sites located within the minimal cyclin A2 
promoter will prevent the transactivation of Gal4/NF-YA (fusion protein of Gal4 binding 
domain with nuclear factor Y, alpha) which binds upstream of the minimal cyclin A2 
promoter on 8× Gal4 binding site (Nettelbeck et al., 1999). On the other hand, absence of 
CDF-1 repressor protein in dividing cells would allow the transactivation of minimal cyclin 
A2 promoter by Gal4/NF-YA to initiate the gene transcription as illustrated in Figure 1.9. 
Such proliferation-dependent TSTA system has been successfuly used to drive the transgenes 
in proliferating cell-specific, proliferating melanoma-specific and proliferating glioma-
specific manners in various studies as summarized in Table 1.3. The TSTA system is also 
furhter exploited to amplify the transgene expression levels for various weak promoters as 
summarized in Table A.1 (See Appendix III).  
 


















Table 1.3 Proliferation-dependent two-step transcriptional activation (TSTA) system in 
various studies. 
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1.4 Potential therapeutic genes for HSV-1 amplicon viral vector in cancer gene therapy 
Selection of a right therapeutic gene may be the most challenging task in constructing the 
viral vector for cancer gene therapy. Various approaches have been adopted for genetic 
therapy of cancer from different directions which may include (1) restoration of the 
expression of tumor suppressor genes that is inactivated in cancer, (2) activating the patient 
own immune defense systems to have enhanced anti-tumoral activity and (3) expressing a 
apoptosis or suicide genes to kill the tumor cells. 
 
The formation of the cancer cells can be derived from mutations that lead to inactivation of 
tumor suppressor gene and/or overexpression of oncogene. Various strategies have been 
developed to target and correct these mutations. For example, tumor suppressor gene such as 
wild-type p53 genes (Liu et al., 2011), retinoblastoma gene (Roig et al., 2004) and breast 
cancer-1 gene (BRCA-1)(Marot et al., 2006) could be expressed to restore the loss of function 
of tumor suppressor gene in cancer. Recent advances in understanding the cancer biology also 
suggest that some miRNA downregulated in HCC cancer such miR-26a (Kota et al., 2009), 
miR-122 (Tsai et al., 2009) and miR-223 (Wong et al., 2008) may serve as putative tumor 
suppressor genes for HCC and could potentially be used as therapeutic genes to treat HCC. 
On the other hand, expression of interference shRNA, ribozymes and antisense RNA that 
target to the particular oncogene such as Stat5 (Zhang et al., 2012b), c-myc (Cheng et al., 
2000), IGF-1 (Upegui-Gonzalez et al., 1998) and TGF-β2 (Maggard et al., 2001) may also be 
useful to block the expression of these oncogene that fuel the formation of HCC. However, 
the effectiveness of these strategies were dependent on the capability of the available vectors 
to deliver the therapeutic genes to all tumor cells in order to restore the normal gene function 
of these mutated cells for efficient tumor growth inhibition. 
 
Apart from that, the expression of the cytokine genes such as IL-2 (Zhang et al., 1998), IL-4 
(Elkins et al., 1994), IL-6 (Tanaka et al., 1997), IL-10 (Kokura et al., 2005), IL-12 (Shibata et 
al., 2006), IL-24 (Xie et al., 2011), IFN-γ (Nomura et al., 1999), GM-CSF (Bristol et al., 
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2003) or TNFα (Koshita et al., 1995) in poorly immunogenic tumor cells have been proven 
effective in eradicating the tumor in various in vivo animal models. These cytokine genes 
could be used to increase the immunogenicity of the tumors and potentially protect the 
patients from cancer recurrence. Therapeutic genes that directly kill the cancer cells via the 
induction of apoptosis such as TRAIL (Wang et al., 2010), FasL (Ho et al., 2010), BikDD (Li 
et al., 2011) etc. and various suicide gene expression systems have also been employed and 
shown to be effective to different extents depending on the type of preclinical animal model 
used. 
 
1.4.1 Advantages of prodrug activated suicide gene system 
Among all the therapeutic genes, prodrug activated suicide gene therapy system is the most 
famous and regularly used in designing a gene viral vector for use in cancer gene therapy 
(Portsmouth et al., 2007). Table 1.4 summarized the current available suicide gene and its 
corresponding prodrug. A major advantage of such therapeutic gene is that the expression of 
suicide gene is not toxic and the therapeutic effect could be fine-tuned with the dosing of the 
prodrug to activate the therapeutics effect to an optimal therapeutic level. In addition, if 
adverse effects are observed or the treatment is no longer needed, therapeutic effect could be 
terminated upon withdrawal and clearance of prodrug. Such system could solve the major 
limitation of endogenous gene regulation system where once administrated, it will be virtually 
impossible to stop the therapeutic effect in the event of an adverse reaction. Therefore, in this 
thesis, yeast cytosine deaminase (yCD) suicide gene and its prodrug 5-fluorocytosine (5-FC) 
were used as a proof-of-principle for showing the effectiveness of transcriptional regulated 




Table 1.4 Prodrug activated suicide gene system for cancer gene therapy. 
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1.4.2 Advantages of yeast cytosine deaminase/5-fluorocytosine suicide gene system 
Cytosine deaminase (CD) is an enzyme that does not found in mammalian cells but expressed 
in fungi and bacteria (Yao et al., 2005). The CD gene, commonly used in current gene 
therapy, is cloned from Escherichia coli or Saccharomyces cerevisiae (yeast) and is generally 
known as bCD or yCD, respectively. The enzyme itself is not toxic but is able to catalyze the 
hydrolytic deamination of cytosine to uracil which allows the conversion of 5-FC to anti-
cancer metabolite 5-FU (Yao et al., 2005). The 5-FU is further metabolized by intracellular 
enzymes to several pyrimidine anti-metabolites such as 5-fluorodeoxyuridine-5’-mono-
phosphate (5-FdUMP), 5-fluorodeoxyuridine-5’-triphosphate (5-FdUTP) and 5-fluorouridine-
5’-triphosphate (5-FUTP). 5-FdUMP is thymidylate synthase inhibitor that prevents the 2-
deoxythymidine-5’-triphosphate synthesis (a precursor of DNA) leading to preferential 
incorporation of 5-FdUTP into DNA to cause the DNA damages and thereby inhibiting the 
replication process. Whereas, 5-FUTP replaces the UTP in RNA including (1) rRNA to 
inhibit precursors processing, (2) mRNA to inhibit polyadenylation and (3) tRNA to inhibits 
methylation. Combinational effects of these metabolites eventually lead to cell death via 
apoptosis (Kurozumi et al., 2004). Overall metabolic pathway is summarized in Figure 1.10.  
 




inhibition of  
protein synthesis
5-FdUMP inhibition of  thymidylate syntase
inhibition of  
DNA synthesis
 
Figure 1.10 Mode of action in 5-FC metabolic pathway with yCD. 5-FC, fluorocytosine; 5-
FU, 5-fluorouracil; 5-FUMP, 5-fluorouridine monophosphate; 5-FUDP, 5-fluorouridine 
diphosphate; 5-FUTP, 5-fluorouridine triphosphate; 5-FdUMP, 5-fluorodeoxyuridine 
monophosphate (Vermes et al., 2002). See Appendix II for permission to reproduce. 
 
When comparing between the bCD and yCD, yCD converts 5-FC to 5-FU more efficiently 
than bCD due to the reason that the yCD has a higher affinity for 5-FC (Km is 22-fold lower) 
(Kievit et al., 1999). Thus, most of recent studies are using the yCD as their therapeutic 
suicide gene of choice (Badr et al., 2011; Christensen et al., 2010; Kucerova et al., 2011).  
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1.4.2.1 Prodrug activatation 
One of the advantages of such enzyme prodrug gene therapy is its safety properties. 
Expression of yCD suicide gene itself is not toxic and do not cause cell death in the absence 
of its prodrug, 5-FC. Thus, it is very safe where the dose of the prodrug can be controlled to 
limit the toxicity. Initially in early 1960s, 5-FC was synthesized at the laboratories of Roche 
in Basel as an anti-metabolite for cytosine in the search for anti-leukemia drugs. Later, it has 
been used as a drug with very low toxicity to treat fungal infections since 1968 (Scholer, 
1968). The use of CD/5-FC is also proven safe in several Phase I clinical trials (Crystal et al., 
1997; Pandha et al., 1999). This strategy of using the suicide gene to activate the non-toxic 
prodrug to toxic metabolite is promising and could increase the efficacy of a chemotherapy 
drug for selective anti-tumor effect (Mahato et al., 2011). 
 
1.4.2.2 Produce anti-cancer metabolite 5-FU in cellulo  
The anti-cancer metabolite converted from 5-FC by yCD is 5-FU which is a well-known 
chemotherapeutic agent for colorectal (Saltz et al., 2012), liver (Petrini et al., 2012), breast 
(Sun et al., 2012), head and neck (Kao et al., 2011), and pancreatic (Pelzer et al., 2011) 
cancers . Unfortunately, patients receiving high doses of 5-FU systemic treatment often suffer 
from various severe side effects including disruption of the gastrointestinal and 
haematological systems that eventually lead to myelosuppression, mucositis, dermatitis, 
diarrhea and cardiac toxicity (Dachs et al., 2009). Therefore, the current enzyme prodrug gene 
therapy system that enable the non-toxic 5-FC prodrug conversion of 5-FU within the tumor 
cells may increase the 5-FU concentration only at tumor regions, thereby potentially 
increasing the therapeutic efficacy and decreasing the systemic side effects of 5-FU. 
Furthermore, 5-FU is known to act as a radiosensitizer that may enhance the therapeutic effect 
in the presence of radiotherapy (Lawrence et al., 1994). The mechanism may involve 5-
FdUMP (one of the 3 pyrimidine anti-metabolites convert from 5-FU; see Figure 1.10) which 




1.4.2.3 Bystander effect 
In viral vector intratumoral gene delivery, it is unlikely that the infectivity of the target tissue 
could exceed more than 10% (Dachs et al., 2009). The infectivity becomes even worse if the 
viral vector is delivered via systemic route of injection. Hence, ability of yCD/5-FC to confer 
robust bystander effect is definitely a desired advantage for application in viral cancer gene 
therapy. Bystander effect is defined as the death of non-transduced cells due to indirect toxic 
effect comes from adjacent transduced cells. With this mechanism, the chances in killing 
more surrounding tumor cells are increased and are not limited to only the transduced tumor 
cells. In addition, in vivo tumor regression has been shown in both local and distant bystander 
effect with cells expressing CD at level as low as 2% (Freeman et al., 1993; Haack et al., 
2000).  
 
In term of bystander effect, yCD/5-FC system is considered more efficient than HSV-
TK/GCV system due to the produced 5-FU does not depend on intercellular communication 
of gap junction or direct cell-to-cell contact (Huber et al., 1994). In other words, 5-FU can 
freely diffuse and enter neighboring cells through simple diffusion process while GCV 
requires gap junctions to affect surrounding cells. The only concern for bystander effect is 
that uncontrolled spread of toxic metabolite may increase the risk of the in vivo toxicity. 
However, in the evidences that have been gathered in various studies, bystander approaches 
were shown to have more advantages than no-bystander approaches in the clinic (Dachs et al., 
2009). Thus, bystander effect is still preferred in cancer gene therapy system utilizing the 
viral vector.  
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1.5 Strategies for non-invasive imaging of therapeutic gene expression in cancer studies 
For generating a safe and efficient gene viral vector, the distribution and level of therapeutic 
gene expression needs to be non-invasively monitored with a good indicator. This is 
important to prevent any unexpected and unwanted side effect derived from the use of gene 
vectors. Besides that, this strategy may also help to optimize the expression of the therapeutic 
gene for improved and enhanced in vivo cancer treatment. 
 
In recent years, bioluminescence and fluorescence imagings have become useful tools in 
cancer and gene therapy research. They can be used for determining the transduction 
efficiency, promoter activity, growth kinetics of tumor xenograft mouse models and various 
other applications (Shah et al., 2004; Waerzeggers et al., 2009; Zinn et al., 2008). Using 
engineered lentiviral vectors co-expressing the mutant EGFR variant III and reporters 
consisting of green fluorescent and Renilla luciferase proteins, a group of researchers showed 
that there is a direct correlation between EGFR expression and glioma cell proliferation in the 
initial stages of glioma progression (Arwert et al., 2007). All of these studies require co-
expression of reporter gene with gene of interest. This could be achieved by two coordinately 
acting promoters (Jacobs et al., 2001; Ray et al., 2008; Winkeler et al., 2007), gene fusion 
(Winkeler et al., 2007) and by including proteases proteolytic cleavable sites such as fusagene 
or translational linkers such as the IRES or self-processing peptides (de Felipe, 2002). Table 
1.5 summarizes the advantages and disadvatanges of various strategies for multiple proteins 
expression.  
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Table 1.5 Strategies for multiple proteins expression and its advantages and disadvantages. 
 









-Desired expression level 
of specific protein by well 
characterized promoter 
-Simple to construct 
-Large size 
-Affected by inserted 
position in a vector 
-Unable to express equal 
ratio of multiple proteins 




-Two ORFs regulate 
by single promoter -Small size 
-Splicing event is not 
consistent 
-Mixture of spliced and 
unspliced product 
-Unable to express equal 








-Express equal ratio of 
multiple proteins 
-Good for reporter genes 
such as GFP and DsRed2 
-No additional sequences 
-Fusion may affect the 
functionalities and activity 
of both proteins. 






regulated by single 
promoter 
-Express equal ratio of 
multiple proteins 
-Protease may not function 
properly on certain 





mRNA containing 2 
ORFs 
-Regulated by single 
promoter 
-Small size 
-Unable to express equal 
ratio of multiple proteins 
-Second protein tends to be 
expressed at lower level 










translational start site 
before second ORF 
-Cap independent 
mechanism 
-Do not interfere with 
subcellular localization of 
proteins 
-Widely use for co-
expressing two proteins  
-Large size 
-Unable to express equal 
ratio of multiple proteins 
-Second protein tends to be 
expressed at lower level 
-Affected by inserted 





with single ORF 
-Translational nick at 
2A peptide to produce 
separate proteins  
-Small size 
-Highly efficient cleavage 
-Produce equal molar 
ratio of multiple proteins 
-Ideal for multiple 
proteins expression (more 
than two) 
-Low recombination risk 
-Residual 2A peptide on 
first protein may affect 
protein function and 
contributed to antigenicity 
-Some nascent  proteins 







to activate expression 
of two ORFs 
-Gene expression is 
amplified for weak 
promoter 
-Ensured co-expression  
-Large size 
-Multiple elements needed 
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1.6 Aims of the study 
 
HSV-1 amplicon viral vector is a powerful and efficient gene delivery tool that may hold an 
important role to improve HCC prognosis and potentially use to efficiently treat non-
resectable HCC. Thus, the goal of this study is to generate an efficient HSV-1 amplicon based 
vector platform that could mediate therapeutic transgene expression in a cell type-specific and 
cell cycle-dependent manner. The vector is designed to bicistronically expressed the 
therapeutic gene together with a reporter gene in an attempt to fully characterize the 
distribution and kinetics of therapeutic gene expression using a non-invasive imaging system 
in pre-clinical animal models to further evaluate the effectiveness of the generated vector. 
More specifically, the aims are: 
 
1. To evaluate the specificity of liver-specific promoters and cell cycle-dependent 
promoter in the context of HSV-1 amplicon viral vector to limit the transgene 
expression only in proliferating HCC cell in vitro and in vivo.  
2. To monitor the viral kinetics and therapeutic gene expression using non-invasive 
imaging system in an attempt to understand the functionality of viruses in a tumor 
microenvironment in pre-clinical animal models to complete the missing knowledge 
of viral therapy in clinical trials. 
3. To characterize and evaluate the specific killing efficacy of proliferating HCC cells 
with yeast cytosine deaminase prodrug-activated suicide gene that could be 
monitored via luciferase reporter gene, in vitro and in vivo. 
4. To improve the stability of transgene expression conferred by HSV-1 amplicon viral 















Materials and methods 
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2.1  Materials 
2.1.1 25% Sucrose solution 
Dissolved 25 g of sucrose (Merck, Whitehouse Station, NJ) in 100 ml of HBSS. Filter 
sterilized and stored at 4˚C. 
 
2.1.2 4% Paraformaldehyde 
Purchased from Sigma-Aldrich, St. Louis, MO. Dissolved in PBS in heated water bath set at 
65˚C with constant stirring. Adjusted the pH to 7.4. Stored at 4˚C. 
 
2.1.3 5-fluorocytosine (5-FC) 
Purchased from Sigma-Aldrich. Freshly prepared with 37˚C pre-warm PBS to desired 
concentration. May take some time to dissolve.  
 
2.1.4 5-fluorouracil (5-FU) 
Purchased from Sigma-Aldrich. Freshly prepared with PBS to desired concentration. 
 
2.1.5 Adenosine 5'-Triphosphate, Disodium salt (ATP) 
Stock solution of 0.5 M ATP (Amersham Biosciences, Princeton, NJ) was prepared by 




Stock solution of 100 mg/ml ampicillin (Sigma-Aldrich) was prepared by dissolving 1 g of 
ampicillin in 10 ml of dH2O. Filter sterilized and then aliquoted. Stored at -20˚C. 
 
2.1.7 Animals 
All BALB/C nude mice and severe combined immunodeficiency (SCID) mice were 
purchased from Animal Resource Centre, Western Australia. Immunocompetent BALB/c 
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mice were purchased from Laboratory Animal Unit of National University of Singapore, 
Singapore. Mice with primary HCC 26-1004 and RCC 09-1210C tumors xenograft were 
kindly provided by Dr. Huynh Hung (Laboratory of Molecular Endocrinology, National 
Cancer Centre, Singapore). 
 
2.1.8 Antibodies 
For western blot 
Mouse anti-actin (Lab Vision, Fremont, CA) 
Rabbit anti-eGFP (Millipore, Temecula, CA) 
Rabbit anti-luciferase (Santa Cruz Biotechnology, Santa Cruz, CA) 
Sheep anti-yeast cytosine deaminase (Abcam, Cambridge, MA) 
 
For immunohistochemistry or immunocytochemistry 
Mouse anti-cyclin A (BD Biosciences, Franklin Lakes, NJ) 
Mouse anti-human cytokeratin peptide 18 (Sigma-Aldrich) 
Mouse anti-human fibroblast (Millipore) 
Mouse anti-human hepatocellular carcinoma (ANOGEN, Mississauga, ON) 
Mouse anti-human Ki-67 (Dako, Glostrup, Denmark) 
Mouse anti-human nuclei (Millipore) 
Rabbit anti-human active caspase 3 (BD Biosciences) 
Rabbit anti-hAAT (Dako) 
 
For immunofluorescence 
Rabbit anti-cyclin A (clone C-19; Santa Cruz Biotechnology)  
Rabbit anti-hAAT (Abcam)  
Rabbit anti-luciferase (Sigma-Aldrich) 
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2.1.9 Cells-freezing medium 
Prepared by adding tissue culture grade dimethyl sulfoxide (DMSO)(Sigma-Aldrich) to fetal 
bovine serum (FBS) (Hyclone Laboratories, Logan, UT) to a final concentration of 10%. 
Stored at 4˚C.  
 
2.1.10 Cesium chloride (CsCl) /Ethidium bromide (EtBr) solution 
1.16 g of CsCl (Life Technologies, Grand Island, NY) was dissolved in 8 ml of TE buffer. 1 
ml of 10 mg/ml EtBr (Bio-Rad Laboratories, Hercules, CA) was then added. Freshly prepared 
when needed. 
 
2.1.11 Dithio-DL-threitol (DTT) 
Stock solution of 1 M DTT (Sigma-Aldrich) was prepared by dissolving 3.08 g of DTT in 20 
ml of 10 mM sodium acetate (pH5.2). Filter sterilized and aliquoted before stored at -20˚C.  
 
2.1.12 D-Luciferin 
Stock solution of 10 mM D-luciferin (Roche Diagnostics, Mannheim, Germany) was prepared 
by dissolving 10 mg of D-luciferin powder in 3.57 ml of 25 mM Glycylglycine (pH7.8; 
Sigma-Aldrich). Aliquoted, wrapped in aluminium foil and stored in -20˚C.  
 
2.1.13 Dulbecco’s modified Eagle’s medium (DMEM) 
Purchased from Sigma-Aldrich (Product number D5648). The medium was buffered with 
7.5% w/v sodium bicarbonate. Stored at 4˚C. 
 
2.1.14 Escherichia coli stain TOP 10 
The competent cell is commercially available (Life Technologies). The genotype of the strain 
is [F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara leu) 
7697 galU galK rpsL (StrR) endA1 nupG]. Stored at -80˚C. 
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2.1.15 Immunohistochemistry blocking buffer 
Prepared with 0.1% Tween-20 (Sigma-Aldrich) and 10% goat serum (Sigma-Aldrich) in PBS. 
Freshly prepared when needed.  
 
2.1.16 Lovastatin 
Stock solution of 25 mg/ml lovastatin (Merck) was prepared by dissolving 25 mg of 
lovastatin into 500 μl of 95% ethanol. This was followed by addition of 400 μl of 1M NaOH. 
Next, the pH was adjusted to pH7.2 with 1M HCl. Finally, ddH2O was added to a final 
volume of 1 ml. Aliquoted and stored away from light at -20˚C.  
 
2.1.17 Luciferase assay buffer 
Mixed 25 mM Glycylglycine (pH7.8), 15 mM MgSO4, 4 mM EGTA and 15 mM potassium 
phosphate (pH7.8) in dH2O. Stored at 4 ˚C.  
 
2.1.18 Luciferin buffer 
Mixed 25 mM Glycylglycine (pH7.8), 15 mM MgSO4 and 4 mM EGTA in dH2O. Stored at 
4˚C.  
 
2.1.19 Luria Bertani broth (LB) 
Mixed 10 g Bacto-tryptone, 5 g Bacto-yeast extract and 10 g sodium chloride in 900 ml of 
dH2O. Adjusted pH to 7.0 with NaOH. Sterilized by autoclaving. Stored at 4˚C.  
 
2.1.20 Phosphate buffered saline (PBS) 






2.1.21 Propidium iodide (PI) solution 
Stock solution of 100 μg/ml of PI (Sigma-Aldrich) was prepared by dissolving 1 mg of PI in 
10 ml of PBS containing 0.1% Triton X-100. Aliquoted, covered with aluminium foil and 
stored at -20˚C. 
 
2.1.22 Protein loading buffer 
Prepared by mixing 62.5 mM Tris-Cl (pH6.8), 10% glycerol, 2% SDS, 100 mM DTT, 0.05% 
bromophenol blue (Sigma-Aldrich) in ddH2O. Stored at r.t. 
 
2.1.23 Protein lysis buffer 
Prepared with 50 mM Tris-Cl (pH7.6), 150 mM NaCl and 1% Triton X-100 in ddH2O. Store 
at 4˚C. Add 1× protease inhibitor (Roche Diagnostics) before used. 
 
2.1.24 Protein transfer buffer 
Mixed 25 mM Tris, 190 mM glycine and 20% methanol in dH2O. Stored at r.t. 
 
2.1.25 RNase A (DNase free) 
Stock solution of 20 mg/ml of RNase A (Sigma-Aldrich) was prepared by dissolving 20 mg 
of RNase A in 1 ml of PBS. Aliquot and store at -20˚C. 
 
2.1.26 SDS electrophoresis buffer 
Mixed 25 mM Tris-base, 192 mM glycine (electrophoresis grade) and 0.1% SDS in dH2O. 
Stored at r.t.  
 
2.1.27 SOB 
Mixed 20 g Bacto-tryptone, 5 g Bacto-yeast extract, 0.5 g NaCl and 2.5 ml of 1 M KCl in 900 
ml of dH2O. Adjusted the pH to 7.0 with NaOH. Sterilized by autoclaving and stored at 4˚C. 
Added 9 ml of 1M MgCl2 before used. 
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2.1.28 TE-saturated butanol 
TE buffer was added to butanol (Merck) with intermittent mixing until two phases were 
observed. Upper phase was the TE-saturated butanol. Stored at r.t. 
 
2.1.29 Tris-acetate EDTA (TAE) buffer 
Mixed 40 mM Tris-acetate, glacial acetic acid and 1 mM EDTA in dH2O. Stored at r.t. 
 
2.1.30 Tris-EDTA (TE) buffer 
Prepared with 10 mM Tris (pH8.0) and 1 mM EDTA (pH8.0) in dH2O. Sterilized by 
autoclaving. Stored at r.t. 
 
2.1.31 Western blot blocking buffer 
Prepared with 5% non-fat milk, 10 mM Tris (pH7.5), 100 mM NaCl and 0.1% Tween-20. 
Freshly prepared when needed.  
 
2.2  General Methods  
2.2.1  Cell Culture techniques 
2.2.1.1  Cell lines and tissue specimens 
A human hepatocellular carcinoma cell line (PLC/PRF/5), human immortalized normal liver 
cell line THLE-3, human cervix epithelial adenocarcinoma cell line HeLa and a human lung 
adenocarcinoma cell line (A549) were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). A human hepatocellular carcinoma cell line (HuH-7) was obtained 
from the Japanese Collection of Research Bioresources (JCRB cell bank, Osaka, Japan). 
Human ΔGli36 glioma cells (also known as Gli36∂EGFR), which were kindly provided by 
Dr. Miguel Sena-Esteves (University of Massachusetts Medical School, Worcester, MA), 
were established by clonal cell selection of the human glioma Gli36 cells transduced with a 
retroviral vector expressing the epidermal growth factor with truncation in exon 2-7 (EGFR 
variant III) cDNA. Gli36 human glioma cells were kindly provided by Campagnoni (UCLA 
  43
School of Medicine, Los Angeles, CA). CNE2 cells were derived from undifferentiated 
human nasopharyngeal carcinoma (gift from Wang, Cancer Institute, Guangzhou, PRC). 
African green monkey kidney 2-2 cells were derived from Vero cells that constitutively 
expressed the HSV-1 ICP27 proteins (kindly provided by Sandri-Goldin RM, University of 
California, Irvine, CA). The immortalized untransformed human neonatal liver cell line 
(NeHepLxHT) was kindly provided by Lee CG (National Cancer Centre, Singapore). Human 
primary HCC and its adjacent match normal liver tissues were obtained from the SingHealth 
Tissue Repository following approval from the SingHealth Centralized Institutional Review 
Board, and with patient informed consent. 
 
2.2.1.2  Culture condition 
All cells, except THLE-3, NeHepLxHT, primary HCC and its match normal liver cells, were 
cultured in Dulbecco’s modified Eagle medium (DMEM; Sigma-Aldrich) supplemented with 
10% Fetal Bovine Serum (FBS; Hyclone Laboratories), penicillin (100 U/ml; Life 
Technologies), streptomycin (100 µg/ml; Life Technologies), 2 mM L-glutamine (Life 
Technologies). For HCC cell lines, the medium was further supplemented with 0.1 mM non-
essential amino acid (Life Technologies) and 1 mM sodium pyruvate (Life Technologies). 
The ΔGli36 cells were supplemented with 1 µg/ml puromycin (Invivogen, San Diego, CA), 
while the 2-2 and PLC/PRF/5-DsRed2 (PLC/PRF/5 cell stably expressed DsRed2 protein) 
cells were cultured in the presence of 500 µg/ml of Geneticin (Life Technologies). THLE-3 
was cultured in BEBM basal medium (Lonza, Basel, Switzerland) supplemented with 
recombinant human EGF, o-Phosphoethanolamine, FBS, BPE, hydrocortisone, hEGF, insulin, 
triiodothyronine, transferrin and retinoic acid. NeHepLxHT, primary HCC and its match 
normal liver cells were cultured in hepatocytes culture medium, HCM Bullet Kit (Lonza). All 
cells were maintained at 37 °C in a 5 % CO2-95 % air atmosphere. 
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2.2.1.3  Subculturing 
Cells were subcultured using 0.25% trysin-EDTA. Briefly, when cells were ready for 
subculturing, the medium was discarded and the cell monolayer was washed once with PBS. 
After that, appropriate amount of 0.25% trypsin-EDTA was added for approximately 2 to 5 
min until most of the cells became resuspended. This was followed by adding equal volume 
of complete medium and centrifuged for 5 min at 1000 rpm with J6 centrifuge machine 
(Beckman Coulter, Palo Alto, CA). The pelleted cells were then resuspended in appropriate 
amount of complete medium and dispensed into new flask at appropriate dilution ratio.  
 
2.2.1.4  Cryopreservation 
To cryopreserve cells, cells were trypsinized and pelleted as above. The pellet was then 
resuspended in cell-freezing medium and stored in liquid nitrogen in cryovials (Nunc, 
Roskilde, Denmark). 
 
2.2.1.5  Single cell suspension 
HCC tumor or match normal liver specimens (about 1000 mm3 or less) were washed with ice 
cold Hanks’ Balance Salt Solution (HBSS; Life Technologies). Tumor necrotic regions were 
carefully removed. The specimens were then minced with scissors on a dry sterile petri dish 
on ice. After that, the minced specimens were washed with 10 ml of cold HBSS and settled 
down for 2 min before the supernatant was discarded. The minced specimens were washed 
again with 30 ml of cold HBSS and centrifuged at 100× g for 10 min to pellet down the 
minced specimens. This was followed by adding 10 ml of Liver Digest Medium (Life 
Technologies) to resuspend the pellets and incubate them at 37˚C shaking waterbath for 1 h. 
The cell suspensions were further subjected to dissociation using 10 ml syringe (without 
needle) for about 10× and let them settle for 2 min. Supernatants were then collected in new 
15 ml tubes and subjected to centrifugation at 100× g for 10 min. The pellets were later 
resuspended in 0.5 ml cold HBSS and gently mixed with 4.5 ml of NH4Cl solution 
(STEMCELL Technologies, Vancouver, Canada) to lyse the red blood cells. Next, the 
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mixtures were incubated on ice for 10 min before 5 ml of HCM medium (Lonza) 
supplemented with 2% FBS (Life Technologies) was added. The isolated single cell 
suspensions were pelleted down again with 100× g centrifugation for 10 min and resuspended 
with appropriated volume of HCM medium (Lonza) supplemented with 2% FBS (Life 
Technologies) before seeding in 24-well plate that was freshly coated with 60 µg/cm2 of 
collagen I from rat tail (BD Biosciences) at cells density of 1 × 105 cells. 
 
2.2.1.6 DNA transfections 
Cells (3 × 105) were transfected in six-well plates (Nunc) using lipofectamine (Life 
Technologies) and Plus reagent (Life Technologies) according to the manufacturer’s 
instructions. Briefly, 3 μg of plasmids were mixed with 5 μl of Plus reagent in 300 μl of 
OptiMEM (Life Technologies) for 5 min at r.t. Eight μl of lipofectamine in 300 μl OptiMEM 
was then added and further incubated at r.t. for another 30 min. The complexes were topped 
up to 1 ml with OptiMEM and added to cells in 6-well plate. After 6 h incubation at 37˚C, the 
cells were replenished with fresh culture medium. 
 
2.2.1.7  Cell stable clone generation 
Cells were transfected with a desired plasmid. After transfection, cells were replenished with 
complete culture medium with appropriate antibiotic twice a week. The concentration of 
antibiotic used should able to lead to a massive cell death in control non-transfected cells at 
about day 7. The single colony was then picked out using the forceps and sterile filter paper 
(1 mm × 1 mm) and transferred to 24-well plate. Cells were expanded to T25 culture flask 
before cryopreserved in liquid nitrogen.  
 
2.2.1.8 Fluorescence-activated cell sorting (FACS) analysis 
FACS analysis was performed to determine the cell cycle profile as well as transfection and 
transduction efficiency using a flow cytometer (FACSCanto II; BD Biosciences). All 
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generated data were analyzed using FlowJo software (version 7.6.5; TreeStar Inc. San Carlos, 
CA). 
 
2.2.1.9  Synchronization and cell cycle analysis 
Depending on the cell lines, fresh culture medium supplemented with 0.2% FBS and 50-70 
μM of lovastatin (Merck) were added to induce G1-arrest for 48 h. Cells were then harvested 
by trypsinization and resuspended in 500 μl of ice cold 70% ethanol. After an overnight 
fixation at 4˚C, cells were washed thrice, before resuspending in solution containing 100 μl of 
PBS, 200 μl of RNase A (2 mg/ml; Sigma-Aldrich) and 200 μl of PI (100 μg/ml; Sigma-
Aldrich). The samples were kept on ice for an hour before subjected to FACS analysis using a 
flow cytometer (FACSCanto II; BD Biosciences). 
 
2.2.1.10 Cell viability assay 
Cell viability was assayed with the cell counting kit-8 (CCK-8; Dojindo Laboratories, 
Kumamoto, Japan). To assay for cell viability after a certain amount of treatment time, 10 μl 
(for a 96-well plate) or 60 μl (for a 24-well plate) of CCK-8 solution (equivalent to 10% of 
total volume of culture medium) was added to each well and the plate was incubated for 
another 2 to 4 h depending on cells at 37 °C, 5% CO2. The absorbance was then read at 450 
nm with a reference at 650 nm using a Victor 3V plate reader (PerkinElmer Life Sciences, 
Waltham, MA). 
 
2.2.2 Helper virus-free packaging of HSV-1 amplicon viral vector 
2.2.2.1 Cosmids packaging of virions 
The 2-2 cells (3 × 106) seeded in 100 mm dish were co-transfected with 2 µg of amplicon 
DNA and 6 µg of a mixture of five overlapping PacI digested cosmids (cos 6Δa, cos 14, cos 
28, cos 48Δa and cos 56) that represent the entire HSV-1 genome but lack the pac signal 
(Fraefel et al., 1996) using 45 µl of Lipofectamine (Life Technologies) and 15 ul of Plus 
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reagent (Life Technologies), as instructed by the manufacturer. After 12 h of transfection, the 
cells were replenished with fresh complete medium and incubated for an additional 60 h. 
 
2.2.2.2 Harvesting of virions 
Crude viral supernatant was harvested 60 h post-transfection. Cells were scrapped into the 
medium using cell lifter (Corning Enterprise, Corning, NY). The suspension was then quick 
frozen in liquid nitrogen and quick thawed in 37˚C shaking waterbath for 3 times without 
allowing the suspension to warm up. Next, the suspension was sonicated twice for 60 s in a 
waterbath sonicator (Grant, Cambridge, England). The cellular debris was removed by 
centrifugation for 10 min at 2000 rpm with J6 centrifuge machine. The debris in supernatant 
was further removed by using 0.45 μm sterile membrane filter unit with glass fibre pre-
membrane filter (Sartorius, Goettingen, Germany). 
 
2.2.2.3 Sucrose gradient purification 
The crude viral lysates harvested above were purified by sucrose gradient centrifugation 
through a 5 ml of 25% sucrose/HBSS solution that was carefully pipetted onto the bottom of 
the ultracentrifuge tube. This was followed by ultracentrifugation at 25000 rpm for 1 h at 4°C 
with a Beckman SW28 swing-out rotor. The pellet was finally resuspended overnight in 50 μl 
of HBSS (Life Technologies) and stored at -80°C. 
 
2.2.2.4 Virus titer determination 
To determine virus titers in transduction units (TU) per milliliter or TU/ml, 1 × 105 2-2 cells 
were first seeded in 24-well plate. The cells were infected in triplicate with appropriate 
dilution of virus stock in 300 μl complete medium for overnight at 37˚C. Green fluorescent 
cells were counted under 10× objective lens of a inverted fluorescence microscope (Eclipse 
TE300; Nikon, Tokyo, Japan) equipped with an 10× ocular lens fitted with a 10 × 10 counting 
grid. Five random fields were counted in each well. The titer of virus was calculated using the 
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formula, TU/ml = n × 190 × DF, where n is average number of green fluorescence cells and 
DF is the dilution factor. The number 190 is the amplification factor for the entire field in a 
24-well plate under a 10× objective lens. 
 
2.2.2.5 HSV-1 amplicon viral vector transduction 
Vector transduction was carried out with diluted virus stock in complete culture medium so as 
to achieve a constant multiplicity of infection (MOI) depending on the number of cells 
seeded. The cells were infected with virus vector for 6 h and replenished with fresh complete 
medium. After 24 h of incubation at 37˚C, the transduced cells were ready for further 
analysis.  
 
2.2.3 DNA methods 
2.2.3.1 Isolation of plasmid DNA – miniprep 
The plasmid DNA isolation for screening the positive bacteria clone was carried out using the 
plasmid miniprep kit (QIAGEN, Hilden, Germany) according to manufacturer’s instruction.  
 
2.2.3.2 Isolation of plasmid DNA – maxiprep 
For large scale plasmid DNA isolation for DNA transfection and virus packaging experiment, 
plasmid maxiprep kit (QIAGEN) was used according to manufacturer’s instructions.  
 
2.2.3.3 Isolation of cosmid DNA 
For cosmid DNA isolation, CsCl gradient DNA ultracentrifugation method was used. Firstly, 
a single bacteria colony was picked and inoculated into 9 ml SOB broth with 50 μg/ml of 
ampicillin and incubated for 8 h in 37˚C and 225 rpm of agitation speed. This starter culture 
was then transferred into 900 ml of SOB broth containing 50 μg/ml of ampicillin and further 
cultured for another 16 h at 37˚C and 250 rpm of agitation speed. The pellet was then 
resuspended with 60 ml of resuspension buffer (2.25 g/L glucose; 10 mM EDTA, pH 8; 25 
mM TRIS, pH 8) followed by 120 ml of freshly prepared lysis buffer (0.2 M NaOH; 1% SDS) 
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and 60 ml of ice cold neutralizing buffer (61.3 g/L potassium acetate; 141 ml/L glacial acetic 
acid). The mixture was then centrifuged at 5000 rpm for 10 min and filtered with filter paper 
to remove all the precipitate before 160 ml of ice cold isopropanol was added to precipitate 
the DNA. The precipitate was gently resuspended with 8.5 ml of TE buffer (pH 7.4) for 
overnight at 4oC. The suspension were then added with 9.5 g of CsCl and mixed gently in a 
roller. When all the CsCl salt had dissolved, 1 ml of EtBr (10 mg/ml) was added and finally 
loaded into an ultracentrifuge tube and spun overnight at 55K, 25oC with 70Ti rotor using a 
Beckman ultracentrifuge without break. The cosmid DNA band was later extracted using the 
TE-saturated butanol to remove EtBr and precipitated using ethanol or isopropanol before 
resuspended in 1 ml of TE buffer (pH 7.4; pre-warmed to 65oC). 
 
2.2.3.4 Isolation of whole cellular DNA 
Whole cellular DNA was extracted using QIAamp DNA blood mini kit (QIAGEN) according 
to manufacturer’s instruction with RNase treatment.  
 
2.2.3.5 Vector gene copy number quantification  
Whole cellular DNA was extracted as describe above. Exactly 10 ng or 100 ng of whole 
cellular DNA samples were subjected to quantitative PCR analysis for vector gene copy 
number quantification. The quantitative PCR reaction was setup using QuantiTect SYBR 
Green PCR Kit (QIAGEN) with 0.6 μl of forward primer, 0.6 μl of reverse primer, 10 μl of 
2× SYBR master mix, 7.8 μl of dH2O and 1 μl of whole cellular DNA. PCR reaction was run 
at 15 min at 95°C and then 45 cycles of 15 s at 94°C, 30 s at 46°C and 30 s at 72°C using a 
Rotor-Gene Q real-time PCR system (QIAGEN). A set of PCR primers specific to the luc 
gene (5’-GAATCCATCTTGCTCCAAC-3′ and 5′-TCTCTCTGATTTTTCTTGCGTC-3′) 
was used to quantitate the luc genome copy numbers based on a standard curve generated 
with the pcDNA3-Luc plasmid DNA. The standard curved was constructed with a known luc 
gene copy number from 40 to 4 × 107 copies of luc gene.  
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2.2.3.6 Quantification of nuclei acid concentration 
The DNA concentration was determined using a Nanodrop ND 1000 spectrophotometer 
(Thermo Scientific, Wilmington, DE). To measure the DNA concentration, 1.5 μl of DNA 
solution was pipetted onto the lower measurement pedestal. Sample arm was closed and the 
DNA measurement software on the PC was used to determine the DNA concentration at 260 
nm. 
 
2.2.4 Protein methods 
2.2.4.1 Preparation of total cell lysate 
Cells were first washed twice with PBS and directly added with protein lysis buffer to lyse the 
cells on ice for 10 min. The mixture was then transferred to 1.5 ml microcentrifuge tube and 
centrifuged at 13000 rpm for 10 min at 4˚C to remove the cell debris. The supernatant (total 
cell lysate) was transferred into a new 1.5 ml microcentrifuge tube, aliquoted and stored in -
80˚C until used. 
 
2.2.4.2 Preparation of total tumor lysate 
For tumor samples, about 100 mg of tumor tissue was harvested and minced with scissors in 
0.6 ml homogenization buffer (250 mM Sucrose, 2 mM EDTA, 10 mM Tris-Cl, 1 mM 
PMSF). The samples were then subjected to mechanical homogenization for 30 s followed by 
three freeze/thaw cycles in liquid nitrogen and 37°C waterbath. The mixture was then 
transferred to 1.5 ml microcentrifuge tube and centrifuged at 13000 rpm for 10 min at 4˚C to 
remove the cell debris. The supernatant (total tumor lysate) was transferred into a new 1.5 ml 
microcentrifuge tube, aliquoted and stored in -80˚C until used. 
 
2.2.4.3 Protein concentration estimation 
Protein concentration was spectrophotometrically estimated using Bradford method with 
protein binding dye (Bio-Rad Laboratories) according to manufacturer’s instruction. Briefly, 
the sample was diluted with dH2O for 5 to 10 times to a final volume of 10 μl. The sample 
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was pipetted into the 96-well plate and 200 μl of diluted dye was added. After 5 min of 
incubation at r.t. the absorbance at 595 nm was measured using a Victor 3V plate reader 
(PerkinElmer Life Sciences).  
 
2.2.4.4 Luciferase assay 
Cells were harvested from 6-well plate following transfection and total cell lysate was 
prepared as described above. A total of 100 μl of the total cell lysate was used for assaying 
the luciferase activity using the Auto-Lumat LB952 luminometer (EG&G Berthold, Bad 
Wildbad, Germany) to measure the relative light unit (RLU) produced. To do this, 100 μl of 
total cell lysate was mixed with 350 μl of LAB buffer in a 5 ml round bottom polystyrene 
tube (BD Biosciences). The tube was loaded into the chamber of the luminometer, which 
could automatically inject 200 μl of LB buffer and measure the RLU produced. Protein 
concentration was estimated as described above. The luciferase activity was presented as 
RLU produced per μg of total protein in the unit of RLU/μg.  
 
2.2.4.5 Yeast cytosine deaminase assay 
Cells (5 × 105 cells) were washed twice with PBS before resuspended in 100 µl of PBS. This 
was followed by five cycles of freezing and thawing processes. A total of 50 µl cell lysate was 
then mixed with 950 µl of 3 mM 5-FC substrate in PBS and incubated at 37°C. At various 
time points, 50 µl of samples were taken and quenched with 950 µl of 0.1 mM HCl. The 5-FU 
and 5-FC concentrations were then determined with spectrophotometer using the formulas: 5-
FC (mM) = 0.119(A290) - 0.025(A255); 5-FU (mM) = 0.185(A255) - 0.049(A290) (Senter et al., 
1991). Each experiment was performed independently three times. CD activities (U/mg) were 
calculated. One unit (U) of CD activity was defined as the amount of enzyme releasing 1 
μmol of 5-FU per minute under standard assay conditions at 37 °C. 
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2.2.4.6 ALT assay and AST assay 
The ALT assay was performed using the liquid ALT (SGPT) reagent set (Pointe Scientific, 
Canton, MI). The blood was drawn from the tail vein of mice at several defined time points 
post-intravenous injection of viruses. The serum was separated by centrifugation at 4000 rpm 
at r.t. for 30 minutes and 10 µl of serum was used to assay each ALT assay. The kinetic of 
enzymatic activities at 37˚C were monitored at absorbance of 340 nm using the 
SPECTRAFluor Plus microplate reader (Tecan, Männedorf, Switzerland). Similar method 
was used for AST assay with liquid AST (SGOT) reagent set (Pointe Scientific) 
 
2.2.4.7 Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) 
The SDS-PAGE gel was cast using the Mini-PROTEAN III gel system (Bio-Rad 
Laboratories). The 10% resolving gel was made with 3.3 ml of 30% acrylamide mix (37.5:1), 
2.5 ml of 1.5 M TRIS pH8.8, 50 μl of 20% SDS, 100 μl of 10% ammonium persulfate, 12 μl 
of TEMED and 4 ml of ddH2O. The gel was allowed to set at r.t. for about 30 min. A 5% 
stacking gel was then prepared with 830 μl of 30% acrylamide mix (37.5:1), 630 μl of 1 M 
TRIS pH6.8, 25 μl of 20% SDS, 50 μl of 10% ammonium persulfate, 8 μl of TEMED and 3.4 
ml of ddH2O. This stacking gel was loaded on top of the resolving gel. The protein samples 
(100 μg) were boiled for 10 min in 1× protein loading buffer before loading onto the gel. 
Next, the gel was run at 180 V for 1.5 h in 1× SDS electrophoresis buffer. A pre-stained high 
molecular weight protein marker (10 kDa to 170 kDa, Fermentas, Burlington, ON) was also 
run as reference. 
 
2.2.4.8 Western blot 
After separation by SDS-PAGE, the proteins were transferred from the gel to polyvinylidene 
difluoride (PVDF; Millipore) membrane at 20 V constant voltage for 30 min at r.t. in transfer 
buffer. The membrane was then placed into the blocking buffer for 2 h at r.t. before 
immunoblotted with antibody at appropriate dilution in blocking buffer overnight at 4°C. The 
PVDF membrane was then incubated in blocking buffer containing secondary HRP-
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conjugated antibodies for 1 h at r.t.. Next, the membrane was subjected to an ECL reaction 
using a Western Lightning chemiluminescence reagent plus kit (PerkinElmer Life Sciences) 
for 1 min before being exposed on film in the M35 X-OMAT Processor (Kodak, Rochester, 
NY). The blot was stripped and reprobed with mouse anti-human actin monoclonal antibody 
(1:10000; 0.2 mg/ml; Lab Vision).  
 
2.2.4.9 Hematoxylin and Eosin (H&E) staining 
H&E staining was performed by incubating the sections in Harris hematoxylin (Sigma-
Aldrich) for appropriate duration. This was followed by rinsing in running tap water until the 
blue color was observed. Next, the sections were dipped into 70% and 90% ethanol for 30 s 
each followed by counterstaining with eosin for appropriate duration. The sections were then 
dehydrated in 95% ethanol for 1 min and 2 changes of 100% ethanol for 1 min each. After 
dehydration, the sections were incubated in xylene twice at 5 min intervals. Excess xylene 
was drained from the sections before DPX (Sigma-Aldrich) was applied. Finally, the sections 
were mounted with coverslips and stored at r.t. until examined under microscope. 
 
2.2.4.10 Immunohistochemistry (IHC) staining 
Tissue sections were first fixed in 4% paraformaldehyde solution for 10 min at r.t. This was 
followed by washing with PBS for another 10 min at r.t. To quench endogenous peroxidase 
activity, the sections were treated with 3% hydrogen peroxide for 10 min at r.t. The sections 
were then rinsed with distilled water. If antigen retrieval was needed, the slides were 
subjected to heat-induced epitope retrieval in 10 mM sodium citrate buffer, pH 6 in steam 
antigen retrieval unit (model 2100; PickCell Laboratories, Leiden, Netherlands). To remove 
the non-specific binding, the sections were incubated in blocking buffer for 30 min at r.t. 
Next, the primary antibody at appropriate dilution was added to the sections and incubated for 
1 h at r.t or overnight at 4°C. After washing with PBT (PBS with 0.1% Tween-20) for 3 × 3 
min, the appropriate amount of HRP-conjugated secondary antibody was applied to the 
sections and incubated for another 30 min at r.t. The sections were further washed with PBT 3 
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× 3 min. Finally, the colorimetric development was visualized after the addition of 3,3’-
diaminobenzidine (DAB) substrate solution (MaxVision Biosciences, Bothell, WA) and 
incubated for 5-10 min at r.t. The slides were counterstained with hematoxylin before 
mounting on microscopic slides for examination using the microscope (BX51; Olympus, 
Tokyo, Japan). Similar concentration of rabbit IgG (Dako) or mouse IgG1 (Dako) were used 
as negative control. 
 
2.2.4.11 Immunofluorescence (IF) staining 
Tissue sections were first fixed in 4% paraformaldehyde solution for 10 min at r.t. The slides 
were then washed with 100 mM glycine in PBS for 3 × 3 min to reduce the background 
staining caused by paraformaldehyde. Next, the cells were permeabilized with 0.5% Triton-X 
100 (BDH, Poole, UK) in PBS for 10 min at 4°C and incubated in blocking buffer (0.1% 
Tween-20 [Sigma-Aldrich], 5% BSA [Sigma-Aldrich] and 10% goat serum [Sigma-Aldrich] 
in PBS) for 1 h at r.t. This was followed by incubation with primary antibody at appropriate 
concentration for 1 h at r.t. or overnight at 4°C before rinsing thrice at 3 min intervals with 
PBT (PBS with 0.1% Tween-20). The slides were then incubated with Alexa Fluor® 350 or 
Alexa Fluor® 594 goat anti-rabbit antibody (Molecular Probe, Eugene, OR) for an hour. 
Finally, the cells were also stained with DAPI if needed before mounted with mounting 
medium (Vector laboratories, Burlingame, CA) and examined using the fluorescence 
microscope (Eclipse 90i; Nikon). Similar concentration of rabbit IgG (Dako) was used as 
negative control. 
 
2.2.5 Gene cloning techniques 
2.2.5.1 Electrophoresis 
Electrophoresis of plasmid DNA or PCR fragments were carried out according to the method 
described by Sambrook and colleagues (Sambrook et al., 1989). 1% of agarose gel was 
usually prepared in 1× TAE buffer with DNA grade agarose (Life Technologies) and run in 
the same buffer. 
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2.2.5.2 Polymerase Chain Reactions (PCR) 
Phusion high fidelity DNA polymerase (Finnzymes, Espoo, Finland) was used in PCR to 
amplify the DNA fragment for cloning purposes. For other PCR purposes, HotStarTaq 
polymerase (QIAGEN) was used. The PCR was carried out according to manufacturer’s 
instruction. Briefly, 10 ng of template DNA, 0.5 μM of each forward and reverse primer, 200 
μM of each dNTP and 0.5 μl of DNA polymerase were added into 1× reaction buffer. Sterile 
dH2O was added to 50 μl of final volume before the PCR reaction started with the initial 
denaturation temperature at 95-98˚C for 30 s – 5 min. This was followed by 30 cycles of 
denaturing at 95 - 98˚C for 10 s – 1 min, annealing at appropriate temperature depending on 
the Tm of primers for 30 s – 1 min and extension at 72˚C for appropriate time depending on 
the length of the PCR product and DNA polymerase used. Next, the final extension at 72˚C 
for 10 min was applied before the reaction was cooled to 4˚C.  
 
2.2.5.3 Gel extraction of DNA fragment 
The DNA fragment in agarose gel was excised using a scalpel and transferred into a 1.5 
microcentrifuge tube. The DNA in the agarose gel was then extracted out by using Gel 
Extraction Kit (QIAGEN) according to manufacturer’s instruction.  
 
2.2.5.4 Purification of PCR product 
DNA fragment after PCR reaction was purified from the reaction buffer and primers 
contamination with PCR purification kit (QIAGEN) according to the manufacturer’s 
instruction.  
 
2.2.5.5 Restriction endonuclease digestion 
The restriction endonuclease digestions were performed with restriction enzymes purchased 
from New England Biolabs, Beverly, MA. Generally, 1 μg DNA was added into the 1× 
appropriate reaction buffer with or without BSA, dH2O to 20 μl final volume and 1 μl of 
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restriction enzyme(s). The digestion reaction was incubated at optimum temperature (usually 
37˚C) for 1 – 2 h to achieve complete digestion.  
 
2.2.5.6 Dephosphorylation DNA ends 
To prevent the self ligation of vector DNA with similar overhang end or blunt end, phosphate 
group at the DNA ends was removed using Antarctic phosphatase (New England Biolabs) 
where 1 μg of digested DNA was added into 1× reaction buffer containing 1 μl of Antarctic 
phospatase and dH2O to final volume of 10 μl. The reaction was incubated at 37˚C for 15 min 
(for sticky ends) or 60 min (for blunt end) before the enzyme could be inactivated at 65˚C for 
5 min. The vector DNA was ready for ligation reaction after the heat inactivation step.  
 
2.2.5.7 Phosphorylation of DNA ends 
PCR reaction generated a DNA fragment lacking the phosphate group at DNA ends. To add 
the phosphate group to the DNA ends so that the DNA fragment could be ligated to the 
vector, T4 polynucleotide kinase (New England Biolabs) was used where 1 μg of digested 
DNA was added into 1× reaction buffer containing 1 mM ATP, 10 units of T4 polynucleotide 
kinase and dH2O to final volume of 50 μl. The reaction was incubated at 37˚C for 30 min. 
 
2.2.5.8 Blunting the DNA ends 
The sticky end of DNA ends was blunted by using the DNA polymerase I, Large (Klenow) 
Fragment (New England Biolabs) where 1 μg of digested DNA with sticky end was added 
into 1× EcoPol reaction buffer containing 33 μM of each dNTP, 1 unit of Klenow and dH2O 
to final volume of 20 μl. The reaction was incubated at 25˚C for 15 min before the enzyme 
could be inactivated by adding EDTA to a final concentration of 10 mM and incubated at 
75˚C for 20 min. 
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2.2.5.9 Ligation reaction 
The ligation reaction was carried out in a vector over insert ratio of 1:1 to 1:3 using the T4 
DNA ligase (New England Biolabs). For example, 50 ng of digested vector DNA was added 
with 1 to 3 molar excess of insert DNA fragment into 1× ligase reaction buffer containing 1 μl 
of ligase and dH2O to final volume of 10 μl. The reaction was incubated at r.t. for 10 min (for 
sticky ends) or 2 h (for blunt end). The ligated plasmid was then placed on ice or stored in -
20˚C until use.  
 
2.2.5.10 Transformation of ligated plamid into bacteria cells 
The competent bacteria, TOP 10 (Life Technologies), were thawed on ice. 2 μl of ligated 
plasmid was further diluted with 15 μl of sterile dH2O and added into the 50 μl of competent 
cells. The tube was gently taped before kept on ice for 30 min. The cells were then heat 
shocked at 42˚C for exactly 30 s and immediately placed on ice for 1 min before addition of 
250 μl of SOB broth. The bacteria were then incubated at 37˚C with 225 rpm agitation speed 
for 1 h. Next, the bacteria were spread on 37˚C pre-warm LB agar plate with appropriate 
antibiotic depending on the resistant gene on the transformed plasmid. This was followed by 
overnight incubation at 37˚C incubator. After the incubation, the positive clones were picked 
and screened.  
 
2.2.5.11 Generation of HSV-1 amplicon plasmid constructs 
The parental pHGCX (Figure 2a) plasmid was kindly provided by Chiocca EA, Ohio State 
University Medical Center, OH, USA. To construct the pHGCX-Luc (Figure 2b), firefly 
luciferase gene (Luc) was excised out from GalCycA plasmid (kindly provided by Müller R, 
Institute of Molecular Biology and Tumor Research, Marburg, Germany) (Nettelbeck et al., 
1999) using the HindIII and XbaI and subcloned into the parental pHGCX. Subsequently, the 
CMV promoter from pHGCX-Luc was removed using the BglII and NheI, blunt ended and 
self ligated to generate pHGX-Luc (Figure 2c). The pApoE/hAAT-Luc (Figure 2d) was 
constructed by HindIII digestion of pApoE/hAAT-CC-Luc (see Figure 2h) to release the 
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cassette from Gal4 DNA binding domain to minimal cyclin A promoter. The digested product 
was blunt ended and self ligated to generate pApoE/hAAT-Luc with 4 copies ApoE enhancer 
(650 bp) and hAAT promoter (1,551 bp) that drive the expression of luciferase gene. The 
pAFP/AFP-Luc (Figure 2e) was generated by releasing the human AFP enhancer (1,854 bp) 
and human AFP promoter region (287 bp) derived from pDRIVE-AFP-hAFP (Invivogen) 
using PstI and NotI restriction enzyme sites. This fragment was blunt ended and ligated into 
the promoterless pHGX-Luc fragment to generate the recombinant construct. Similar strategy 
was used to construct pSV40/Alb-Luc (Figure 2f) containing the SV40 enhancer (235 bp) 
and human albumin promoter (213 bp) from pDRIVE-SV40-hAlb (Invivogen). For 
construction of the pIH8GalLuc plasmids (Figure 2g), the 8GalLuc DNA fragment 
(containing 8× Gal binding sites, minimal cyclin A promoter and firefly luciferase gene) was 
released from GalCycA plasmid and subcloned into the NheI and BamHI restriction enzyme 
sites of pHGCX. The preexisting CMV promoter in pHGCX was subsequently removed by 
SpeI and NheI to generate pIH8GalLuc plasmid. To construct the pApoE/hAAT-CC-Luc 
plasmid (Figure 2h), the hAAT promoter (1,551 bp) was first removed using KpnI site from 
pBS-hAAT-bpA (Van Linthout et al., 2002a; Van Linthout et al., 2002b) and subcloned into 
pHGX-9 plasmid, using the same restriction enzyme site, to generate pHGX-hAAT. Plasmid 
pHGX-9 is similar to its parental vector, pHGCX with the exception that the CMV promoter 
was excised. Four copies of the human ApoE enhancer (650 bp), derived from the previously 
reported parental pUC19 construct (De Geest et al., 2000), were excised with EcoRI and 
HindIII. The fragment was blunt-ended and ligated into pHGX-hAAT to generate pHGX-
ApoE/hAAT. Finally, by using PmeI, the DNA fragment consisting of the Gal4/NF-YA and 
the 8GalLuc cassette was removed from pC8-36 amplicon plasmid (Ho et al., 2004) and 
subcloned into the pHGX-ApoE/hAAT to generate pApoE/hAAT-CC-Luc plasmid. For the 
construction of pHGCX-L2C (Figure 2i), pMGMT-2A-yCD containing in-frame fusion of 
FMDV 2A sequence and yeast cytosine deaminase (yCD) gene was first generated by 
releasing the 1.2 kb MGMT-2A fragment from MGMT-2A-GFP (Chinnasamy et al., 2006) 
(8.1 kb) using the EcoRI restriction enzyme. The MGMT-2A fragment was then treated with 
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mung bean nuclease and subcloned into the nuclease treated, linearized, NcoI digested pORF-
Fcy (which contained the yCD gene; Invivogen) to generate pMGMT-2A-yCD. This was 
followed by in-frame fusion of firefly luciferase (Luc) gene and 2A-yCD where Luc gene was 
first extracted by PCR from pHGCX-Luc without a stop codon, using a forward primer 
introducing an XhoI cut site (5’-CTCGAGCCACCATGGAAGACG-3’) and the reverse 
primer (5’-CACGGCGATCTTTCCGCCCTTC-3’). The 1.7 kb PCR product was then 
purified using the QIAquick PCR Purification Kit (QIAGEN) and subjected to T4 
polynucleotide kinase treatment before being blunt end ligated with mung bean nuclease and 
a calf intestinal alkaline phosphatase (CIAP) treated 2.9 kb 2A-yCD fragment, released from 
pMGMT-2A-yCD (4.9 kb) using the XhoI restriction enzyme, to generate the pLuc2ACD 
vector. The 2.2 kb bicistronic cassette containing Luc-2A-yCD (L2C) in pLuc2ACD was 
released using the XhoI and NheI cut sites and subcloned into pHGCX using the XhoI and 
XbaI sites (which produce ends compatible with NheI) to generate pHGCX-L2C. To generate 
pAH-6CC-L2C (Figure 2j) HSV-1 amplicon plasmid, 6CC promoter was first PCR from 
pC8-6CC-Luc plasmid (Wang et al., 2007) using the forward primer (5’- 
CTGTCCTCCGTCTAGAATAGTCGCGGGATAC-3') and reverse primer (5’-
GATATAGAATTCAGACCACGCAGGGCCGAGG-3') with introduction of XbaI and 
EcoRI sites. The PCR product of 6CC was then used to replace the minimal cyclin A 
promoter of pApoE/hAAT-CC-Luc using the same restriction sites to generate pApoE/hAAT-
6CC-Luc. Finally, Luc-2A-yCD (L2C) cassette was released from the pHGCX-L2C construct 
and swapped with Luc gene in pApoE/hAAT-6CC-Luc using the NotI and PacI restriction 
site to generate pApoE/hAAT-6CC-L2C. This construct was later renamed as pAH-6CC-
L2C. Similar strategies were used to construct the pAH-CC-L2C (Figure 2k). In the 
construction of pAH-L2C (Figure 2l), pAH-6CC-L2C was first digested with HindIII and 
EcoRI to remove all the cell cycle regulation elements from Gal4/NF-YA gene to 8× Gal 
binding site and 6CC promoter. The fragment generated was allowed to self-ligate after blunt-
ended with DNA polymerase I, Large (Klenow) Fragment (New England Biolabs) to generate 
pAH-L2C. To generate pHCAG-Luc construct (Figure 2m), the CMV promoter of pHGCX-
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Luc was replaced by the cytomegalovirus early enhancer/chicken β-actin promoter/rabbit β-
globin intron (CAG) hybrid promoter via the BglII and XbaI sites. CAG promoter was 
obtained from pZCAG-Cre. The pZCAG-Cre was pSecTag2A vector (Life Technologies) 
based where the CAG-Cre fragment from pCAGGS-Cre plasmid (kindly provided by 
Sabapathy K, National Cancer Centre, Singapore) was swapped with the CMV promoter in 
the pSecTag2A using the SpeI and EcoRI sites. To generate pHCAG-L2EOP construct 
(Figure 2n), Luc gene was first fused in-frame with FMDV 2A sequence and ΔEBNA-1 gene 
with oriP. The DNA fragments containing ΔEBNA-1/oriP elements were first PCR from 
pREP7 (Life Technologies) with forward primer (5’-ATCATGTCTGACGAGGGGC-3’) and 
reverse primer (5’-CTAGCTAGCCCTTTATGTGTAACTCTT-3’; incorporated with the 
NheI site). After amplification, the PCR products were treated with T4 polynucleotide kinase 
following NheI digest. The DNA fragments, which contained the ΔEBNA-1/oriP elements, 
were cleaned up using the QIAquick PCR Purification Kit (QIAGEN) before subcloning into 
the SmaI (blunt end) and NheI sites of the recipient plasmid, pLuc2ACD. Using this cloning 
strategy, the yeast cytosine deaminase gene was replaced by the ΔEBNA-1/oriP DNA 
fragment, resulting in a recombinant plasmid contained in-frame fusion of Luc, FMDV 2A 
and ΔEBNA-1/oriP. The construct was denoted as pL2EOP. Next, the bicistronic cassette 
containing the Luc2AΔEBNA-1/oriP was released from the shuttle vector pL2EOP using 
XhoI and PacI restriction enzymes and gel purified. This fragment was inserted into the 
respective sites of pHCAG to generate pHCAG-L2EOP. All recombinant plasmids were 
amplified in OneShot TOP10 (Life Technologies) competent cells and verified via restriction 
enzyme mapping analysis and DNA sequencing (AIT Biotech, Singapore). All enzymes were 
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Figure 2 Schematic representation of the HSV-1 amplicon viral vector constructs. (a) 
pHGCX was a basic HSV-1 amplicon plasmid. (b) pHGCX-Luc contained Luc reporter gene 
regulated by the CMV promoter. (c) pHGX-Luc was a promoterless backbone vector that 
served as the negative control. (d) pApoE/hAAT-Luc contained 4× ApoE enhancer inserted 
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upstream hAAT promoter. (e) pAFP/AFP-Luc contained human AFP enhancer with the 
human AFP promoter. (f) pSV40/Alb-Luc contained the SV40 enhancer inserted upstream of 
the human albumin promoter. (g) pIH8GalLuc contained the reporter module (8GalLuc) but 
lacking the activator module. (h) pApoE/hAAT-CC-Luc contained both the activator module 
(Gal4/NF-YA) regulated by 4×ApoE/hAAT promoter and the reporter module (8GalLuc). (i) 
pHGCX-L2C contained the CMV promoter that drove the bicistronic expression of 
luciferase-FMDV 2A- yeast cytosine deaminase (Luc2ACD). (j) pAH-6CC-L2C contained 
the activator module (Gal4/NF-YA) regulated by 4×ApoE/hAAT promoter and the reporter 
module similar to 8GalLuc except minimal cyclin A promoter and Luc reporter gene were 
swapped with 6CC promoter (i.e., minimal cyclin A promoter with 6 tandem repeat of cell 
cycle-dependent element [CDE]/cell cycle homology element [CHR] region) and Luc2ACD, 
respectively. (k) pAH-CC-L2C was similar with pAH-6CC-L2C except the minimal cyclin A 
promoter only contained a CDE/CHR region. (l) pAH-L2C contained 4×ApoE/hAAT 
promoter that drove the bicistronic expression of Luc2ACD. (m) pHCAG-Luc contains the 
Luc reporter gene regulated by CAG promoter. (n) pHCAG-L2EOP contained the CAG 
promoter that drove the bicistronic expression of Luc and ΔEBNA-1 mediated by FMDV 2A. 
The plasmid also contained EBV oriP. Other common elements in the construct included 
ampR, ampicillin resistance gene; bGHp(A), bovine growth hormone poly-adenylation signal; 
eGFP, enhanced green fluorescent protein; oriS, HSV origin of replication; p(A), SV40 poly-
adenylation signal; pac, HSV-1 packaging signal; and IE4/5p, HSV-1 immediate early gene 
4/5 promoter. See Table A.2 for list of purposes of various HSV-1 amplicon viral vectors 
constructs (in Appendix III). 
 
 
2.2.6 Techniques involving animals 
All animal experiments were performed according to the guidelines and protocols approved 
by the SingHealth Institutional Animal Care and Use Committee, Singapore. 
 
2.2.6.1 Establishment of subcutaneous (s.c.) HCC tumor model 
A total of 1 × 107 HCC tumor cells were first resuspended in 100 μl of PBS containing 50% 
of BD Matrigel matrix (BD biosciences). Next, the tumor cells were subcutaneously injected 
into left or right flank of 6 – 8 weeks old SCID or BALB/c nude mice using 1 ml syringe 
connected with a 27G needle. Tumor volumes were then quantified with calipers, using the 




2.2.6.2 Establishment of liver orthotopic HCC tumor model 
After subcutaneous tumor size was about 1000 mm3, the tumor was harvested and cut into 1 – 
2 mm3 tumor cubes for orthotopic implant into the left lateral liver lobe of 6 weeks old female 
SCID or BALB/c nude mice using 8-0 absorbable suture (Johnson & Johnson, St-Stevens-
Woluwe, Belgium). Alternatively, the orthotopic HCC tumor could be established by 
subcapsular injection of 5 × 106 cells in 20 µl of PBS into the left lateral liver lobe of the 
female SCID mice using a 27G needle. 
 
2.2.6.3 Establishment of primary human HCC 26-1004 and RCC 09-1210C tumor 
xenograft 
HCC 26-1004 or RCC 09-1210C tumors were derived, with informed consent, from patients 
undergoing liver resectioning and histology analysis with confirmed diagnoses of HCC or 
RCC, respectively. This study has received the approval from National Cancer Center 
Institution Review Board. For the establishment of HCC 26-1004 or RCC 09-1210C in SCID 
mice, freshly sectioned primary tumor tissues were first placed in RPMI 1640 in an ice bath 
immediately after tumor sectioning. Thin slices of tumor were then weighed, diced into 2 – 3 
mm3 pieces and washed 3 times with RPMI 1640 medium. They were minced finely to pass 
through an 18G needle. The tissue fragments obtained were then mixed with Matrigel 
(Collaborative Research, Bedford, MA) at 1:1 (v/v) to give a total volume of 0.2 ml per 
injection. The tissue mixture was then subcutaneously injected into the right flank of 8 weeks 
old male immunodeficient SCID mice (Animal Resource Centre). 
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2.2.6.4 Small animal non-invasive imaging – luciferase imaging 
Mice were subjected to non-invasive bioluminescence imaging using the Xenogen IVIS 
Lumina (Caliper Life Sciences, Hopkinton, MA) system. For all bioluminescence imaging, 
mice were first intraperitoneally (i.p.) injected with 0.17 mg/g body weight D-luciferin 
(Caliper Life Sciences) in PBS. Five minutes later, mice were anesthetized with 
ketamine/xylazine (120/10 mg/kg) and kept warm on a 37°C isothermal pad. After 20 min 
post i.p. injection of D-luciferin, bioluminescence images were acquired at 10 min of 
exposure time, binning at 4 and f/stop at 1. Images analysis and bioluminescence signal 
quantifications were performed using Living Image® software version 3.0 (Caliper Life 
Sciences). Regions of interest (ROI) were defined by drawing a circle depending on the size 
of tumor. Background photon flux was defined from an ROI drawn over the regions on mice 
where no vector had been administered.  
 
2.2.6.5 Small animal non-invasive imaging – red fluorescence protein imaging  
Mice were subjected to non-invasive red fluorescence protein (RFP) imaging using the 
Xenogen IVIS Lumina (Caliper Life Sciences) system. Mice harboring the DsRed2 tumors 
were first anesthetized with ketamine/xylazine (120/10 mg/kg). After the mice were knocked 
out, the RFP images were acquired at 30 s of exposure time, binning at 1 and f/stop at 4. 
Images analysis and RFP signal quantifications were performed using Living Image® 
software version 3.0 (Caliper Life Sciences). ROI were defined by drawing a circle depending 
on the size of tumor. Background RFP signal efficiency was defined from an ROI drawn over 








2.2.6.6 Partial hepatectomy (PHx) 
Female BALB/c mice (6 – 8 weeks old) were anesthetized with an i.p. injection of 
ketamine/xylazine (120/10 mg/kg), followed by the removal of 70% of the liver tissues as 
described by Higgins and Anderson (Higgins and Anderson, 1931). Forty-eight hours post-
PHx, 1 × 106 TU of viruses were administered via the tail vein. Regenerated liver tissues, as 
well as normal liver tissues from sham-operated groups were subsequently removed and 
assayed for luciferase activities. 
 
2.2.6.7 General treatment procedures of tumors with viral vectors 
After 4 – 5 days of tumors implantation, 1.5 – 3.0 × 106 TU of viral vectors in 100 µl HBSS 
were intratumorally injected. For systemic delivery, the viral vectors were intrasplenic 
injected at 3 × 106 TU in 100 µL of HBSS. This was followed by intraperitoneal injection of 
5-FC at 500 – 1000 mg/kg dose, twice a day. At various designated time points, subcutaneous 
tumor volumes were quantified with calipers, using the formula V (volume) = π/6 × [L × 
(W)2], where L is length and W is width. At the same time point, mice were subjected to non-
invasive bioluminescence imaging using the Xenogen IVIS Lumina (Caliper Life Sciences) 
system. All images analysis and bioluminescence signal quantifications were performed using 
Living Image® software version 3.0 (Caliper Life Sciences). ROIs were defined. Background 
photon flux was defined from an ROI drawn over the regions on mice where no vector had 
been administered. In vivo viral vector transduction in spleen (site of injection) and liver were 
observed with eGFP positive regions in these organs using the SMZ 1500 stereoscopic zoom 
fluorescence microscope (Nikon). 
 
2.2.7 Statistically analysis 
Data are presented throughout this thesis as means ± standard error of the mean (SEM). 
Statistical significance was determined using Microsoft Excel (Microsoft, Redmond, WA) by 
an unpaired Student’s t-test, and values of P<0.05 were considered statistically significant and 
















Development of liver-specific and cell cycle-dependent HSV-1 amplicon viral vector 
  67
 
Clinical advances in cancer research are slow to materialize because the therapeutic efficacy 
needs to be balanced against potential toxicity in normal tissues. In this respect, viral-based 
approaches have made great advances since its early setback as better knowledge has been 
gained into the biology behind each vector system and the various signaling pathways that are 
activated or silenced in the host cancer cells. In the present chapter, active proliferation 
feature of the tumor cells is exploited as a “regulator” to turn on the specific transgene 
expression only in vector transduced HCC with endogenous cellular promoters such as liver-
specific promoter and cell cycle-dependent promoter. The specific aims are summarized as 
below: 
 
1. To assess the optimal tissue-specific promoters in HCC cell lines in vitro.  
2. The construction and characterization of cell type-specific and cell cycle-dependent 
HSV-1 amplicon viral vectors.  
3. To evaluate the potential liver toxicity of the HSV-1 amplicon viral vectors. 
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3.1 The analysis of different promoter systems for efficient transgene expression in HCC 
In an attempt to identify the optimal tissue-specific promoter that could confer the highest 
transgene expression and yet retains its specificity in HCC cells, commonly used liver-
specific promoters, i.e., the hybrid hAAT promoter containing 4 copies of ApoE enhancer 
(Van Linthout et al., 2002a) and the human albumin promoter containing SV40 enhancer 
(Kuriyama et al., 1997) as well as a HCC tumor-specific human AFP promoter containing 
AFP enhancer (He et al., 2000) were constructed into the same basic HSV-1 amplicon 
plasmid backbone vector (pHGCX; Figure 2a). These constructs were denoted as 
pApoE/hAAT-Luc (Figure 2d), pSV40/Alb-Luc (Figure 2f) and pAFP/AFP-Luc (Figure 
2e), respectively. To serve as negative control, a promoterless vector in the same backbone 
denoted as pHGX-Luc (Figure 2c) was also constructed. 
 
Luciferase reporter activities mediated by pApoE/hAAT-Luc were observed to be highest in 
human HCC cell lines, followed by pSV40/Alb-Luc and pAFP/AFP-Luc amplicon plasmids 
(Figure 3.1). In contrast, non-HCC cell lines (A549, CNE2, Gli36, HeLa) and human 
immortalized normal liver cell line (THLE-3) exhibited low level of luciferase reporter 
activities. Low expression of luciferase reporter gene in THLE-3 normal liver cells with 
various liver-specific promoters were probably attributed by overexpression of AFP (Gorog et 
al., 2005), Albumin (Ohguchi et al., 1998) and hAAT (Qin et al., 2013) in HCC when 
compared to immortalized normal liver cells. Although AFP/AFP promoter exhibited 
specificity, the overall luciferase reporter activities were low. For SV40/Alb promoter, the 
promoter not only suffered from low gene expression level in HCC when compared to 
4×ApoE/hAAT promoter, it also showed high leakiness of gene expression in non-HCC cells 









































Figure 3.1 Liver-specific promoters activities in a range of different human cell lines. 
Luciferase expression in HCC, non-HCC and normal liver cell lines were determined after 48 
h post transfection with pApoE/hAAT-Luc (closed bars), pAFP/AFP-Luc (horizontal line 
bars), pSV40/Alb-Luc (crossed line bars) and pHGX-Luc (open bars). Data are presented as 
mean ± SEM, n = 3. 
 
 
Since high level of gene expression was an important characteristic for gene therapy vectors 
in expressing transgene at clinical therapeutic level (Bouard et al., 2009), 4×ApoE/hAAT 
promoter was selected as choice of promoter in this thesis to confer liver-specific gene 
expression in the rest of the studies. Furthermore, various studies have confirmed that (1) 
hAAT promoter conferred higher gene expression levels with better stability than other liver-
specific promoters in mouse liver (as summarized in Table A.3 in Appendix III) and (2) 
multiple copies of ApoE enhancers consistently increased the gene expression level of various 
promoters (as summarized in Table A.4 in Appendix III) further convinced the use of  






3.2 Generation of a liver-specific and cell cycle regulatable HSV-1 amplicon viral 
vectors, ApoE/hAAT-CC-Luc 
Based on these results, the hybrid 4×ApoE/hAAT promoter was employed to regulate the 
transcriptional activities of Gal4/NF-YA fusion gene in an attempt to target the transcriptional 
activities specifically to HCC cells. The new recombinant vector was denoted as 
pApoE/hAAT-CC-Luc (Figure 2h). The functionality of these vectors to the proliferation 
status of the host cells was subsequently confirmed. Luciferase reporter activities in 
proliferating HCC cells (HuH-7 and PLC/PRF/5) were observed to be significantly higher 
than the corresponding G1-arrested cells (Figure 3.2a). In contrast, background level with no 
significant difference between the proliferating and corresponding G1-arrested cells was 
observed in non-HCC cells (Gli36 and HeLa). Immunoblot analysis performed on the 
representative HuH-7 cells showed a significantly higher level of endogenous cyclin A 
protein expression in proliferating cells when compared with the corresponding G1-arrested 
cells (Figure 3.2b), providing additional support to the cell cycle status of these two cell 
populations. To confirm that the ApoE/hAAT-CC-Luc could confer luciferase expression in a 
cell cycle-dependent at a single cell level, confocal microscopic study was performed. HuH-7 
cells infected by ApoE/hAAT-CC-Luc (MOI = 1.0) for 6 h, were fed in either standard tissue 
culture medium or in the presence of lovastatin to induce G1-arrest. Similar transduction 
efficiency in both the proliferating and G1-arrested cells population (~20%) was observed by 
FACS analysis (Figure 3.2c). The proliferating status was also confirmed by IHC staining 
against endogenous cyclin A proteins. Confocal microscopy studies demonstrated that 
ApoE/hAAT-CC-Luc transduced HuH-7 cells, as shown by the presence of exogenous eGFP 
expression, were positively stained for luciferase (blue). In contrast, luciferase expression was 
minimal or not detectable in G1-arrested cell populations. Thus, these results demonstrated 
that the ApoE/hAAT-CC-Luc confer transcriptional activities in a cell cycle- and cell type- 









Figure 3.2 Cell cycle-dependent transgene expression mediated by ApoE/hAAT-CC-Luc. (a) 
Cell cycle-regulated luciferase reporter activities mediated by pApoE/hAAT-CC-Luc 
amplicon plasmid transfected in proliferating (closed bars) and G1-arrested (open bars) cell 
populations of HuH-7, PLC/PRF/5, Gli36 and HeLa cells. Luciferase activities were assayed 
after 48 h post transfection. Data are presented as mean ± SEM, n = 3. (b) Western blot 
analysis on cyclin A expression in proliferating and G1-arrested HuH-7 cells. Cell free extract 
from A-431 was used as positive control whereas β-tubulin was used as an internal control. 
(c) Transgene expression mediated by ApoE/hAAT-CC-Luc in proliferating versus G1-
arrested HuH-7 cells. FACS analysis on transduction efficiencies (row 1), ICC analysis of 
endogenous cyclin A expression level (row 2), infectivity of ApoE/hAAT-CC-Luc amplicon 
viral vectors (row 3) and IF analysis of luciferase gene expression (row 4) on proliferating 







































































3.3 The assessment of liver-specific and proliferation-dependent transgene expression 
mediated by ApoE/hAAT-CC-Luc amplicon viral vectors in a HCC versus non-HCC 
tumor xenografts model in mice 
To confirm the cell type-specificity of luciferase activities conferred by ApoE/hAAT-CC-Luc 
in vivo, similar number of HCC (HuH-7) and non-HCC (HeLa) cells were implanted on left 
and right flanks of the same mouse, respectively. When the tumors reached similar size, the 
animals were injected intratumorally with 1 × 106 TU of ApoE/hAAT-CC-Luc. As shown in 
Figure 3.3a, HuH-7 tumors injected with ApoE/hAAT-CC-Luc conferred the strongest 
luciferase signals. The ratio of luciferase activities measured in photons per second was ~13-
fold higher in HuH-7 mouse in comparison to HeLa tumors. To confirm that the differential 
transgene expression is not a result of tissue depth variation between the reporter gene 
activities and the CCD detector, the tumors were removed and lysed for luciferase activities 
measurement. Results obtained showed that luciferase reporter activities were consistent, i.e., 
13-fold higher in HuH-7 when compared with HeLa tumors in mice injected with 
ApoE/hAAT-CC-Luc (Figure 3.3b). Taken together, these data confirmed that transgene 
expression conferred by ApoE/hAAT-CC-Luc is HCC cell type-specific. 
 
 
Figure 3.3 Non-invasive luciferase imaging of transcriptional activities mediated by 
ApoE/hAAT-CC-Luc in HCC versus non-HCC tumors. (a) ApoE/hAAT-CC-Luc (1 × 106 
TU) was intratumorly injected into the subcutaneous HeLa and HuH-7 tumors in SCID mice. 
The expression of luciferase activities were measured after 24 h post-viral injections using 
non-invasive imaging system. (b) Corresponding luciferase activities in HeLa and HuH-7 
tumor lysates harvested from mice as measured using luciferase enzymatic assays. Data are 
presented as mean ± SEM, n = 5. 
 
 Flux = 296 Ph/s  






















3.4 The assessment of cell cycle-dependent transgene expression mediated by 
ApoE/hAAT-CC-Luc amplicon viral vectors in a partial hepatectomy mouse model 
The liver is an excellent tissue for the study of growth regulation because of its potent 
regeneration capacity by a process of compensatory growth following surgical resection or 
toxic injury. Thus, the normal liver regeneration following partial hepatectomy was chosen as 
an animal model to study cell cycle-dependent regulation of transgene expression conferred 
by ApoE/hAAT-CC-Luc in vivo. 
 
Female BALB/c mice were separated into two experimental groups: the group that underwent 
PHx and the sham-operated. Following PHx, the resected liver lobes were weighed 
immediately. The kinetics of liver regeneration was monitored closely and the peak of the 
regeneration process was noted to occur at day 2 following PHx (Figure 3.4a). Similar 
finding was also observed by Noguchi and colleagues where a sharp peak of DNA synthesis 
was observed at 48 h in mice after partial hepatectomy (Noguchi et al., 1991).  Flow 
cytometry analysis confirmed that the percentage of S-phase cells in actively proliferating 
cells has increased markedly from 12.25% in the sham-operated group to 36.42% in the PHx 
group (Figure 3.4b). On day 2 post-PHx, both the PHx and sham-operated mice (n = 5 per 
group) were injected, via tail vein, with 1 × 106 TU of either ApoE/hAAT-CC-Luc or 
IH8GalLuc (Figure 2g) viral vectors. After 24 h, the mice were sacrificed and luciferase 
activities in the liver tissues were assayed. In mice injected with ApoE/hAAT-CC-Luc, 
luciferase activities were ~7.7-fold higher in the PHx liver than sham-operated (P=0.019) 
(Figure 3.4c). In contrast, control viral vectors (IH8GalLuc) lacking the cell cycle regulatory 
elements failed to induce significant level of luciferase activities in PHx mice in comparison 
to sham-operated group.  
 
To further confirm that the observed increase in transcriptional activities is restricted to 
actively dividing liver cells and not other proliferating cells, the biodistribution of luciferase 
activities was analyzed in other organs. The results showed that the ratio of cell cycle 
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regulation, as measured by luciferase activities in PHx compared to non-PHx mice, was 
augmented by 11-fold in the livers of mice injected with ApoE/hAAT-CC-Luc. In contrast, 
other organs exhibited 2-fold or less of cell cycle regulation, which were consistent to that 
observed by the negative controls in vitro. These data demonstrated that luciferase expression 
conferred by the viral vector ApoE/hAAT-CC-Luc is targeted to actively proliferating 
hepatocytes during liver regeneration. 
 
 
Figure 3.4 Cell cycle-controlled expressions mediated by ApoE/hAAT-CC-Luc in the mouse 
liver regeneration model. (a) Liver regeneration kinetics in BALB/c mice. At each time point, 
the regenerated livers from mice undergoing PHx were removed and weighed. The 
regenerated liver mass was expressed as a percentage when compared to livers obtained from 
similar region of control mice sacrificed at the same time point. (b) Flow cytometry analysis 
on cell cycle profiles of liver cells in sham-operated and PHx mice. (c) In vivo luciferase 
activities in various organs mediated by ApoE/hAAT-CC-Luc for PHx mice. Sham-operated 
and PHx mice were injected with similar viral dosages (1 × 106 TU) via tail vein. pIH8GalLuc 
was used to served as negative control (shaded bars) and ApoE/hAAT-CC-Luc (closed bars). 
Luciferase activities from various organs from all groups were analyzed 24 h post viral 
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G0/G1 : 87.18% ± 1.21%           
S        : 12.25% ±  1.75%  
G2/M  : 0.57% ±  0.55% 
G0/G1: 60.35% ±  0.79%      
S        : 36.42% ±  0.78%  
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3.5 The serum activities of hepatic enzymes after systemic administration of 
ApoE/hAAT-CC-Luc amplicon viral vector 
To examine the cytotoxic effect of ApoE/hAAT-CC-Luc viral vector in vivo, the levels of 
hepatic transaminases (alanine aminotransferase, ALT, and aspartate aminotransferase, AST) 
were analyzed in immunocompetent BALB/c mice (n = 5 per group) receiving 1 × 106 TU of 
ApoE/hAAT-CC-Luc amplicon viral vectors via tail vein injection. Mice injected with either 
HBSS or hrR3 (replication-competent HSV-1 viruses) were used as negative and positive 
controls, respectively. No significant levels of elevated transaminases were observed in mice 
injected with ApoE/hAAT-CC-Luc compared with HBSS (Figures 3.5a,b). In contrast, 
elevated hepatic transaminases activities were noted in mice injected with the hrR3 helper 
viruses at day 1 post-viral injection, which returned to near normal levels over the subsequent 
days. These data suggested that the regulatory elements employed in the context of HSV-1 
















































































Figure 3.5 Potential liver cytotoxicity induced by ApoE/hAAT-CC-Luc in BALB/c mice. (a) 
ALT and (b) AST assays at day 1 (closed bars), 3 (hatched bars) and 7 (open bars) post 
injection with 1 × 106 TU of ApoE/hAAT-CC-Luc via tail vein. HBSS was used as negative 
control whereas similar dose of hrR3 was used as positive control. Data are presented as mean 
± SEM, n = 5. N.S., P>0.05. 
 
Summary of findings in this chapter 
In summary, the transcriptional activation of transgene expression in association with the 
onset of cellular proliferation was demonstrated for the first time by using the mouse partial 
hepatectomy model. Taken together, these results demonstrated the promise of using 
transcriptionally regulated HSV amplicon viral vectors as a means of targeting proliferating 
HCC cells. 
P<0.005 P<0.001 

















Strategy for in vivo non-invasive imaging of therapeutic gene expression  
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Multiple doses of p53 expressing recombinant adenovirus (rAd-p53) via hepatic arterial  
injection with 5-fluorouracil (5-FU) after TACE (transcatheter arterial chemoembolization) 
have been shown to prolong the overall survival of patients with non-resectable HCC when 
compared to TACE alone in a pilot phase II study (Tian et al., 2009). However, it is unclear 
whether the improvement of overall survival was contributed by expression of p53 delivered 
via multiple injection doses of rAd-p53 or the effect from 5-FU chemotherapeutics drugs per 
se since there was no system to monitor the kinetics of viral vector in real-time.  
 
Additionally, many of the vector-based clinical trials only rely on the crude assessment of 
patient survival data as an indirect correlation to the possible functionality of the viruses. 
Therefore, the exact role and functionality of the vector in the progress to treat the cancer 
patients have yet to be fully understood.  
 
In this chapter, the aim was to monitor the viral kinetics and therapeutic gene expression 
using non-invasive imaging system in an attempt to understand the functionality of viruses in 
a tumor microenvironment in pre-clinical animal models to complete the missing knowledge 
of viral therapy in clinical trials. The specific aims include:- 
 
1. Construction and characterization of a bicistronic expression of yCD suicide gene and 
luciferase reporter gene in the context of HSV-1 amplicon viral vector (denoted as 
HGCX-L2C) 
2. To evaluate the therapeutic efficacy mediated by HGCX-L2C in HCC patient-derived 




4.1 Bicistronic expression of luciferase reporter gene and yeast cytosine deaminase in a 
basic HSV-1 amplicon viral vector, HGCX-L2C 
In order to monitor the therapeutic gene expression in vivo, the firefly luciferase reporter gene 
(Luc) was cloned in-frame with the yeast cytosine deaminase gene (yCD) via a sequence 
encoding for foot-and-mouth disease virus 2A autoprotease (FMDV 2A) to generate Luc-2A-
yCD (L2C) cassette in pHGCX-L2C (Figure 2i). This 20 amino acid FMDV 2A sequence has 
been reported to mediate self-processing through a proposed ribosomal-skip mechanism, 
resulting in two protein products of similar amount (Donnelly et al., 2001; Szymczak et al., 
2004).  
 
The functional expression of proteins conferred by pHGCX-L2C in vitro was first examined. 
Human hepatocellular carcinoma cells, PLC/PRF/5 cells, were transfected with the pHGCX-
L2C plasmids and control plasmid pHGCX (Figure 2a) or pHGCX-Luc (Figure 2b). Cell 
lysates were then harvested after 24 h post-transfection and analyzed using western blot 
analysis. The results showed that the expression of cells transfected with pHGCX-L2C were 
able to express both Luc and yCD proteins in separate proteins at different molecular weight 
at 62 kDa and 17 kDa, respectively (Figure 4.1). Cells expressing yCD were also successfully 
detected using ICC using the anti-yCD antibody in PLC/PRF/5 cells transfected with 
pHGCX-L2C but not pHGCX-Luc (Figure 4.2). 
 
 
Figure 4.1 Bicistronic expressions of Luc and yCD genes mediated by the FMDV 2A peptide 
in the context of a HSV-1 amplicon plasmid. Western blot analysis showed expression of Luc 
(62 kDa) and yCD (17 kDa) in PLC/PRF/5 cells after 24 h post-transfected with pHGCX, 
pHGCX-Luc or pHGCX-L2C. Actin (42 kDa) was used as loading control. 
pHGCX pHGCX-Luc pHGCX-L2C 
Luc (62 kDa) 
yCD (17 kDa) 





Figure 4.2 Immunocytochemistry (ICC) analysis on yCD expression by PLC/PRF/5 cells 
transfected with pHGCX-Luc or pHGCX-L2C. Black arrow indicated the cells that 
expressing yCD. Magnification is 400×. 
 
Next, the stability of proteins conferred by pHGCX-L2C in vitro was examined. PLC/PRF/5 
cells were first transfected with the pHGCX-L2C plasmids. Cell lysates were then harvested 
at various time points post-transfection. The results showed that the expression of Luc 
proteins correlated with those of yCD proteins. However, luciferase proteins diminished faster 
in comparison to yCD proteins (Figure 4.3). 
 
Figure 4.3 Correlation of bicistronic expression of Luc reporter gene and yCD prodrug 
activated suicide genes expression mediated by the FMDV 2A peptide. Western blot analysis 
showed stability of expression of Luc (62 kDa) and yCD (17 kDa) in PLC/PRF/5 cells 
transfected with pHGCX-L2C at days 1, 3, 5 and 7. Actin (42 kDa) was used as loading 
control.  
 
To further determine whether this may be due to a difference in the half-life of these two 
proteins, the experiment was repeated with cells transfected with pHGCX-Luc as controls. 
For better visualization of protein expression, only half of the amount of cell lysates was used. 
Similar results were obtained in that luciferase protein expression mediated by pHGCX-L2C 
Luc (62 kDa) 
yCD (17 kDa) 
Actin (42 kDa) 
Day 1 3 5 7
pHGCX-L2C 
pHGCX-L2C pHGCX-Luc  
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amplicon viral vectors declined rapidly at day 3 (Figure 4.4). By contrast, luciferase proteins 
could be detected at day 3 and day 5 in cells transfected by pHGCX-Luc vectors, suggesting 
that the short 2A peptide that remained fused to the C-terminus of the “upstream” luciferase 
protein could have affected, albeit minimally, the stability of the proteins. 
 
 
Figure 4.4 Western blot analysis showed stability of Luc (62 kDa) expression in PLC/PRF/5 
cells transfected with pHGCX-Luc compared to pHGCX-L2C at days 1, 3, 5 and 7. Actin (42 
kDa) was used as loading control. 
 
 
Similar results were obtained by measuring the luciferase reporter activities in cells 
transfected separately with pHGCX-Luc and pHGCX-L2C plasmids. The level was lower in 
the latter although the difference was not statistically significant (P>0.05; Figure 4.5a). 
Approximately 5 U/mg of yCD activity could also be detected in PLC/PRF/5 cells transfected 
with pHGCX-L2C compared to background in pHGCX-Luc transfected cells (Figure 4.5b). 
Taken together, the FMDV 2A-mediated bicistronic expression of Luc and yCD proteins were 
successfully expressed by pHGCX-L2C vectors. 
Figure 4.5 Enzymatic assay for (a) Luc and (b) yCD activity in the cell lysate of PLC/PRF/5 
cells transfected with pHGCX-Luc or pHGCX-L2C. Transfected cells were harvested after 24 
h post transfection. Data are presented as mean ± SEM of triplicate experiments. N.S., 
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The functionality of yCD suicide gene was next examined in PLC/PRF/5 cells (Figure 4.6a). 
When PLC/PRF/5 cells were transfected with pHGCX-Luc plasmid expressing only Luc 
gene, no significant different of cell viability was observed after 6 days post treatment in 
various 5-FC concentration ranging from 0 to 5000 µM (Figure 4.6b). In contrast, significant 
cell kill was observed in pHGCX-L2C transfected PLC/PRF/5 cells at a low concentration of 
50 µM (Figure 4.6c). For the rest of the study, we have chosen a dosage of 5-FC that is forty 
times that of 50 µM (i.e., 2 mM) to ensure effective cell kill since 5-FC was shown to be 
relatively non-cytotoxic to PLC/PRF/5 cells up to 5 mM. 
 
 
Figure 4.6 Functionality of yCD suicide gene expressed by pHGCX-L2C in the presence of 
its prodrug, 5-FC. (a) Effect of 5-FU on survival of PLC/PRF/5 cells. (b) Effect of 5-FC on 
survival of PLC/PRF/5 cells transfected with pHGCX-Luc. (c) Effect of 5-FC on survival of 
PLC/PRF/5 cells transfected with pHGCX-L2C. All cell viability experiments were 
performed after 6 days post treatment with 5-FC or 5-FU. Data are presented as mean ± SEM 
of triplicate experiments. N.S., P>0.05. 
 
In order to determine the bystander effect mediated by pHGCX-L2C, PLC/PRF/5 cells were 
transfected with pHGCX-Luc or pHGCX-L2C and then mixed with parental non-transfected 
PLC/PRF/5 in different % ratios from 5 to 25% of transfected PLC/PRF/5 cells (Figure 4.7). 
These cells were then cultured in complete medium with or without 2 mM 5-FC. This result 
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also demonstrated that no significant killing effect was observed in the control groups. Cell 
killing was only observed in PLC/PRF/5 cells transfected with pHGCX-L2C in the presence 
of 2 mM of 5-FC. The IC50 was determined to be about 3.3% of the pHGCX-L2C transfected 
PLC/PRF/5 cells mixed with parental PLC/PRF/5 cells. 
  
 
Figure 4.7 Bystander effect of 5-FU generated in celullo by yCD/5-FC against PLC/PRF/5 
cells. PLC/PRF/5 cells were transfected with the pHGCX-Luc or pHGCX-L2C plasmid and 
mixed with parental non-transfected PLC/PRF/5 cells at 0 to 25%. The cells were then treated 
with or without the presence of 2 mM 5-FC. Cell viability assays were carried out at day 6 




4.2 In vitro cell kill efficiency of the HGCX-L2C amplicon viral vector in HCC cell lines 
and short-term culture derived from HCC patient tumor biopsy 
The pHGCX-Luc and pHGCX-L2C amplicon plasmids were next packaged into infectious 
HSV-1 amplicon viral vector using the helper virus-free method. The functionality of HGCX-
L2C HSV-1 amplicon viral vectors were examined in HCC (PLC/PRF/5; HuH-7) and non-
HCC (ΔGli36; A549) cell lines using a pre-optimized condition of MOI = 1; and 2 mM 5-FC 
treatment up to 6 days. Under these conditions, HuH-7 cells infected with HGCX-L2C 
amplicon viral vectors and treated with 5-FC started to die at day 4 to day 6 (Figure 4.8). 
This was not observed in the absence of 5-FC. Likewise, effective cell kill was observed in 
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IC50 = ~3.3% transfected cells 
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Figure 4.8 Killing efficacy of HGCX-L2C HSV-1 amplicon viral vector on HuH-7 cells in 
vitro. HuH-7 cells infected with HGCX-L2C at MOI of 1 were treated with or without 2 mM 


































Figure 4.9 Cell viability of HCC cell lines (HuH-7 and PLC/PRF/5) and non-HCC cell lines 
(∆Gli36 and A549) infected with HGCX-L2C or HGCX-Luc (negative control) amplicon 
viral vectors and treated with 2mM of 5-FC. HuH-7 and ΔGli36 were infected at MOI 1 
whereas PLC/PRF/5 and A549 were infected with MOI of 8 and 10, respectively. The cell 
viability assays were carried out at day 6 post treatment with 5-FC. The cell viability of 
infected cells without 5-FC added to the complete culture medium was used as a 100% cell 










Next, the potential of HSV-1 based amplicon viral vector to serve as the vector of choice for 
treatment of patient-derived primary HCC was evaluated. HCC are easily infectable by HSV-
1 amplicon viral vectors possibly due to the types of glycoproteins expressed on HCC. Apart 
from characterizing these glycoproteins on HCC (as discussed under Chapter 7.4), the 
infectibility of HSV-GFP (basic HSV-1 amplicon viral vector expressing GFP regulated by 
HSV-1 IE 4/5 promoter) was compared with Ad-GFP (adenovirus expressing GFP regulated 
by CMV promoter) and Lenti-GFP (second generation lentivirus expressing GFP regulated by 
CMV promoter) in short-term culture of primary HCC cells. Virus titration method was 
employed to adjust for differential infectivity of the various viral vectors. This was described 
under materials and methods in details (see Chapter 2.2.2.4). Both CMV and IE 4/5 
promoters are strong ubiquitous promoters that could drive the expression of high level of 
eGFP protein for tittering. However, lentivirus vector may take longer time before the eGFP 
expression could be seen. Therefore, for HSV-GFP and Ad-GFP, the titers were counted after 
24 h post transduction, whereas, for Lenti-GFP, the titers were counted after 48 h post 
transduction. The results showed that the HSV-1 amplicon viral vector was 3- and 2-fold 
more efficient in transducing the primary HCC cells when compared with adenovirus and 
lentivirus, respectively (Figure 4.10). The difference was highly significant when the relative 
infectivity of HSV-1 vector was compared to adenovirus and lentivirus by Student’s t-test 






Figure 4.10 Differential infection capabilities of primary HCC 26-1004 cells by GFP 
expressing HSV-1, adenovirus and lentivirus. The HCC 26-1004 cells were infected with 
each virus at a MOI of 1. GFP positive cells observed under the fluorescent microscope were 
recorded. Data are presented as mean ± SEM of triplicate experiments. ***, P<0.0005 
(Student’s t-test). The differences analyzed using one-way ANOVA was also highly 
significant (overall F = 271.7; P<0.0001). Post hoc test using the Tukey's multiple comparison 
also revealed that the differences between the relative infectivity with the different vector 
types were highly significant (P<0.001) for HSV-GFP versus Ad-GFP, and also for HSV-




The in vitro cell killing efficiency of these primary HCC cells was further confirmed using 
cell viability assay. Primary HCC cells were infected with the HGCX-L2C amplicon viral 
vector at MOI of 1 and 2 in the presence of 2 mM 5-FC (Figure 4.11). Effective cell kill was 
observed at day 7 with less than 20% and 10% viable cells in the experimental group infected 
with MOI 1 or 2 of HGCX-L2C, respectively.  




























Figure 4.11 Killing efficacy of the HGCX-L2C amplicon viral vector in primary HCC 26-
1004 cells at different MOI of 0, 1 and 2. The cells were treated with or without 2 mM 5-FC 
for 7 days in complete culture medium. Cell viability assays were carried out at day 7 post 
treatment with 5-FC. Cell viabilities were normalized against untreated HCC 26-1004 cells, 
which was set at 100%. Data are presented as mean ± SEM of triplicate experiments. NS, 
P>0.05; **, P<0.01.  
 
 
4.3 In vivo therapeutic efficacy of the HGCX-L2C amplicon viral vector on primary 
HCC 
The HGCX-L2C HSV-1 amplicon viral vector was further characterized in vivo by 
intratumoral injection of 1.5 × 106 TU of HGCX-L2C into HCC 26-1004 primary HCC 
xenograft models in SCID mice (confirmed with anti-human HCC monoclonal antibody 
against an unknown HCC antigen [CHALV-1] as in Figure 4.12), whereas control tumors 
were injected with HBSS (Figure 4.13a). High luciferase activities were detectable in 
representative mice injected with HGCX-L2C at day 5. The functional expression of yCD 
was confirmed by analyzing the tumors using western blot analysis (Figure 4.13b). These 
results indicated that the FMDV 2A-mediated bicistronic expression of Luc and yCD could 
facilitate the monitoring of yCD therapeutic gene expression in vivo by imaging luciferase 
































Figure 4.12 IHC analysis on primary HCC 26-1004 tumor sections. The tumor sections were 
stained with anti-human HCC. Non-HCC ΔGli36 glioma section and similar concentrations of 




Figure 4.13 In vivo expression of the Luc reporter gene and the yCD therapeutic gene in HCC 
26-1004 tumors injected with the HGCX-L2C HSV-1 amplicon viral vector. (a) Tumors were 
intratumorally injected with either 100 μL of HBSS (negative control) or 1.5 × 106 TU 
HGCX-L2C. At day 5 post injection, mice were subjected to non-invasive imaging to 
determine luciferase expression where 100 % of mice still showed positive in luciferase signal 
(n = 4). (b) Tumors were harvested and subjected to western blot analysis to confirm yCD 
gene expression in vivo. 
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Next, the therapeutic efficacy of HGCX-L2C amplicon viral vectors was determined by an 
intratumoral (i.t.) administration of the viral vectors (1.5 × 106 TU) into pre-established 
subcutaneous primary HCC mouse xenograft (Figure 4.14a). The mice were then divided 
into two groups. One group received an intraperitoneal injection of 5-FC while the other 
group received similar volume of PBS. Similar procedure was performed in another two 
groups of HCC-tumor bearing mice injected with HBSS. Anti-tumor effect was observed in 
the group of mice treated with HGCX-L2C and 5-FC. At day 20, the mean tumor volume of 
mice treated with both viral vector and prodrug (94 ± 3 mm3) was 8.9-fold smaller compared 
to the control group injected with similar viral dosage and PBS (837 ± 89 mm3). The control 
group injected with HBSS and 5-FC also showed partial tumor suppression when compared to 
control group injected with HBSS and PBS which may be due to the cytotoxic effect of the 
prodrug. Nevertheless, the difference was not significant (P>0.05). Mice injected with viral 
vector and PBS showed similar tumor growth kinetics to the control tumor group with HBSS 
and PBS. Although HGCX-L2C induced an efficient anti-tumor response, the luciferase 
reporter activities were diminished to barely detectable levels at day 17 post injection (Figure 
4.14b and 4.14c). This was not surprising considering that the amplicon viral vectors are 
defective in replication. Based on a one time injection, the 89% of tumor regression must be, 
in part, attributed by the bystander effect of 5-FU.  
 
To confirm that tumor regression was truly due to the cytotoxic and bystander effect of 5-FU 
and not to that of 5-FC, SCID mice harboring bilateral primary HCC tumors of similar size 
were established. HGCX-L2C amplicon viral vectors were injected to only one of the two 
tumor nodules while the other was injected with similar volume of HBSS. Both tumor 
nodules on the mouse were exposed to 5-FC as injected via intraperitoneally (i.p.) route 
(Figure 4.15). After 17 days of treatment, tumors injected with the HGCX-L2C amplicon 
viral vector were considerably smaller and less vascularized compared with adjacent tumors 
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Day 20 Day 17 Day 14 Day 11 Day 9 Day 5 Day 7 
that were injected with HBSS, confirming that the regressed tumor was not due to the 






Figure 4.14 Regression of in vivo HCC 26-1004 primary tumor xenografts treated with a 
HGCX-L2C HSV-1 amplicon viral vector and 5-FC. (a) In vivo killing efficacy of the 
HGCX-L2C amplicon viral vector (1.5 × 106 TU) after intratumoral (i.t.) injection into the 
subcutaneous primary HCC 26-1004 tumor xenograft and treatment with 2 daily doses of 5-
FC at 6 h intervals at 1000 mg/kg via i.p. injection. Control groups were either i.t. injected 
with HBSS or treated with 2 daily doses of PBS at 6 h intervals via i.p. injection. Red arrows 
indicate when the viral vectors were injected. Green arrows indicate the period during which 
5-FC or PBS was administered via i.p. injection. Data are presented as mean ± SEM, n = 5; *, 
P<0.05; **, P<0.01. (b) Corresponding expression levels of the luciferase gene (indirect 
monitoring of yCD gene expression) were measured with a non-invasive imaging system. The 
total flux was calculated by drawing a ROI (region of interest) with the Living Image® 
software. (c) Representative images of luciferase non-invasive imaging for HCC 26-1004 
tumor injected with 1.5 × 106 TU HGCX-L2C amplicon viral vector throughout the imaging 
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Figure 4.15 Progression of bilateral HCC 26-1004 primary tumor xenografts in mice after i.t. 
injection with HBSS or HGCX-L2C amplicon viral vector. The mice were injected with or 
without 5-FC at 1000 mg/kg doses via i.p. route twice a day. Luciferase non-invasive imaging 
was also carried out to confirm the expression of the Luc gene in vivo before the tumors were 
harvested. Red stars (*) indicate the injection sites of 1.5 × 106 TU of HGCX-L2C amplicon 
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4.4 In vivo dual-monitoring of host cell proliferation via DsRed2 and transgene 
expression via luciferase reporter systems for evaluating the systemic delivery potential 
of HSV-1 amplicon viral vector 
For these viral vectors to be of clinical relevance, they would need to be administered 
systemically instead of intratumorally. For this purpose, a liver orthotopic PLC/PRF/5-
DsRed2 tumor model in SCID mice was generated by subcapsular injection with 5 × 106 
PLC/PRF/5-DsRed2 cells into the left lateral liver lobe using a 27G needle. After 1 month, 
PLC/PRF/5-DsRed2 tumors were established in liver as shown in Figure 4.16a. The mice 
harboring the orthotopic PLC/PRF/5-DsRed2 tumors were then systemically tail vein injected 
with 3 × 106 TU HGCX-L2C HSV-1 amplicon viral vector in 100 µl HBSS. After 24 h post 
injection, the distribution of viral vector in liver versus tumor region was examined. Using a 
dual color bioimaging system, the results showed that luciferase activities were located 
throughout the liver region, and some were localized in the DsRed2 positive tumor regions (as 
regionally outlined in white, Figure 4.16b). 
 
Normal liver and DsRed2 positive tumors were harvested separately and the copy number of 
Luc-encoding vector DNA and luciferase reporter activities were determined (Figure 4.16c 
and 4.16d, respectively). The results obtained were consistent with the non-invasive imaging 
results in that the luciferase gene copy number found in the liver was about 2.1-fold higher as 
compared to the tumor region (Figure 4.16c) and the luciferase activity found in the liver was 
also 1.8-fold higher in the normal compared to the tumor region (Figure 4.16d). Very little 












Figure 4.16 Systemic delivery of HSV-1 amplicon viral vector to deliver the therapeutic gene 
into PLC/PRF/5-DsRed2 liver orthotopic tumors. (a) Liver orthotropic PLC/PRF/5-DsRed2 
tumor model established in the left lateral liver lobe of SCID mice. (b) Imaging of luciferase 
gene expression (indicating the target to which the yCD therapeutic gene was delivered) and 
DsRed2 gene expression (indicating the PLC/PRF/5-DsRed2 tumor region) for mice after 24 
h post tail vein injection with 3 × 106 TU of HGCX-L2C HSV-1 amplicon viral vector. White 
lines drawn in the luciferase images correspond to the PLC/PRF/5-DsRed2 tumor regions 
obtained. (c) Viral gene copy number and (d) luciferase activities quantification in 
PLC/PRF/5-DsRed2 tumor and its matching liver after 24 h post viral injection via tail vein. 


























































To further understand whether the mouse liver matrix proteins could modulate viral entry 
differently to human HCC, similar number of normal hepatocyte cells and human HCC cells 
(PLC/PRF/5-DsRed2) were infected with HGCX-L2C at MOI of 1.0. The result indicated that 
the primary mouse hepatocytes were about 7-fold less infectable when compared to HCC 
(Figure 4.17). Thus, the higher luciferase activities in the normal part of the mouse liver 
when compared to the HCC tumor region is unlikely to be due to differential infectivity of 




Figure 4.17 Infectivity of HGCX-L2C on hepatocyte from SCID mouse and PLC/PRF/5-
DsRed2 cells. A total of 5 × 105 cells of either single cell suspension of primary mouse 
hepatocyte or PLC/PRF/5-DsRed2 cells were infected with HGCX-L2C at MOI of 1. After 24 
h, FACS analyses on eGFP positive cells were performed to quantitate the transduction 
efficiency. Uninfected cells were also prepared in parallel to serve as background control. 




























Summary of findings in this chapter 
In the present study, (i) the ability of FMDV 2A sequence to mediate the bicistronic gene 
expression of a therapeutic gene (yeast cytosine deaminase) and a reporter gene (luciferase) in 
the context of the HSV-1 amplicon viral vector; (ii) the regression of a primary human HCC 
tumor xenograft treated by a HSV-1 amplicon viral vector harboring the yCD therapeutic 
gene after 5-FC prodrug administration; and (iii) the possibility of monitoring therapeutic 
gene expression by firefly luciferase using a non-invasive bioimaging system to confirm that 















Therapeutic efficacy of liver-specific and cell cycle-dependent                                     
HSV-1 amplicon viral vector 
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In this chapter, the aim was to develop a unique vector that combines all desirable features 
from the previous studies. Thus, ApoE/hAAT-CC-Luc amplicon viral vector generated in 
Chapter 3 was further improved by (i) combining the liver-specific promoter with 
multimerized CDE/CHR regulatory motifs within the minimal cyclin A2 promoter (denoted 
as 6CC promoter) to improve the kinetics of cell cycle regulation; (ii) replacing the luciferase 
reporter gene with the bicistronic 2A-mediated therapeutic and reporter gene expression 
cassette for assessing the pre-clinical therapeutic efficacy while providing real-time 
monitoring of the vector activities. The newly generated vector is denoted as AH-6CC-L2C. 
 
The specific aims included:- 
 
1. To determine the functionality of AH-6CC-L2C HSV-1 amplicon viral vectors in 
different mouse models: 
(i) Cell cycle dependency of AH-6CC-L2C was performed by administering 
amount of AH-6CC-L2C viral vectors into normal mouse liver (represent 
post-mitotic regions) versus orthotopic HCC (represent proliferating regions). 
Figure 5.2 and 5.3 was based using HCC cell lines and Figure 5.5 was based 
using patient-derived HCC tissue implants. 
(ii) Cell-type specificity of AH-6CC-L2C viral vectors. This was performed by 
administering equal amount of AH-6CC-L2C viral vectors into animals 
bearing patient-derived HCC versus RCC tissue implants (Figure 5.9). 
(iii) Therapeutic efficacy of AH-6CC-L2C viral vectors. This was performed by 
administering appropriate amount of AH-6CC-L2C viral vectors, by 
monitoring the levels of luciferase activities, in subcutaneous animals 
harboring PLC/PRF/5 (Figure 5.13) and HCC 26-1004 (Figure 5.14). 
2. To validate the liver-specific and proliferation-dependent expression of AH-6CC-
L2C HSV-1 amplicon viral vectors in short-term cultures derived from HCC patients 
and their corresponding matched normal controls. 
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5.1 Improving ApoE/hAAT-CC-Luc amplicon viral vectors by multimerizing cell cycle 
regulatory elements 
The functionality of pAH-6CC-L2C (Figure 2j) was first studied for its cell cycle-dependent 
expression regulated by 6CC promoter. The plasmids were transfected into proliferating 
PLC/PRF/5 HCC cells cultured in complete culture medium or G1-arrested PLC/PRF/5 cells 
induced with culture medium containing 0.2% FBS and 70 μM lovastatin. Figure 5.1a 
showed cell cycle analysis of the corresponding PLC/PRF/5 cells in proliferating and G1-
arrested states. As can be seen in Figure 5.1b, PLC/PRF/5 HCC cells transfected with pAH-
6CC-L2C were shown to exhibit 5.9-fold increase in luciferase gene activities in proliferating 
versus G1-arrested cell population. When comparing with pAH-CC-L2C (Figure 2k) that 
contained minimal cyclin A2 promoter with only 1 CDE/CHR region, 6CC promoter in pAH-
6CC-L2C showed 1.5-fold improved in cell cycle-dependent gene expression regulation. 
Similarly, when pre-optimized concentration of 5-FC prodrug was added to the transfected 
cells, the results showed a corresponding decrease in cell viability (Figure 5.1c; 10-fold) 

































































































































Figure 5.1 Cell cycle-regulated luciferase reporter activity mediated by the pAH-CC-L2C 
and pAH-6CC-L2C amplicon plasmids. (a) Cell cycle analysis of PLC/PRF/5 in proliferating 
and G1-arrested states. (b) Luciferase gene expression of pAH-6CC-L2C and pAH-CC-L2C 
in proliferating and G1-arrested cell populations in PLC/PRF/5 cells after 48 h post 
transfection. Total RLU was normalized with total protein contents and % of GFP positive 
cells that presents the transfection efficiency. (c) Killing efficacy of pAH-6CC-L2C 
transfected PLC/PRF/5 cells in the presence of 2 mM 5-FC. Cell viability was measured at 
day 6 and normalized to untreated cells as 100%. All data are presented as mean ± SEM, n = 
3. 
 
5.2 Characterizing the newly generated vector, AH-6CC-L2C in different mouse models 
5.2.1 Orthotopic cell line-derived HCC tumor xenograft 
An orthotopic HCC tumor model using PLC/PRF/5-DsRed2 cells was generated as described 
in materials and methods (Chapter 2.2.6.2). The proliferating status of these tumor cells was 
confirmed by flow cytometry analysis whereby the primary cells from the tumor exhibited 
9.7-fold higher fractions of S-phase compared to hepatic cells derived from adjacent normal 
liver tissues (Figure 5.2a). To study the infectivity of vector in vivo, similar amount of AH-
6CC-L2C amplicon viral vectors were administered into HCC tumor region versus normal 
liver. Luciferase activities, as measured by total photon counts using non-invasive imaging 
system, were found to be significantly enhanced in tumors when compared to normal regions 
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Figure 5.2 Luciferase expression conferred by AH-6CC-L2C (3 × 106 TU) in normal livers 
and PLC/PRF/5-DsRed2 liver orthotopic tumors in SCID mice after 24 h post injection. (a) 
Cell cycle analysis of primary cells isolated from normal liver versus orthotopically implanted 
PLC/PRF/5-DsRed2 tumors in SCID mice. (b) Non-invasive imaging of luciferase and 
DsRed2 protein expression. (c) Corresponding total flux emitted from AH-6CC-L2C injected 
sites as indicated by (*). All data are presented as mean ± SEM, n = 3. 
 
 
In order to confirm this enhanced expression, the experiment was repeated and the luciferase 
expression was assessed using luciferase assay to measure the luciferase gene expression in 
lysates prepared from tumor and liver harvested from mice. Additionally, a control vector that 
is similar to AH-6CC-L2C except all the cell cycle regulation elements were deleted, denoted 
as AH-L2C (Figure 2l), was also included. As shown in Figure 5.3a, AH-6CC-L2C still 
showed significantly enhanced gene expression for about 19-fold higher in tumor when 
compared to normal liver. In contrast, when AH-L2C control vector without cell cycle 
regulatory elements was used, only 1.6-fold change in luciferase activities were detected and 
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the difference was not significant. Cell cycle analysis for the corresponding vector injected 
liver and tumor also suggested that the injection of the vectors did not alter the proliferation 
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Figure 5.3 Induction of luciferase gene expression conferred by AH-6CC-L2C (3 × 106 TU) 
in PLC/PRF/5-DsRed2 liver orthotopic tumors compared to normal liver in SCID mice after 
24 h post injection. (a) Fold change in luciferase gene expression in proliferating PLC/PRF/5-
DsRed2 tumor compared to non-proliferating normal liver injected with cell cycle-dependent 
AH-6CC-L2C vector. Similar doses of AH-L2C vector without cell cycle regulatory elements 
were also injected as control. (b) Corresponding cell cycle profiles of PLC/PRF/5-DsRed2 
tumor and normal liver injected with either AH-6CC-L2C or AH-L2C. All data are presented 




5.2.2 Orthotopic patient-derived HCC tissue implants 
The functionality of AH-6CC-L2C in proliferating versus post-mitotic hepatocytes was 
further confirmed in primary patient-derived HCC 26-1004 mouse xenografts. These cells 
were derived from primary HCC tissues (histological grade 3, as confirmed by pathologist), 
and were serially transplanted into immunocompromised SCID mice (Huynh et al., 2006). 
They are better representative of human HCC architecture because the tumors, stromal 
fibroblast cells and inflammatory cells are retained. The human HCC origin of the xenograft 
was confirmed by staining the tumor sections derived from representative animal against 
human nuclei and cytokeratin peptide 18 (Yilmaz, 2009) (Figure 5.4a). Most of the cells in 
the tissue section displayed increased nuclei:cytoplasm ratio while staining with human 
fibroblasts was modest, indicating that these tumors consisted mostly of human tumor cells. 
Furthermore, the Ki-67 labeling index in the tumor section was 75 ± 2.6%, indicating a high 
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Figure 5.4. IHC and IF analysis on primary HCC 26-1004 tumor. (a) IHC on primary HCC 
26-1004 tumor with antibodies against human nuclei, human fibroblast, cytokeratin peptide 
18 and proliferation marker Ki-67. (b) IF staining of cyclin A expression in tumor sections 
derived from normal liver and HCC 26-1004 bearing SCID mice. Similar concentrations of 
mouse IgG1 or rabbit IgG antibodies were used as negative control. 
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In this experiment, AH-6CC-L2C was injected in the tumor and adjacent normal liver in a 
close proximity causing the difficulty to accurately quantitate photon emitted with non-
invasive imaging from the site of injection as shown in Figure 5.5a, left panel. Since the light 
emitted was diffracted to some extent by the skin, the mice skin was removed and exposing 
injection sites of implanted tumor at left lateral liver lobe and normal liver at right medial 
liver (Figure 5.5a, middle and right panel) for accurate quantification of photon flux as 
shown in Figure 5.5b. In agreement to previous observation (Figure 5.2), significantly higher 
luciferase reporter activities were detected in patient-derived tumor compared to normal 
tissues in HCC patient-derived mouse xenografts when both regions were injected with the 
same amount of AH-6CC-L2C amplicon viral vectors (Figure 5.5a,b). The enhanced 
luciferase expression in tumor was not due to higher infectivity of HCC by AH-6CC-L2C. In 
fact, AH-6CC-L2C viral vector infect liver cells just as efficiently if not better as determined 
by western blot analysis (Figure 5.5c). The lower levels of eGFP in tumor as compared to 
liver may be due to the differential expression of the IE4/5 promoter that regulated the 
expression of eGFP gene in tumor versus normal liver although additional studies are required 
to confirm this. Nevertheless, the results showed that the enhanced luciferase expression 






































































Figure 5.5 AH-6CC-L2C conferred tumor-specific gene expression in primary human HCC 
26-1004 but not normal liver. (a) Non-invasive imaging of the luciferase gene expression (left 
panel); bright field photo image of orthotopic HCC 26-1004 tumor after removal of skin 
(middle panel) and bioluminescence image of luciferase gene expression after removal of skin 
(right panel). Bioluminescence imaging was acquired at 24 h post infection of AH-6CC-L2C 
on HCC 26-1004 tumor after 7 days post tumor implantation. Normal right medial liver lobe 
was served as normal liver control for the injection of same amount of viral vectors as the 
tumor region. Blue asterisk (*) indicated the intrahepatic or intratumoral injection sites of 3 × 
106 TU of AH-6CC-L2C. Red circles indicated the ROI where the AH-6CC-L2C was 
intratumoral or intrahepatic injected. The total flux measurements of photon emitted from 
tumor or normal liver regions per second were stated above the ROI circles. (b) 
Corresponding quantifications of the emitted luciferase signal measured from luciferase 
imaging. Data are presented as mean ± SEM, n = 3. (c) Western blot analysis of eGFP 
expression level in normal liver versus tumor injected with 3 × 106 TU AH-6CC-L2C. Actin 
was used as an internal control.  
 
 
To exclude tissue difference between normal mouse hepatocytes and human HCC, primary 
cells derived from HCC 26-1004 tumors were infected and compared to a human telomerase 
reverse transcriptase (hTERT) immortalized human liver cell line, NeHepLxHT. At 24 h post 
infection with AH-6CC-L2C, the number of transduced eGFP-positive cells was similar in 
HCC 26-1004 versus NeHepLxHT (Figure 5.6a). Transgene expression was nevertheless 
significantly higher in HCC 26-1004 compared to NeHepLxHT based on luciferase activities 
normalized to either total proteins (Figure 5.6b) or number of infected eGFP-positive cells 
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(Figure 5.6c). The low reporter gene expression level in immortalized normal liver cells may 
be due to the low in vitro growth rate of NehepLxHT in culture flasks where longer time was 
needed for NeHepLxHT to get confluent when compared to HCC 26-1004 tumor cells 
although further investigations are required to confirm the proliferation rates of these two 
cells by cell cycle FACS analysis for validation purpose. Taken together, these results 
demonstrated that AH-6CC-L2C could mediate elevated transgene expression in proliferating 



























































































































































Figure 5.6 AH-6CC-L2C conferred tumor-specific gene expressions in primary human HCC 
26-1004 but not immortalized human neonatal liver cell line. (a) Total number of eGFP-
positive cells at 24 h post infection with AH-6CC-L2C (MOI = 1). NeHepLxHT represented 
immortalized human liver cells while HCC 26-1004 cells were derived from HCC tumor 
biopsy material. (b) Corresponding luciferase gene expression level mediated by AH-6CC-
L2C in HCC 26-1004 and NeHepLxHT. (c) Specific luciferase activities conferred by AH-
6CC-L2C after normalized with the quantitated eGFP-positive cells per well. All data are 
presented as mean ± SEM, n = 3. 
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5.2.3 Comparing transcriptional activities mediated by AH-6CC-L2C in subcutaneous 
HCC versus RCC mouse models  
Given that most proliferating tumor cells would display elevated Ki-67 and cell cycle 
proteins, it was essential to determine whether AH-6CC-L2C could function preferentially in 
patient-derived HCC versus non-HCC mouse xenograft models. This was first performed by 
comparing the AH-6CC-L2C transfected and infected cells in vitro. Using A549 as a more 
stringent representative of non-HCC lines, HuH-7 and PLC/PRF/5 cells exhibited a 
corresponding 6.8 to 12.3-fold increase in transgene expression (Figure 5.7a).  
Next, pAH-6CC-L2C plasmids were packaged into infectious but non-replicating amplicon 
viral vectors, and used to infect HCC and non-HCC cells. After 6 h of infection, the cells 
were replenished with either complete medium or treated with lovastatin for the induction of 
cell proliferation and G1-arrest, respectively. Pre-optimized 5-FC was immediately added to 
the cells and cell viability was determined at 72 h post prodrug treatment. In G1-arrested HCC 
cell lines and all non-HCC cell lines regardless of their proliferation status, no significant 
reduction of cell viabilities was observed (Figure 5.7b). The result demonstrated that AH-


















































































































































Figure 5.7 AH-6CC-L2C conferred specific gene expression in human HCC but not non-
HCC cells in vitro. (a) Luciferase expressions were measured in non-HCC (ΔGli36 and 
A549) and HCC (HuH-7 and PLC/PRF/5) cells at 48 h post transfection with pAH-6CC-L2C. 
Total RLU was normalized with total protein contents and % of eGFP-positive cells. (b) Cell 
viability of AH-6CC-L2C infected HCC cell lines (PLC/PRF/5 and HuH-7) and non-HCC 
cell lines (∆Gli36 and A549) in proliferating and G1-arrested states. Cell viability were 




The cell-type specificity of AH-6CC-L2C was further confirmed in primary patient-derived 
HCC 26-1004 and RCC 09-1210C mice xenografts. Single cell suspension of HCC 26-1004 
and RCC 09-1210C tumors were prepared and at 24 h post seeding, the cells were infected 
with varying MOIs of AH-6CC-L2C. As can be seen in Figure 5.8a, when compared to RCC 
09-1210C, high luciferase activities were consistently observed in HCC 26-1004 cells 
infected with AH-6CC-L2C in a dose-dependent manner. Given that these two tumor types 
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may express different receptors that resulted in differential HSV infectivity, a range of MOI 
of vectors was tested on primary cells derived from RCC 09-1210C against HCC 26-1004 
cells infected at a constant MOI of 0.5. The results indicated that twice as much vector was 
required to infect RCC 09-1210C cells as compared to HCC 26-1004 (Figure 5.8b). 
However, after normalizing the luciferase activities against infected cells, the functional 
expression of luciferase reporter activities remained constant regardless of MOIs, and AH-
6CC-L2C still mediated significantly increased transgene expression in HCC 26-1004 


































































































































































































Figure 5.8. AH-6CC-L2C conferred specific gene expression in human patient-derived HCC 
but not non-HCC cells. (a) Luciferase gene expression in AH-6CC-L2C (MOI = 0.5; 1.0; 1.5; 
2.0) infected primary cells derived from the indicated tumors. (b) Transduction efficiency of 
AH-6CC-L2C in RCC 09-1210C using various indicated MOI against a constant MOI of 0.5 
in HCC 26-1004. (c) Transgene expression in HCC 26-1004 and RCC 09-1210C after 
normalizing with total proteins and number of eGFP-positive cells. All data are presented as 




Based on these findings, twice the amount of AH-6CC-L2C viral vectors was subsequently 
administered intratumorally into RCC 09-1210C tumor-bearing mice. The human origin and 
proliferation status of RCC 09-1210C primary patient-derived xenograft was validated 
through positive staining against human nuclei and Ki-67, respectively (Figure 5.9a). 
Quantitative analysis showed that the light emitted by luciferase upon consumption of its 
substrate luciferin was 4.6-fold higher in HCC 26-1004 than in RCC 09-1210C (Figure 
5.9b,c). Primary cell suspensions were prepared from tumors in representative animal and the 
similar infectivity of AH-6CC-L2C in the two tumor types was confirmed by flow cytometry 


































































Figure 5.9 AH-6CC-L2C conferred specific gene expression in primary human HCC 26-1004 
tumor xenograft but not primary human RCC 09-1210C tumor xenograft in vivo. (a) IHC 
analysis on primary RCC 09-1210C tumor. Tumor sections were stained with antibodies 
against human fibroblast, human nuclei and proliferation marker Ki-67. Similar 
concentrations of mouse IgG1 antibodies were used as negative control. (b) Non-invasive 
luciferase imaging of representative mice after 24 h post intratumoral injection of 3 × 106 TU 
of AH-6CC-L2C into the subcutaneous primary HCC 26-1004 and 6 × 106 TU of AH-6CC-
L2C into the subcutaneous primary RCC 09-1210C tumor xenograft. Red circles indicated the 
ROI where the AH-6CC-L2C was intratumoral injected. The total flux measurements of 
photon emitted from tumor per second were stated above the ROI circles. (c) Corresponding 
quantifications of the luciferase signal (in photon per second) emitted obtained from 
luciferase imaging. All data are presented as mean ± SEM, n = 5. (d) Quantification of tumor 
infectivity with flow cytometry analysis for percentage of eGFP positive cells in single cells 
suspension isolated from the corresponding AH-6CC-L2C infected tumors. HBSS injected 
tumors were included to estimate the background level. 
 
 
In an attempt to address the differential luciferase expression, the tumor sections were stained 
against hAAT antibody. The results showed that HCC tumors expressed significantly higher 
levels of hAAT proteins compared to non-HCC suggesting that the high luciferase expression 
detected in HCC 26-1004 was due to functionality of 4×ApoE/hAAT promoter to limit the 
transgene expression in only HCC cells (Figure 5.10). Taken together, these results 
consistently showed that AH-6CC-L2C mediate enhanced transgene expression in 
proliferating HCC tumors expressing elevated levels of hAAT proteins. 
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Figure 5.10 IF staining for hAAT expression in HCC 26-1004 and RCC 09-1210C. Similar 
concentrations of rabbit IgG antibodies were used as negative control. 
 
5.3 Intratumoral administration of AH-6CC-L2C inhibits growth of cell line-derived 
HCC and human patient-derived HCC mouse xenografts 
Next, the therapeutic efficacy of AH-6CC-L2C viral vectors in subcutaneous and orthotopic 
HCC xenograft models was evaluated. To measure the in vivo viability of the tumor during 
treatment processes, stable clones of PLC/PRF/5 cells expressing either maxGFP from 
copepod Pontellina plumata or DsRed2 from Discosoma sp were first generated and 
compared. This fluorescent imaging of tumor viability and progression was shown to be more 
representative to measure the efficacy of the drug treatment compared to conventional method 
using caliper (Puaux et al., 2011). When PLC/PRF/5-maxGFP and PLC/PRF/5-DsRed2 cells 
were established as subcutaneous tumors in SCID mice as shown in Figure 5.11a, the result 
indicated that DsRed2 expressing PLC/PRF/5 tumor was better in representing the viability of 
tumor when compared to the maxGFP expressing PLC/PRF/5 tumor. The reason was that 
maxGFP signal was significantly blocked by the blood vessel as clearly indicated by the 
visibility of the blood vessel in maxGFP expressing PLC/PRF/5 tumor (black arrow). On the 
contrary, blood vessels of similar size in PLC/PRF/5-DsRed2 tumor model were barely 
visible (white arrow). Thus, to further study the AH-6CC-L2C killing efficacy, PLC/PRF/5-
DsRed2 tumor model was chosen to monitor the tumor viability via non-invasive 
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fluorescence imaging. Further characterization of PLC/PRF/5-DsRed2 tumor also 
demonstrated that the luciferase signal did not interfere with the expression of the DsRed2 









Figure 5.11 Characteristics of PLC/PRF/5 HCC cells expressing fluorescent protein. (a) 
Comparison of in vivo fluorescent signal detected from DsRed2 and maxGFP expressing 
PLC/PRF/5 tumor implanted on left and right flank of SCID mouse, respectively. (b) Non-
invasive imaging of DsRed2 and luciferase gene expression in subcutaneous PLC/PRF/5-
DsRed2 tumors with or without intratumoral administration of luciferase expressing viral 
vector. 
 
The DsRed2 signal of subcutaneous palpable PLC/PRF/5-DsRed2 tumor could be easily 
monitored using non-invasive fluorescent imaging system (pseudocolor image) at day 7 post 
tumor implantation as shown in Figure 5.12a which was difficult to measure using caliper 
(bright field image). At day 28 post implant, an increase in DsRed2 signal was observed when 
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the tumor size increased. Correlation analysis between tumor volumes in mm3 versus DsRed2 
total count in Figure 5.12b revealed a linear relationship between tumor volume and DsRed2 
signal count with R2 of 0.69 and the P value was less than 0.0001. 
 
To confirm that the DsRed2 signal could relatively correlate to the amount of viable tumor 
volumes, PLC/PRF/5-DsRed2 tumors were harvested at day 3, 5 and 7 post tumor 
implantation and subjected single cell suspension preparation. Cell viability was quantitated 
using the trypan blue exclusion test and this was compared to the amount of DsRed2 positive 
cells. Although not all the viable cells showed DsRed2 positive signal due to the presence of 
other mouse cells (i.e., fibroblast and etc.), the DsRed2 signal was able to relatively correlate 













































































Figure 5.12 PLC/PRF/5-DsRed2 subcutaneous tumor model. (a) Bright field images and non-
invasive fluorescent imaging images of PLC/PRF/5-DsRed2 tumor at day 7 and day 28 post 
tumor implantation. (b) Correlation curve between the PLC/PRF/5-DsRed2 tumor volume 
and its DsRed2 signal. (c) Comparison of total viable cells number in single cells suspension 
of PLC/PRF/5-DsRed2 tumor using trypan blue dye and DsRed2 positive cells count. 
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To access the therapeutic efficacy of AH-6CC-L2C in treating the HCC tumor in vivo, 3 × 106 
TU of AH-6CC-L2C were intratumorally injected into PLC/PRF/5-DsRed2 tumor xenograft 
(Figure 5.13a). Previously, studies in this thesis have confirmed that yCD suicide gene 
expression could be monitored via non-invasive imaging of the bicistronically expressed 
luciferase reporter gene mediated by FMDV 2A peptide (see Figure 4.3 and 4.13). Therefore, 
by monitoring the expression of the luciferase reporter gene, the appropriate time for 
subsequent doses of viral vector administration could be determined. As can been seen in 
Figure 5.13b, due to the transient expression of replication-incompetent HSV-1 amplicon 
viral vector, the expression of the therapeutic gene (as indicated by luciferase photon count in 
total flux) dropped gradually. A booster shot of viral dose at 3 × 106 TU was administered 
whenever the total flux level fell to almost background level. Overall, for this experiment, a 
total of 3 doses of AH-6CC-L2C at 3 × 106 TU each were injected intratumorally in the 
PLC/PRF/5-DsRed2 tumor with 2 daily doses of 5-FC at 6 h intervals at 1000 mg/kg via i.p. 
injection. The outcome of the experiment was promising as the tumor suppression effect was 
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Figure 5.13 Effective tumor growth suppression of AH-6CC-L2C in PLC/PRF/5-DsRed2 
subcutaneous tumor in vivo. (a) Killing efficacy of subcutaneous PLC/PRF/5-DsRed2 tumor 
xenograft after 3 intratumoral doses of AH-6CC-L2C at 3 × 106 TU per dose (indicated by red 
arrow) and 2 daily doses of 1000 mg/kg 5-FC at 6 h intervals via i.p. injection in period as 
indicated by green double head arrow. Control groups were either i.t. injected with HBSS or 
treated with 2 daily doses of PBS at 6 h intervals via i.p. injection. Bright field and DsRed2 
signal images of tumors harvested at end point of representative mice were shown at right site 
of the graph. (b) In vivo expression levels of yCD suicide gene measured indirectly using 
non-invasive imaging of luciferase signal. All data are presented as mean ± SEM, n = 3. 
 
Two way ANOVA: P<0.0001 
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In order to further evaluate the potential of the AH-6CC-L2C, therapeutic efficacy of the 
vector was further examined in primary human HCC 26-1004 tumor xenograft. Similarly, 
with yCD gene fused in-frame with the luciferase reporter gene in AH-6CC-L2C vector, the 
estimated levels of therapeutic proteins produced in vivo could be monitored (Figure 5.14a), 
and the mice were injected with a booster shot of vectors whenever decline in the luciferase 
activities were observed (Figure 5.14b; red arrows). Similar volume of HBSS to vectors was 
injected as controls. The results showed that intratumoral administration of AH-6CC-L2C 
amplicon viral vectors significantly inhibited the growth of the patient-derived HCC 
xenografts in the presence of 5-FC when compared to the various control groups (Figure 
5.14c; 3.1-fold), which corresponded to reduced tumor volume in the representative animal 
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Figure 5.14 Effective tumor growth suppression mediated by AH-6CC-L2C in subcutaneous 
HCC 26-1004 tumor xenografts in SCID mice. (a) In direct non-invasive in vivo monitoring 
of yCD suicide gene expression via luciferase imaging in representative mouse from each 
experiment group. (b) Indirect non-invasive imaging of AH-6CC-L2C yCD suicide gene 
expression through bicistronic co-expression of luciferase reporter gene in subcutaneous HCC 
26-1004 tumor models. (c) In vivo killing efficacy of the AH-6CC-L2C after three optimum 
doses of i.t. injection of AH-6CC-L2C into subcutaneous HCC 26-1004 tumor and 5-FC 
treatment. (d) Corresponding bright field images of subcutaneous tumors of representative 
mice harvested at end point. Control groups were either i.t. injected with HBSS or i.p. 
injected with PBS. Red arrows indicated day of vector injection. Blue double head arrow 
indicated the period during which 5-FC (1000 mg/kg) or PBS was administered via i.p. 
injection twice a day at 6 h interval. (*) indicated that P<0.05. Data are presented as mean ± 
SEM, n = 6. 
Two way ANOVA: P<0.001 
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Tumors from representative animals were excised, cryopreserved and sectioned. The results 
showed that tumor from control groups exhibited active proliferation, as indicated by 
increased expression of proliferation marker Ki-67 and minimal active caspase 3 expression 
(Figure 5.15a). However, after treatment with AH-6CC-L2C/5-FC, the levels of Ki-67 was 
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Figure 5.15 IHC analysis of tumors harvested at end point in subcutaneous HCC 26-1004 
tumor model. (a) Tumor sections from each experiment groups were stained with cell 
proliferation marker (Ki-67) and apoptosis marker (active caspase 3). (b) Quantification of 
Ki-67 index of tumors from each of the experiment group in % of positive cells. Data are 
presented as mean ± SEM, n = 3.  
 
To confirm the functionality of these viruses in the lysosome-enriched liver 
microenvironment, similar experiment was performed in orthotopically implanted HCC 26-
1004 animals injected with AH-6CC-L2C viral vectors. The timeline of the experiment 
procedure was summarized in Figure 5.16a. The results showed that there was a significant 
decrease in tumor volume and weight in animals treated with AH-6CC-L2C/5-FC when 
compared to HBSS/5-FC group (Figure 5.16bi and ii, respectively). Expression of yCD was 
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monitored indirectly through the reporter activities (Figure 5.16c) with booster shots of 
vectors administered at the indicated times (Figure 5.16d). Corresponding tumors in the 
representative animals were shown in Figure 5.16e. Similar to previous findings, high-levels 
of Ki-67 was observed in control animals but not in AH-6CC-L2C/5-FC group (Figure 
5.17a,b). Taken together, these studies clearly demonstrated that AH-6CC-L2C could mediate 
specific therapeutic gene expression in HCC and show suppressive effect in patient-derived 
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Figure 5.16 Effective tumor growth suppression mediated by AH-6CC-L2C in primary 
human HCC 26-1004 liver orthotopic tumors in SCID mice via intratumoral route of vector 
administrations. (a) Timeline of the experiment where the tumors bearing animals were 
intratumorally injected with either vector or HBSS as controls. Mice were subsequently 
treated with 5-FC at 500 mg/kg twice a day. (bi) Tumor volumes and (bii) tumor weight 
measurements for orthotopic HCC 26-1004 tumors harvested at end point. Data are presented 
as mean ± SEM, n = 5. (c) In direct monitoring of yCD suicide gene expression in vivo via 
luciferase imaging in representative mouse from each experiment group and (d) its 
corresponding total flux quantification. (e) Corresponding bright field images of orthotopic 
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Figure 5.17 IHC analysis of tumors harvested at end point in orthotopic HCC 26-1004 tumor 
model. (a) Tumor sections were stained with cell proliferation marker (Ki-67) and apoptosis 
marker (active caspase 3). (b) Quantification of Ki-67 index of tumors from each of the 
experiment group in % of positive cells. Data are presented as mean ± SEM, n = 3. 
 
 
5.4 Validating the capabilities of AH-6CC-L2C amplicon viral vectors to deliver 
enhanced transgene expression in freshly isolated HCC patient samples compared to 
normal controls 
For clinical relevance, it is important to determine whether the AH-6CC-L2C could also 
confer elevated reporter activities in short-term cultures consisting of patient-derived HCC 
compared to the corresponding matched normal adjacent liver cells. Representative tumor 
sections showed increased proliferation as characterized by the Ki-67 labeling index (Figure 
5.18a), which may be used as prognostic markers of HCC associated with poor survival 
(Ohashi et al., 2001). 
 
Further analysis revealed that despite similar infectivity in tumor versus normal (Figure 
5.18bi), the luciferase activities normalized to either total proteins (Figure 5.18bii; 6.9-fold) 
or number of infected eGFP-positive cells (Figure 5.18biii; 5.1-fold) were significantly 
elevated in tumors compared to normal. Similar infectivity was observed in another patient-
derived short term cultures (Figure 5.18ci). The luciferase activities after normalizing to total 
proteins (Figure 5.18cii; 4.5-fold) or number of infected eGFP-positive cells (Figure 5.18ciii; 
3.3-fold) were significantly elevated in tumor versus normal. Thus, AH-6CC-L2C virions 
were shown to mediate preferential transgene expression in HCC. 




















































































































































































































































































































































































































































Figure 5.18 Tumor-specific gene expression conferred by AH-6CC-L2C with clinical patient-
derived primary HCC and its match normal liver. (a) IHC staining for expression of Ki-67 in 
livers and tumors obtained from human patients. Similar concentrations of mouse IgG1 
antibodies were used as negative control. (bi) Quantification of total infected eGFP-positive 
cells after 24 h post infection with AH-6CC-L2C at MOI 1 in z1719-liver and z1719-tumor. 
(bii) Corresponding luciferase gene expression level mediated by AH-6CC-L2C in z1719-
liver and z1719-tumor. (biii) Specific luciferase activities conferred by AH-6CC-L2C after 
normalized with the quantitated eGFP-positive cells per well in (ai) for z1719-liver and 
z1719-tumor. (c) Another match of patient-derived primary HCC tumor and its match normal 
liver, z1136-liver and z1136-tumor, were subjected to similar studies of (i) quantification of 
total infected eGFP-positive cells, (ii) luciferase gene expression and (iii) specific luciferase 
gene expression. All data are presented as mean ± SEM, n = 3. 
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Summary of findings in this chapter 
Taken together, a newly generated vector, AH-6CC-L2C, was demonstrated to confer 
enhanced transgene expression in patient-derived primary HCC but not renal cell carcinoma 
(RCC) in vitro and in vivo. In addition, intratumoral delivery of AH-6CC-L2C showed 
effective suppression of subcutaneous as well as orthotopic HCC tumor growth and more 
importantly, these vectors could also confer significantly elevated luciferase activities in 
short-term cultures of patient-derived HCC versus primary cells derived from adjacent 




























The Herpes Simplex Virus type -1 (HSV-1) amplicon viral vector is a good candidate as a 
gene-transfer vehicle. However, one of the limitations of the HSV-1 vector is its non-
integrating and non-replicating nature. As such, transgene expression is transient as the 
infected cells undergo cell division. This transient expression pattern of HSV-1 amplicon viral 
vector was clearly inherited by HGCX-L2C and AH-6CC-L2C as shown in Chapter 4 and 
Chapter 5, respectively. Muller and colleagues have demonstrated that the incorporation of 
episomal elements from EBV could prolonged the expression of transgene in hepatocytes to 
at least 6 weeks when compared to 2 weeks with conventional HSV-1 amplicon viral vector 
(Muller et al., 2005). Thus, the specific aims of this chapter are: 
 
1. To generate the hybrid HSV-1/EBV vector for improved stability of transgene 
expression. 
2. To evaluate the stability of the generated HSV-1/EBV vector in cancer cell lines in 
vitro. 
3. To examine the stability of the generated HSV-1/EBV vector in normal as well as 
tumor cells in vivo. 
 
6.1 Incorporation of episomal elements such as ΔEBNA-1 and oriP increases the stability 
of HSV-1 amplicon viral vectors, HSV-1/EBV 
We first generated a vector denoted as pHCAG-L2EOP (Figure 2n) that differs from 
Muller’s group in three ways for stable gene expression. Firstly, the mutant EBNA-1 gene 
(ΔEBNA-1) that contains a deletion of approximately 566 base pairs in the IR3 region was 
used instead of the wild-type EBNA-1 gene. The ΔEBNA-1 protein was reported to exhibit 
lesser cytotoxicity when compared to the wild-type EBNA-1 (Wang et al., 1997). Secondly, 
the expression of the ΔEBNA-1 was regulated by CAG promoter instead of RSV promoter to 
reduce the possibility of transgene silencing (Alexopoulou et al., 2008; Nitta et al., 2005). In 
fact, CAG promoter has been shown to sustain transgene expression in vivo in rat hepatocytes 
(Kosuga et al., 2000) and human embryonic stem cells (Alexopoulou et al., 2008; Costa et al., 
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2005; Muotri et al., 2005). Thirdly, ΔEBNA-1 was bicistronically co-expressed with the 
luciferase reporter gene mediated by the foot-and-mouth disease virus (FMDV) 2A peptide 
(Donnelly et al., 2001). The inclusion of the luciferase reporter gene will enable the 
monitoring of ΔEBNA-1 expression in real-time. This is useful to understand the 
functionality of ΔEBNA-1 gene expression in the context of HSV-1 amplicon viral vectors in 
mammalian cells. To serve as controls in subsequent experiments, pHCAG-Luc (CAG 
promoter; Figure 2m) and pHGCX-Luc (CMV promoter; Figure 2b) amplicon constructs 
without the EBV replicon elements were also generated.  
 
To confirm ΔEBNA-1 protein expression, western blot analysis was performed. The expected 
~55 kDa ΔEBNA-1 protein could be detected in ΔGli36 cells transfected with the parental 
plasmid, pREP7, but not with control plasmid pHCAG-Luc (Figure 6.1). By contrast, the 
Luc2AΔEBNA-1 fusion protein in pHCAG-L2EOP-transfected ∆Gli36 cells migrated at a 
higher molecular weight of ~117 kDa. The presence of the 2A sequence allowed the cleavage 
of the ΔEBNA-1 polyprotein from the Luc2AΔEBNA-1 fusion proteins through a 
translational nick mechanism (Donnelly et al., 2001). As shown in Figure 6.1, the expression 
of the ΔEBNA-1 individual protein was significantly higher than that of the Luc2AΔEBNA-1 
fusion protein, thus confirming that the Luc and ΔEBNA-1 were translated as 2 individual 
proteins. 
 
Figure 6.1 Expression of ΔEBNA-1 as confirmed by western blot analysis in ΔGli36 cells. 
The cells were transfected with pHCAG-L2EOP. pREP7 and pHCAG-Luc were used as 
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Next, the transgene expression mediated by pHCAG-L2EOP was evaluated in a series of 
human tumor cell lines. The amplicon DNAs, either pHCAG-L2EOP or pHCAG-Luc, were 
first packaged into replication-incompetent but infectious amplicon viral vectors. Previous 
report has suggested that the inclusion of the EBNA-1/oriP could enhance the maintenance of 
the amplicon plasmid in transfected cells, which resulted in higher amplicon viral titers when 
the helper virus packaging method was employed (Wang et al., 1997). Using the helper virus-
free packaging method, a significant increase in the yield of HCAG-L2EOP amplicon viral 
vectors (2.42 × 107 TU/ml) was not observed when compared with that of the HCAG-Luc 
amplicon viral vectors (2.14 × 107 TU/ml). However, consistent enhancement of luciferase 
activities mediated by the hybrid vectors were observed in different human tumor cell types 
examined (Figures 6.2a-d; ranging from 2.2-fold to 9.5-fold when compared to the control 
vector at day 10 post-infection). Taken together, these results clearly demonstrated that the 
presence of the ΔEBNA-1 could mediate enhanced transgene expression to varying extents in 
different human tumor cells. 
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Figure 6.2 The enhancement of transgene expression in human cancer cells through EBV 
elements. Enhanced transgene expression was observed in (a) PLC/PRF/5, (b) HuH-7, (c) 
HeLa and (d) ΔGli36 cells infected with HCAG-L2EOP. These cells were infected with either 
HCAG-Luc or HCAG-L2EOP at MOI of 1 in a 24-well plate containing 1 × 105 cell per well. 




6.2 Prolonged in vivo transgene expression mediated by hybrid vector could be detected 
in patient-derived primary human HCC and normal mouse brain 
Next, the potential of newly generated HSV/EBV hybrid vector in conferring high levels of 
transgene expression in the more complex in vivo tumor model, which consisted of patient-
derived primary human hepatocellular carcinoma cells (HCC 26-1004), was examined. To 
compare the activities of HCAG-L2EOP to HCAG-Luc, similar viral dosages (1.5 × 106 TU) 
were intratumorally administered into the right and left flanks of mice bearing HCC 26-1004 
xenograft, respectively. Luciferase activities in the tumors injected with the basic HCAG-Luc 
amplicon viruses diminished shortly after injection (Figure 6.3a). By contrast, increasing 




















of HCAG-L2EOP viral vectors where at day 10, the reporter activities were 28-fold higher 
when compared to the corresponding control vector (Figure 6.3b). Although the luciferase 
activity mediated by HCAG-L2EOP declined after day 10, it was nevertheless maintained at a 
level similar to that observed at day 1, until day 17 when the tumor burdens have became too 
big. Taken together, the results showed that the presence of EBV replicon elements conferred 
enhanced and stable transgene expression in human tumor cells. 
 
To further confirm the enhanced transgene expression observed in the subcutaneous HCC 
tumors, the ability of the HCAG-L2EOP was investigated to maintain stable transgene 
expression in normal non-proliferating brain cells in vivo. A total of 1 × 106 TU of HCAG-
L2EOP HSV-1 amplicon viruses were intracranially inoculated into BALB/c nude mice. 
Control viruses (either HCAG-Luc or HGCX-Luc) were also similarly injected. In the 
absence of ΔEBNA-1 and oriP in both control viruses, the luciferase activities could only be 
maintained up to day 7 (Figure 6.4a). Quantitative analysis of the luciferase signal revealed 
that the luciferase signal detected in mice group injected with HCAG-L2EOP was overall 
significantly higher, at an average of ~4-fold over the period of study, than mice injected with 
the control viruses (Figure 6.4bi). After 1 year of monitoring, luciferase reporter activity 
could still be detected in mice injected with HCAG-L2EOP amplicon viral vectors (as 
represented in Figure 6.4bii). This residual activity was ~7.7% of the original luciferase 






Figure 6.3 Enhanced transgene expression mediated by HCAG-L2EOP amplicon viral 
vectors in human patient-derived HCC 26-1004 tumor xenografts in SCID mice as monitored 
using non-invasive bioimaging system. (a) HCC 26-1004 tumors were injected with 1.5 × 106 
TU of either HCAG-L2EOP amplicon viral vectors (right tumor) or HCAG-Luc amplicon 
viral vectors (left tumor). Luciferase bioimaging images were acquired with Xenogen IVIS 
Lumina system. (b) Quantitative analysis of the corresponding luciferase signal (total flux in 
photon per second, p/s) in tumor injected with either HCAG-Luc or HCAG-L2EOP amplicon 












Figure 6.4 Prolonged transgene expression mediated by HCAG-L2EOP amplicon viral 
vectors in vivo. (a) In vivo non-invasive bioimaging of luciferase activities in nude mice 
brains (n = 6) that were intracranially injected with 1 × 106 TU of either HCAG-L2EOP 
amplicon viral vectors or control amplicon viral vectors HCAG-Luc and HGCX-Luc. (bi) 
Quantitative analysis of the corresponding luciferase signal (total flux in photon per second, 
p/s), up to 1 year, that was emitted from brain region injected with either HCAG-L2EOP or 
HCAG-Luc. (bii) Corresponding in vivo bioimaging of mice at 1 year (day 365) post injection 
with amplicon viruses. 
 
 
Summary of findings in this chapter 
Taken together, these results indicated that the presence of the ΔEBNA-1/oriP elements, in 
the context of HSV-1 amplicon viral vector conferred an enhanced and stable transgene 























































7.1 Dysregulation of cell cycle genes in HCC 
In the clinical setting, overexpression of cyclin A and cyclin E proteins have been associated 
with tumor relapse of human HCC, and are independent predictive markers for their 
recurrence and prognosis (Ohashi et al., 2001; Zhou et al., 2003). In addition, silencing of β-
catenin gene in HCC have been shown to induce changes in the expression of cyclin A and 
cyclin E, suggesting that the Wnt/β-catenin signaling pathway may be involved in HCC 
pathogenesis through dysregulation of cell cycle proteins (Wang et al., 2009). Whereas, in 
hepatitis B virus (HBV) induced hepatocarcinogenesis, HBV pre-S2 mutant has been found to 
induce chromosome instability through the induction of aberrant cyclin A expression (Wang 
et al., 2012). While the mechanisms responsible for hepatocarcinogenesis are still under 
investigation, the dysregulation of cell cycle proteins in rapid proliferating HCC tumor is 
clearly demonstrated. This is further supported by a prominent overlap of cell cycle genes that 
are differentially expressed in human HCC versus normal controls in many microarray studies 
(Chen et al., 2002; Lee et al., 2004; Segal et al., 2004). Among these genes are AURORA 
KINASE B (Lin et al., 2010), CDK1 (CDC2) (Ito et al., 2000), CKS1 (Shen et al., 2010), 
CYCLIN A2 (Wang et al., 2012), CYCLIN B1 (Weng et al., 2012) and POLO-LIKE 
KINASE 1 (He et al., 2009) as summarized in Table 7.1. Interestingly, all of these genes are 
regulated by CDE and CHR elements in their promoters. In agreement with findings of others 
(Muller and Engeland, 2010), we have previously demonstrated that mutation of either CDE 
or CHR or both elements in these promoters may lead to a substantial deregulation of gene 
expression via cell cycle control (Wang et al., 2007). Furthermore, multimerization of 
CDE/CHR elements within the cyclin A2 promoter was shown to improve the kinetics of cell 
cycle gene regulation.  
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The mechanism of transcriptional repression of these promoters in quiescent cells is mediated 
through the binding of the CDE/CHR regions with transcriptional repressor proteins that are 
only expressed during the G0/G1 phases of cell cycles (Muller and Engeland, 2010). The relief 
of repression on these cell cycle-regulated promoters starts from S phase and maximum gene 
expression is detected in G2 and mitosis phases. Such mechanism of cell cycle regulation has 
been extensively studied with cyclin A2 promoter where CDF-1 and/or CHF repressor 
proteins have been observed to preferentially bind to the CDE and CHR elements, 
respectively (Liu et al., 1997; Philips et al., 1999). Therefore, due to the expression of these 
repressor proteins, cyclin A2 promoter activity is repressed in non-proliferating cells. On the 
other hand, when cells start to proliferate and progress into S, G2 and mitosis phases, possible  
reduced expression level of CDF-1 and CHF repressor proteins expose the CDE and CHR 
sites and allow the transcriptional activation of gene expression with various transcription 
factors such as NF-YA that bind at CAAT-boxes located upstream of cyclin A2 promoter. 
 
Table 7.1 Experimentally validated CDE/CHR sites from various cell cycle-regulated 
promoters. Class I genes require both CDE and CHR sites for cell cycle-dependent repression. 
Whereas, Class II genes only regulated through a well conserved CHR site and do not contain 
a functional CDE site. Adapted from Muller and Engeland (2010). 
 
Promoter Origin                CDE               CHR Class 
AURORA KINASE B human CCGGGGCGGGAGATTTGAAAAG I 
CDC25C human GGCTGGCGGAAGGTTTGAATGG I 
CDK1 (CDC2) human TTAGCGCGGTGAGTTTGAAACT I 
CKS1 human TGCGGGCGGCGTGTTTGAAAGC I 
CYCLIN A2 human TAGTCGCGGGATACTTGAACTG I 
TOME-1 human GCGTGGCGGGAAGTTTGAAACT I 
B-myb mouse ACTTGGCGGGAGATAGGAAAGT I 
Cks1 mouse TGCGGGCGGTGTGTTTGAAAGC I 
Cyclin B2 mouse CAGCGGCGCGGTATTTGAATCG I 
Tome-1 mouse GCGTGGAGGGAAGTTTGAAACT I 
CYCLIN B1 human GAGCAGTGCGGGGTTTAAATCT II 
CYCLIN B2 human AAGCGACGCGGTATTTGAATCC II 
POLO-LIKE KINASE 1 human TCCCAGCGCCGCGTTTGAATTC II 
Cdc25C mouse AGAGAGTGGAAGGTTTGAATGG II 
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7.2 Liver-specific transgene expression can be mediated by 4×ApoE/hAAT promoter  
The clinical efficacy and safety of HCC targeted gene therapy is dependent upon the ability of 
viral vectors to confer specific and regulatable transgene expression in the desired cell type. 
Specific transgene expression can be achieved by employing tumor-specific promoters; 
however, these promoters are usually weak (Cao et al., 2000; Nettelbeck et al., 2000; 
Papadakis et al., 2004). For example, AFP promoter and its enhancer have been chosen for 
HCC-targeted gene deliveries because AFP is expressed in a high proportion of primary liver 
tumors but not in adult normal livers (Arbuthnot et al., 1996; Mawatari et al., 1998). As 
expected, when AFP/AFP enhancer/promoter and other liver-specific promoters were 
examined in this study (Figure 3.1), AFP/AFP enhancer/promoter demonstrated the weakest 
gene expression capability in HCC. In comparison, 4×ApoE/hAAT hybrid promoter was 
shown to mediate highest levels of gene expression in HCC, much higher than those of 
AFP/AFP and SV40/Alb enhancers/promoters. In agreement with findings in this thesis, 
Condiotti and colleagues have compared five constitutive promoters namely, human α-1-
antitrypsin (hAAT), human PGK (hPGK), murine PGK (mPGK), RSV, and CMV promoters 
in four HCC cell lines. Among these promoters, hAAT leads to the highest number of cells 
expressing the transgene (Condiotti et al., 2004) while CMV is the lowest possibly due to the 
transcriptional silencing in liver tissues (Everett et al., 2004; Gerolami et al., 2000). In a 
different context, this combination of hAAT promoter and human ApoE enhancer have been 
reported to induce an elevated and stable expression of human apolipoprotein A-I protein in 
the liver of female C57BL/6 mice (Van Linthout et al., 2002a). In Figure 3.1, level of 
transgene expression in HCC cells were demonstrated to enhance by 2 to 6-fold in HCC cells 
transfected with the hybrid promoter construct (pApoE/hAAT-Luc) in comparison to the 
liver-specific human albumin promoter. Similarly, a 9 to 15-fold elevated transgene 
expression had been observed when compared with the HCC-specific AFP promoter. 
Therefore, for subsequent studies, 4×ApoE/hAAT promoter was chosen to mediate specific 
gene expression in HCC due to its capability to confer high level of gene expression in liver 
cells.
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7.3 Dual-monitoring of host proliferation and transgene expression 
Conventional methods in tissue removal could not be routinely performed in virotherapy 
related clinical trials due to the invasive nature of the procedure. Even if transduced tissues 
were successfully removed, molecular characterization of the delivered viruses in tumor and 
the associated tumor microenvironment are not easily addressable within a reasonable 
turnaround times for the subsequent informed medical decision. Some of the characterization 
studies that will be of clinical relevance would include information on (1) the presence and 
distribution of viral/transgene genome copy number, (2) the replication potential of the virus 
post administration, (3) the transgene expression levels and (4) the extent of immune 
responses elicited within the tumor microenvironment. With the advent of imaging 
technology, it is now possible to monitor the gene delivery in term of distribution, levels and 
kinetics of vector transgene expression in real-time to achieve a safe and efficient gene 
therapy protocol for clinical application (Jacobs et al., 2007; Rueger et al., 2008; Tangney, 
2012; Tangney and Francis, 2012). 
 
For better monitoring of the strength and duration of the therapeutic gene expression in 
preclinical animal models, luciferase gene was co-expressed with the therapeutic gene of 
interest, i.e., yeast cytosine deaminase via the FMDV 2A peptide sequence. In comparison to 
the IRES element, the FMDV 2A peptide sequence has the advantages of being 5 times 
shorter and capable of mediating bicistronic proteins expression at similar levels  (de Felipe, 
2002; Donnelly et al., 2001; Wong et al., 2002). The result in this study (Figure 4.3) 
demonstrated that the expression of the second gene followed those of the first, although the 
protein expression level of Luc and yCD were quantitatively dissimilar. This slight variation 
could be due to the fact that the Luc and yCD have different protein half-life of about 3-4 h 
(Leclerc et al., 2000) and 8-9 h (Xiong and Kwon, 2005), respectively. Alternatively, several 
studies have demonstrated that the 18 amino acids of cleaved 2A peptide left on the C-
terminus of the first gene product (i.e., Luc) could potentially interfere with post-translational 
modification, trafficking or function of the expressed protein as well as inducing an immune 
  134
response that could limit the protein half-life in vivo (Hasegawa et al., 2007; Lengler et al., 
2005). The single proline residue remains on the N-terminus of second gene product (i.e., 
yCD) does not appear to cause problems (de Felipe et al., 2006). Despite the slight differences 
in protein stability, 2A peptide approach to bicistronically co-express the reporter gene is 
useful in monitoring the strength and duration of the therapeutic gene in vivo via non-invasive 
imaging system, and henceforth could serve as a good indication to follow up with 
subsequence viral doses when necessary. However, the current bicistronic co-expression of 
yCD and Luc may not able to distinguish between the reduced in luciferase activities due to 
the increase killing of proliferating HCC cells by yCD/5-FC or transient expression of 
transgene by HSV-1 amplicon viral vector. Therefore, the specific killing of proliferating 
cells could not be evaluated via non-invasive imaging of luciferase expression. 
 
In an attempt to understand the in vivo tumor host proliferation effect on gene expression 
conferred by AH-6CC-L2C, tumor xenograft models with PLC/PRF/5 cells that stably 
express DsRed2 red fluorescence protein was established. Using non-invasive imaging 
system, host tumor cell proliferation could be indirectly monitored via DsRed2 imaging. This 
was supported by performing a correlation analysis consisting of tumor volumes and its 
corresponding DsRed2 signals that showed a significant correlation between tumor volume 
and DsRed2 signal with good R2 of about 0.69 (Figure 5.12b), and further confirmed by 
scoring the number of viable tumor cells using trypan blue analysis (Figure 5.12c). 
Subsequently, attempt was made to correlate the cell cycle-dependent functionality of AH-
6CC-L2C viral vectors by expressing its luciferase output against the host tumor cell 
proliferation indicator, i.e., DsRed2 count. The mean luciferase output was measured to be 
about 5000 photon/s at day 1 after mice bearing PLC/PRF/5-DsRed2 tumors (5 units of 
DsRed2 count) were intratumorally injected with 3 × 106 TU of AH-6CC-L2C (Figure 5.13). 
In another study, for mice bearing proliferating PLC/PRF/5-DsRed2 tumors with registering 
DsRed2 signals at 133 units of DsRed2 count, elevated level of the luciferase gene expression 
was detected at day 1 post injection (about 160000 photon/s) when exactly the same viral 
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dosages of AH-6CC-L2C were administered (Figure 5.2b). These results indicate that the 
luciferase activities mediated by AH-6CC-L2C were enhanced in tumors with strong DsRed2 
signals, suggesting an actively proliferating tumor microenvironment. 
 
7.4 Using HSV-1 amplicon viral vector for the potential treatment of HCC 
In this study, replication-defective HSV-1 amplicon viral vector was chosen for potential 
treatment of HCC for the following reasons:  
 
(i) HSV-1 amplicon viral vectors exhibited high infectivity in HCC cell lines and primary 
HCC short-term cultures derived from HCC patients (Figure 3.2c and 5.18). The high 
infectivity may be attributed by the overexpression of glypican-3 (GPC3) which is a cell 
surface heparan sulfate proteoglycan. The expression of GPC3 is important in the regulation 
of cellular morphology and variety of cellular behaviors including cell adhesion, proliferation, 
migration, survival and differentiation (Filmus, 2001; Kandil and Cooper, 2009). In HCC, 
GPC3 is differentially expressed during the invasive tumor growth which suggests that GPC3 
might be involved in the initiation of liver cancer and play a critical role in liver cancer 
development (Midorikawa et al., 2003; Ning et al., 2012; Shirakawa et al., 2009). Recently, it 
was reported that GPC3 is a transcriptional target of c-Myc and the expression of c-Myc is 
also regulated by the GPC3 which forms a positive feedback signaling loop (Li et al., 2012a). 
Therefore, GPC3 has been demonstrated to be a specific, sensitive and reliable biomarker for 
diagnosis of HCC (Zhang et al., 2012a). As described in Figure 1.4, heparan sulfate is 
required for entry of HSV-1 amplicon viral vectors into the cells via binding with their gC 
and gB glycoprotein spikes on lipid envelope (Campadelli-Fiume et al., 2007; Spear, 2004). 
Thus, the high infectivity of HSV-1 amplicon viral vectors could be attributed to the 
overexpression of GPC3 in most of the HCC tumors. In order to confirm this assumption, 
preliminary experiments was performed by comparing the infectivities of GPC3-positive 
HCC cells (HuH-7 and PLC/PRF/5) and GPC3-negative HCC cell (Mahlavu) with luciferase 
expressing basic HSV-1 amplicon viral vector, HGCX-Luc at MOI of 1. The result showed 
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that HGCX-Luc preferentially infected HuH-7 and PLC/PRF/5 cells when compared to 
Mahlavu cells. Thus, suggesting that high infectivity of HSV-1 amplicon viral vectors could 
be attributed to the overexpression of GPC3 in most of the HCC tumors. 
(ii) Because HSV-1 amplicon viral vectors are non-integrating, the risk of insertional 
mutagenesis is greatly reduced. Furthermore, it is possible to package amplicon viral vectors 
by replacing the helper viruses with sets of cosmids (Fraefel et al., 1996) or BAC (Saeki et al., 
2001). These systems allow the cloning of the entire HSV-1 genome with the deletion of 
DNA cleavage or packaging signals. The viral genomes help the packaging of only the 
amplicon DNA into virion by providing helper functions in trans and the genome itself are 
not packaged. The resulting packaged amplicon vectors are essentially free from helper virus 
contamination which aid in minimizing unwanted immune responses arising from viral 
components. This was confirmed by a study by Olschowka and colleagues who showed that 
the helper virus-free HSV-1 amplicon viral vector only mildly induce the inflammation after 
the viral vector was stereotactically inoculated into central nevorus system (CNS) of C57BL/6 
mice. In less than 5 days, mRNA levels of cytokines, pro-inflammatory and adhesion 
molecule returned to its baseline level similar to the levels in mice injected with saline. On the 
contrary, when the mice were injected with viral vector contaminated with helper virus, 
increased inflammatory molecule expression and immune cell infiltration were observed even 
at day 5 post injection (Olschowka et al., 2003). Thus, the preparation of helper virus-free 
HSV-1 amplicon viral vector exhibits a safer profile of innate immune response, presumably 
due to the absence of viral proteins expression by helper virus.  
 
Recently, a number of studies in humans have shown that immune responses against vector or 
transgenes may be a major mechanism of efficacy by stimulating an immune bystander effect 
to eliminate the remaining local and metastasis tumor cells (Lamers et al., 2011; Onion et al., 
2009). In addiotion, strategy of using suicide gene to kill the cells has previously been 
demonstrated to have potential of stimulating the immune system to generate antitumor 
immunity in animal models (Vile et al., 1997). However, when the viral vectors are applied in 
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actual clinical treatments with multiple injections approach as suggested in this thesis, too 
much immunity may be generated (after the first vector exposure) to destroy the viral vectors 
before its suicide gene’s actions could be delivered. Nevertheless, Herrlinger and colleagues 
have demostrated that pre-exisitng HSV-1 immunitiy may decrease but does not abolish the 
amount of hrR3 oncolytic HSV-1 viruses in an immunized animal model (Herrlinger et al., 
1998). In addition, HSV-1 amplicon viral vector used in this study is free from helper virus 
contamination and do not express any viral protein, hence, there should essentially no HSV-
specific cellular immune reaction in the infected cells.  
 
When the AH-6CC-L2C treated orthotopic HCC 26-1004 tumors at end-point were examined 
for inflammatory cells and active macrophage with CD11b and F4/80 antibodies, 
respectively, high number of CD11b positive inflammatory cells and some F4/80 active 
marcrophage cells were observed (Figrue 7.1). Interestingly, these cells were not infiltrated 
into the tumors cells and no difference was observed between the treated and control tumors 
suggested that this phenomenon was independent of the activities of viral vector and 
expression of yCD suicide gene. However, the study were done in immunodeficiency SCID 
mouse which has reduced B and T cells to support better engraftment of allogeneic and 
xenogeneic tumors. Therefore, it would be interesting if the current vector system could be 
evaluated in immunocompetent syngenic mouse model with orthotopic mouse HCC tumors in 
future so that the involvement of adaptive immune response could be studied for understading 
the potential of immune responses in augmenting the effcicacy of HSV-1 amplicon viral 
vector infection. Another property of HSV-1 that makes it suitable for cancer gene therapy is 




Figrue 7.1 IHC analysis of inflammatory cells and active marcrophages with CD11b and 
F4/80 antibodies in orthotopic HCC 26-1004 tumors harvested at end point after 21 days post 
treatment with (a) HBSS + 5-FC and (b) AH-6CC-L2C + 5-FC.  
HBSS + 5-FC 




The major limitation of the HSV-1 amplicon viral vectors is its non-replicating nature. As 
such, transgene expression is transient as the infected cells undergo cell division. To address 
this limitation in near future, it is plausible to recapitulate the construction of AH-6CC-L2C in 
the context of a replication-competent virus. This would be the generation of an “armed” 
oncolytic virus whereby the therapeutic gene product under the regulation of cell cycle-
regulatory elements in addition to the continuous replication of the virus could provide a 
therapeutic amplification of the “input dose”, thus, enhancing the overall therapeutic efficacy. 
The generation of replication-conditional recombinant HSV-1, which is defective in ICP6 that 
encodes for the large subunit of ribonucleotide reductase protein (e.g., hrR3 or rRP450), has 
been demonstrated to exhibit potential therapeutic benefit to the destruction of HCC 
(Miyatake et al., 1999; Pawlik et al., 2000). This is because these HCC cells expressed 
significantly higher levels of ribonucleotide reductase compared with the surrounding normal 
liver (Elford et al., 1970). It is therefore presumed that the cytotoxicity induced by these 
replication-conditional viruses were attributed to the more robust viral replication activities in 
HCC cells with high levels of cellular ribonucleotide reductase, rather than in normal 
hepatocytes which expressed comparatively lower levels of ribonucleotide reductase. The 
construction and characterization of these viral vectors are on-going. 
 
Last but not least, it is known that viral vectors are naturally delivered into the liver when 
they are systemically injected (Smith et al., 2011). Therefore, it could be an added advantage 
to consider using viral-based delivery system to target multicentric and metastasis HCC 
tumors that are inaccessible for surgical resection. Preliminary studies have been initiated to 
assess the systemic biodistribution of AH-6CC-L2C via intrasplenic route of vector 
administration in normal SCID mice. The results confirmed that AH-6CC-L2C could be 
efficiently and evenly distributed to entire liver but not other organs (Figrue 7.2) and thereby 













Figrue 7.2 Biodistribution of AH-6CC-L2C after 24 h post intrasplenic systemic delivery of 3 
× 106 TU AH-6CC-L2C in normal SCID mice. Stereomicroscope fluorescence imaging of 
AH-6CC-L2C eGFP signals (indicating the AH-6CC-L2C infected cells) at site of injection 
(spleen) and other organs including liver, lung, kidney, heart and brain. HBSS was also 




7.5 Effectiveness of AH-6CC-L2C HSV-1 amplicon viral vector in treating HCC 
In this thesis, a safe and efficient AH-6CC-L2C HSV-1 amplicon viral vector that confers 
liver-specific and proliferation-dependent therapeutic gene expression has been constructed. 
Although the viral vectors demonstrated a suppressive effect on both cell line-derived 
subcutaneous HCC and patient-derived subcutaneous/orthotopic HCC tumor models as shown 
in Figure 5.13, 5.14 and 5.16, the fold-change in the mean tumor volumes when compared to 
control animals is modest (~2-3-fold). This may be due to the limitation of current cell cycle 
regulation system that have reached its threshold of transcriptional regulation with Gal4/NF-
YA fusion protein and minimal cyclin A2 promoter in the tumor milieu  (Liu et al., 1997; 
Nettelbeck et al., 1999; Philips et al., 1999). These findings are in good agreement with other 
research groups whereby 2-3-fold reduction in mean tumor volumes were observed with 
similar two-step transcriptional activation system expressing prodrug activated suicide gene. 
These systems contained survivin (Sher et al., 2012) or midkine (Hattori and Maitani, 2006) 
tumor specific promoters that drive the transactivator domain (Gal4/VP16) containing fusion 
protein of Gal4 binding domain and VP16 HSV-1 transcriptional activation domain. The 
tumor specific expression of Gal4/VP16 then transactivated the adenoviral E4 or E1B 
minimal promoter by binding to 5× Gal4 binding sites located upstream of these minimal 
promoters to express the endostatin-yCD fusion protein or HSV-tk, respectively. In addition, 
it is also possible that the modest tumor regression could be due to the episomal and non-
replicating nature of HSV-1 amplicon viral vectors. Thus, the therapeutic effect mediated by 
AH-6CC-L2C is lost as the transduced cells divide and the vector could not spread in parallel 
to the proliferation of the tumor cells. 
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Despite the modest tumor suppressive effect conferred by AH-6CC-L2C, it is encouraging 
that when HGCX-L2C was used, tumor regression was observed in patient-derived primary 
HCC 26-1004 subcutaneous tumors (Figure 4.14). Further evidence has been provided to 
confirm that the tumor regression was not due to the high levels of 5-FC administered by 
using a bi-lateral tumor model system. In this model, two similar size HCC 26-1004 tumors 
were implanted into the same animal, and only one of the two tumors was intratumorally 
injected with HGCX-L2C (Figure 4.15). Despite the high dose of 5-FC circulating in the 
animal, only the injected tumor nodule showed regression. Clearly, there are still rooms for 
improvements in engineering the AH-6CC-L2C amplicon viral vector so as to achieve 
complete eradication in HCC tumors. The current vector system that expressed yCD suicide 
gene and produced 5-FU as active anti-cancer metabolite may not readily to eradicate the 
HCC tumors even with increment number of vectors injection and longer 5-FC treatment 
period simply due to the possibility of 5-FU resistant population as observed in various in 
vitro studies (Figure 4.9, 4.11 and 5.1c). Some of these improvements are discussed in the 
next chapter under future directions. 
 
 
7.6 Preclinical evaluation of AH-6CC-L2C HSV-1 amplicon viral vector 
In preparing the viral gene vector to be enrolled in the desired clinical trial, the vector itself 
needs to fulfill some stringent requirements to ensure its effectiveness and safeness in human 
subjects.  
 
7.6.1 Liver-specificity and proliferation-dependency of AH-6CC-L2C 
The functionality of AH-6CC-L2C was examined in HCC patient-derived xenografts and 
short-term culture of resected primary human HCC tissues and matched normal controls 
because these should reflect the human HCC biology more accurately than HCC cell lines in 
the laboratory. The results obtained are encouraging in that AH-6CC-L2C could mediate 
specific transgene expression in HCC but not RCC patient-derived xenografts despite both 
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tumor types originated from patients with advanced grade 3 tumors and expressed high Ki-67 
proliferating index (Figure 5.4a and 5.9a). The preferential transgene expression mediated by 
AH-6CC-L2C vector was sustained in HCC even after careful normalization for differential 
infectivity of the vector in two cell types (Figure 5.8a-c). In addition, specific transgene 
expression was also observed only in HCC but not in adjacent normal liver cells of SCID 
mice (Figure 5.5). More importantly, significant suppressive effect on the growth of 
subcutaneous and orthotopic HCC were observed in various in vivo studies (Figure 5.13, 5.14 
and 5.16). This was consistently accompanied by reduced levels of human Ki-67 proteins, 
which are often associated with biologically aggressive HCC phenotypes and poor overall 
survival rates (Stroescu et al., 2008).  
 
7.6.2 Safety aspect of AH-6CC-L2C 
AH-6CC-L2C HSV-1 amplicon viral vector that was generated in this study contains 
regulatory elements from human origin that are important to reduce the risk of 
immunogenicity. More importantly, the vector could confer specific therapeutic gene 
expression in its target HCC cells at physiological level that enable a therapeutic outcome 
with low basal level of gene expression in non-target normal cells. This property is 
particularly important for safety to prevent any undesired adverse effect on non-target cells if 
the vectors are systemically delivered. In addition, the therapeutic effect of gene of choice, 
i.e., yCD suicide gene, could be further fine-tuned to an optimal level with prodrug, 5-FC 
where cell killing could be induced or repressed whenever the treatment is needed or 
discontinued in a timely manner if adverse side effects are observed. However, it is difficult 
to exclude any induction of immune responses due to the presence of viral structural 
components. Nonetheless, when using ALT/AST assays to evaluate the liver toxicity of an 
earlier version of AH-6CC-L2C, i.e., the ApoE/hAAT-CC-Luc, the viral vector exhibited a 
reduced level of cytotoxicity when compared with the conditionally replicating hrR3 viruses 
(Figure 3.5).  
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In the study with liver regeneration model (Figure 3.4), the transgene expression was shown 
to be active in normal proliferating liver cells when the liver-specific and cell cycle-dependent 
vector was administrated. However, this should not be a concern when yCD is used as 
therapeutic gene because this suicide gene converts 5-FC to 5-FU as its active anti-cancer 
metabolite which has been approved by Food and Drug Administration of the United States of 
America (FDA) since 1962 for treating the cancer patients via systemic route of drug 
administration. Furthermore, expression of yCD in adjacent normal liver cells may also 
contribute to a more localize production of 5-FU which may potentially augment the 
treatment efficacy of orthotopic HCC tumors and reduce the side effects of 5-FU. 
 
7.6.3 Systemic delivery of AH-6CC-L2C 
Last but not least, preliminary studies were performed in an attempt to deliver AH-6CC-L2C 
systemically. Unfortunately, the results suggested that there are some unknown barriers that 
impeded the vectors from reaching the tumor regions when the vectors were administered via 
systemic routes. As indicated by in vivo luciferase imaging and ex vivo eGFP imaging, 
systemic delivery of liver-specific and proliferation-dependent AH-6CC-L2C (Figrue 7.3a) 
and a liver-specific AH-L2C (Figrue 7.3b) via intrasplenic route of vector injection failed to 
deliver these HSV-1 amplicon viral vectors into the orthotopic HCC 26-1004 tumors. In fact, 
such systemic delivery problems were also encountered in adenovirus vectors (Barry et al., 
2009) and oncolytic HSV-1 vectors (Smith et al., 2011). Nonetheless, the factors that might 
prevent the entry of HSV-1 amplicon viral vectors following systemic administration in this 
study are not clear. It is possible that viruses are impeded by blood-tumor barrier (Bilbao et 
al., 2000); high interstitial tumor fluid pressure (Yun, 2008) and fibrotic areas (Fattovich et 
al., 2004) which could prevent effective viral delivery, spreading and infection. Some 
preliminary data also suggested the extent of vascular and architectural network of the tumors 
that may affect viral uptake. For example, when HGCX-L2C was systemically administered 
into mice bearing orthotopic PLC/PRF/5-DsRed2 tumors (Figure 4.16b), some virus uptake 
by the tumor was noted although most remained in the normal murine liver as quantified by 
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the viral gene copy number analysis (Figure 4.16c). This difference suggests that systemic 
uptake of HSV-1 amplicon viral vectors is dependent on the architectural network of 
orthotopic HCC formation although additional experiments will be required to further identify 







Figrue 7.3 Systemic deliveries of HSV-1 amplicon viral vectors to orthotopic HCC tumors. 
In vivo luciferase and eGFP imaging on liver and HCC 26-1004 tumor after 24 h post 
intrasplenic injection with 3 × 106 TU of (a) Liver-specific and proliferation-dependent AH-
6CC-L2C vector and (b) liver-specific AH-L2C vector. All left panel showed luciferase 
imaging where mouse skin was removed to increase the sensitivity of the imaging. Red 
dashed line circled the tumor region while yellow dashed line circled the liver region. All 
right panel showed the bright field images of liver with HCC 26-1004 orthotopic tumor and 
ex vivo fluorescence stereomicroscope imaging for eGFP positive vectors infected cells. Red 
dashed line separated the normal liver and tumor region. L indicated liver region; T indicated 























In this thesis, it was demonstrated that the vector could specifically limit the therapeutic gene 
expression in HCC tumors while sparing the normal cells, efficiently infect the primary HCC 
and effectively suppress the growth of both subcutaneous and orthotopic primary human HCC 
tumor xenografts in vivo. More importantly, the vector is also non-toxic to the liver which 
indicates that it may potentially be of clinical relevance to gene therapy. Despite these 
encouraging findings, the current liver-specific and proliferation-dependent vector still suffers 
from transient transgene expression and systemic delivery issues that may need further 
improvement before complete eradication of tumor could be achieved. Thus, new avenues 
relating to (1) improve the stability of therapeutic gene expression, (2) increase the efficiency 
of in vivo systemic delivery of vector into HCC tumor and (3) enhance the therapeutic 
efficacy remained to be explored.  
 
8.1 Improving the stability and expression of therapeutic gene 
The main problem that has yet to be resolved for the use of HSV-1 amplicon viral vector for 
gene therapy purposes is the transient in vivo therapeutic gene expression. This is due to the 
inherited properties of HSV-1 amplicon viral vector that have been described in Chapter 
1.2.6. In order to improve the stability of therapeutic gene expression in vivo, HSV-1/EBV 
hybrid vector, HCAG-L2EOP was explored and had proven to be effective in prolonging the 
stability of reporter gene expression in patient-derived HCC tumors and mice brain (see 
Chapter 6). The potential of HCAG-L2EOP will be examined in more patient-derived HCC 
tumor xenografts with orthotopic implantation to further evaluate its value and potential in 
conferring stable expression of therapeutic gene for enhanced treatment of primary HCC. 
Nevertheless, in this study, the hybrid HSV-1/EBV viral vector, HCAG-L2EOP had shown a 
stable and enhanced reporter gene expression in primary HCC 26-1004 tumors when 
compared to conventional HSV-1 amplicon viral vectors. Recently, Suzuki and colleagues 
have also tried to prevent the initial host response-induced silencing of transgene expression 
in HSV-1 amplicon viral vector by restoring the expression of an important HSV-1 immediate 
early gene, ICP0 (Suzuki et al., 2009). Interestingly, the transient expression of ICP0 (at MOI 
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= 1) could inhibit the decrease of HSV-1 amplicon-mediated transgene expression by 
protecting the delivered amplicon DNA to associate with histone deacetylase (HDAC1) for at 
least 72 h after infection. In addition, ICP0 expression also did not significantly elicit the IFN-
based responses against the viral vector or alter the cell kinetics/apoptosis of infected cells. In 
vivo time course study of transgene expression in C57Bl/6 mice also demonstrated that 
systemic delivery of ICP0+ HSV-1 amplicon viral vector conferred greater and sustained 
transgene expression in mice liver for 6 weeks when compared to 2 weeks with conventional 
HSV-1 amplicon viral vector. Therefore, restoration of ICP0 expression could potentially be 
employed within HSV-1 amplicon constructs for increasing the transcription level of the 
transgene that lead to sustained in vivo transgene expression. Therefore, if the AH-6CC-L2C 
could be further engineered in a similar manner to HSV-1/EBV hybrid vector and restored the 
expression of HSV-1 ICP0, the in vivo expression of yCD suicide gene could probably be 
prolonged at an elevated level leading to improved in vivo efficacy of AH-6CC-L2C. 
 
Other potential systems that could also be employed to improve the stability of current vector 
include:- 
 
(1) inserting the adeno-associated virus (AAV) inverted terminal repeats (ITRs), flanking a 
transgene of choice, with and without Rep coding sequences outside the ITR cassette into 
HSV-1 amplicon viral vector to generate HSV/AAV (Glauser et al., 2006);  
(2) inserting the Moloney-murine leukemia virus (Mo-MLV) long terminal repeats (LTRs), 
flanking a transgene cassette, and gag, pol and env genes in a separate cassette and elements 
from EBV (oriP and EBNA-1) into HSV-1 amplicon viral vector to generate HSV/EBV/RV 
(Hampl et al., 2003);  
(3) inserting the Sleeping Beauty (SB) transposable elements including inverted/direct repeat 
(IR/DR)-flanked transgene unit and SB transposase gene separately into 2 independent HSV-
1 amplicon viral vector to generate HSV/SB (Peterson et al., 2007);  
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(4) inserting human scaffold/matrix attachment region (S/MAR) with episomal retention 
properties that are able to deliver, maintain and express a genomic DNA transgene at 
physiological levels into HSV-1 amplicon viral vector to generate HSV-BAC-S/MAR (Lufino 
et al., 2007); and  
(5) inserting human artificial chromosomes (HACs) consisting of autonomous molecules of 
17 alphoid DNA (satellite higher-order repeat sequences), that behave as normal 
chromosomes in human cells to segregate during cell division and maintain in the host cell, 
into HSV-1 amplicon viral vector to generate HSV-HAC (Moralli et al., 2006). 
 
8.2 Improving the tumor permeability for HSV-1 amplicon viral vector  
The ultimate goal of viral cancer gene therapy is to target those metastatic tumors and prevent 
their recurrence via systemic route of virus administration. Unfortunately, HSV-1 amplicon 
viral vector also suffered from problems related to systemic delivery whereby the vector is 
unable to be systemically delivered to the tumor (see Figrue 7.3). In fact, systemic delivery of 
viral vectors often encounters overlapping barriers, including: (1) interactions with 
immunological blood components (antibodies); (2) loss to hepatocytes and spleen; (3) passive 
diffusion from leaky vasculature to tumor; (4) small capillaries in tumor that prevent 
penetration; (5) dense network of extracellular matrix (ECM) and cellular compaction that 
prevent interstitial diffusion between solid tumors with little interstitial space; (6) hindered by 
the presence of normal and healthy cells within the tumor; and (7) high tumor interstitial fluid 
pressure (IFP) in tumors that limits the its diffusion out of the blood vessel (Barry et al., 2009; 
Heldin et al., 2004; Smith et al., 2011). The systemic delivery problem presumably caused by 
a blood-tumor barrier was also observed by Bilbao and colleagues in their 
diethylnitrosoamine (DEN)-induced HCC model when adenoviral vector was systemically 
injected in rat (Bilbao et al., 2000). Although, the study was able to overcome the blood-
tumor barrier with a vasoactive compound called nitroglycerin and increase the transduction 
efficiency of adenovirus, the effective dose of nitroglycerin used to permeabilize the tumor 
was about 10 to 20 times more than the dose used to treat the patients with heart disease 
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(Yusuf et al., 1988). To the best of knowledge, there is no drug that could enhance the 
vascular permeability in solid tumor for improved viral vector gene delivery via systemic 
route of vector administration. Therefore, further studies are required to address this gene 
delivery issue to understand the underlying mechanisms so that potential strategies could be 
developed to improve the tumor permeability for systemic delivery of HSV-1 amplicon viral 
vector. In an effort to improve the systemic delivery of oncolytic HSV-1, Yoo and colleagues 
have recently demonstrated that copper chelating agent ATN-224 treatment could increase the 
oncolytic HSV-1 propagation in tumors as well as improve its systemic delivery (Yoo et al., 
2012). ATN-224 improved the stability of oncolytic HSV-1 in serum by rescuing the copper-
mediated inhibition of oncolytic HSV-1 replication, therefore increasing the virus presence in 
tumor tissue after systemic delivery. Moreover, several other groups have also tried to 
improve the virus spread in the tumor by modifying the tumor microenvironment to decrease 
the extracellular matrix (ECM) component with decorin (Choi et al., 2010), hyaluronidase 
(Ganesh et al., 2008), relaxin (Kim et al., 2006) and proteases such as metalloproteinase-9 
(Hong et al., 2010), collagenase/dispase and trypsin (Kuriyama et al., 2000; McKee et al., 
2006). Alternatively, tumor tropism capability of mesenchymal stem cells (MSCs) could be 
exploited to deliver and spread the viral vector into the tumor regions (Fritz and Jorgensen, 
2008).  
 
8.3 Combinational therapy with other therapeutic genes or chemotherapy drugs 
To further improve the therapeutic efficacy of AH-6CC-L2C, the yCD could be coupled with 
therapeutic genes with stronger direct cell killing effect such as TRAIL (Wang et al., 2010), 
iCasp9 (Xie et al., 2001), Pseudomonas exotoxin A (ETA)(Brown et al., 2009) or BikDD (a 
constitutively active mutant form of proapoptotic gene, BIK)(Li et al., 2011). However, it is 
unlikely that a single treatment modality could result in complete abolishment of tumors. 
Rather, the combination therapy, which target different signaling pathways or a concerto anti-
tumor effect from different mechanism, may be considered for future therapeutic design. 
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Chemotherapeutic drugs could be considered for combinational therapy. A possible candidate 
would be the currently most effective drug for advanced HCC treatment, sorafenib 
(previously described in Chapter 1.1.2 and 1.1.3). Sorafenib has been proven to be effective 
in the context of other vector systems where Heo and colleagues have administered oncolytic 
poxvirus followed by sorafenib treatment in three HCC patients (Heo et al., 2011). Although 
it is a small cohort, the combination treatment was shown to be well-tolerated with a 
significant decrease in tumor perfusion and improved clinical responses. Another potential 
chemotherapy drug that has been used for the treatment of HCC is Paclitaxel which acts as a 
mitotic inhibitor that binds to the N-terminal domain of β-tubulin (Marchetti et al., 2002). The 
formation of the microtubule-paclitaxel complex prevents the microtubule disassembly which 
in turn leads to the inhibition of spindle formation in cells undergoing mitosis.  
 
Alternatively, yCD/5FC system could be coupled with other effective modality. In this study, 
approximately 5-20% of viable cells were observed post-treatment in HuH-7 (Figure 4.9) and 
primary HCC 26-1004 cells (Figure 4.11) suggesting a possible resistance population. It may 
be worth noting that 5-FU treatment has recently been reported to increase the level of 
epithelial cellular adhesion molecule (EpCAM) expression (Chiba et al., 2012). EpCAM is a 
type I transmembrane glycoprotein (40 kDa) and is regarded as one of the prognostic markers 
for HCC (Terris et al., 2010). Thus, agent that could efficiently decrease EpCAM expression 
could be coupled with AH-6CC-L2C viral vectors. An example is the adenosylhomocysteine 
hydrolase inhibitor, 3-deazaneplanocin A (DZNep). This inhibitor suppresses the EZH2 
expression (self-renewal regulators in a wide range of normal stem cells and tumor-initiating 
cells) and was demonstrated to efficiently decrease the EpCAMhigh and CD133high fractions in 
HuH-7 cells (Chiba et al., 2012). Another way is to couple AH-6CC-L2C with a modality that 
targets the underlying mechanism for 5-FU resistance. The 5-FU resistance in tumor cells is 
found to be attributed by (i) overexpression of thymidylate synthase which tightly binds to 5-
FdUMP (Peters et al., 2002; Uchibori et al., 2012); (ii) mutation or aberrant expression of 
uridine monophosphate synthetase (UMPS), which primarily involves in the conversion of 5-
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FU to 5-FdUMP (Griffith et al., 2012); and (iii) endogenously expressed miRNAs such as 
miR-10b (Nishida et al., 2012), miR-19b (Kurokawa et al., 2012) and miR-193a-3p (Ma et al., 
2012). 
 
8.4 Limitation in production of HSV-1 amplicon viral vector 
Last but not least, helper virus-free HSV-1 amplicon viral vector that was chosen in this study 
are replication-defective and are limited by the current technology of manufacture and 
production. Although it is possible to increase the virus titer by using the helper virus 
dependent packaging system, the contamination from HSV-1 helper virus particles in the 
vector stock may result in significant cytotoxicity (Olschowka et al., 2003). Hence, currently 
there is no method available to produce very large amounts of helper virus-free HSV-1 
amplicon particles. Recently, miRNA (miR-92944) has been shown to be involved in efficient 
replication and spread of HSV-1 in tissue culture (Munson and Burch, 2012). In parallel, Li 
and colleagues have identified and demonstrated that the nuclear localization and import of 
VP19C (a novel non-classical nuclear localization signal of HSV-1) is required for efficient 
production of HSV-1 in tissue culture (Li et al., 2012b). These findings may be important for 
future work to improve the production of HSV-1 amplicon viral vectors. 
 
8.5 Conclusion 
In summary, a promising HSV-1 amplicon viral vector has been generated in this study. The 
vector has potential uses in clinical treatment of HCC patients for effective eradication of 
primary HCC tumors as well as preventing the recurrence of HCC after surgical resection or 
ablation procedures. Furthermore, non-invasive bioluminescence imaging has been employed 
to advance our knowledge on viral kinetics, transgene stability and distribution. I am hopeful 
that findings from this thesis could potentially be useful for developing improved versions of 
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Table A.1 The uses of two-step transcriptional activation (TSTA) system in various studies. 
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eGFP 5 to 9-fold (Shaw et al., 2009) 
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Table A.2 List of purposes of various HSV-1 amplicon viral vectors constructs. 
 HSV-1 amplicon viral vector  Purpose of construct Summary notes 
(a) pHGCX Parental vector  (without transgene) 
Used for construction of various 
HSV-1 amplicon viral vectors 
(b) pHGCX-Luc Positive control expressing luciferase by CMV promoter 
Express high level of luciferase gene 
in various cell lines 
(c) pHGX-Luc 
Negative control with 
luciferase gene but CMV 
promoter is deleted 
Good negative control for comparing 
various promoters 
(d) pApoE/hAAT-Luc 
Vector to evaluate the 
4×ApoE/hAAT promoter with 
luciferase reporter gene 
4×ApoE/hAAT promoter confers 
high liver specific gene expression 
when compared to AFP/AFP and 
SV40/Alb promoters 
(e) pAFP/AFP-Luc 
Vector to evaluate the 
AFP/AFP promoter with 
luciferase reporter gene 
AFP/AFP promoter is a good HCC-
specific promoter but its expression is 
very weak. 
(f) pSV40/Alb-Luc 
Vector to evaluate the 
SV40/Alb promoter with 
luciferase reporter gene 
SV40/Alb promoter is poor in liver 
specificity and the expression is 
weaker than 4×ApoE/hAAT 
(g) pIH8GalLuc Negative control for cell cycle-dependent gene expression 
Good negative control for evaluating 
the leakiness of minimal cyclin A2 
promoter 
(h) pApoE/hAAT-CC-Luc 
Vector to evaluate the liver 
specific and cell cycle 
dependent gene expression 
with luciferase reporter gene 
This vector is capable to express 
transgene in liver-specific and cell 
cycle-dependent manners. Tested in 
liver regeneration model. 
(i) pHGCX-L2C 
Vector to evaluate therapeutic 
cassette that co-expresses yCD 
suicide gene and luciferase 
reporter gene 
Expression of yCD could be 
indirectly monitored by luciferase 
imaging. HCC tumors regressions 
were observed with this vector. 
(j) pAH-6CC-L2C 
Similar with (h) but containing 
6CC promoter for improved 
cell cycle regulation in 
expressing L2C therapeutic 
cassette from (i) 
Liver-specific and cell cycle-
dependent vector expressing suicide 
gene in only HCC tumors. HCC 
tumors suppressions were observed 
with this vector. 
(k) pAH-CC-L2C 
Similar with (h) but containing 
L2C therapeutic cassette from 
(i) 
Older version of pAH-6CC-L2C with 
minimal cyclin A2 promoter 
(l) pAH-L2C 
Control vector expressing L2C 
therapeutic cassette from (i) 
with 4×ApoE/hAAT promoter 
This vector could express the 
transgene in both normal liver cells 
and HCC tumors in vivo 
(m) pHCAG-Luc 
Negative control vector for 
HSV/EBV hybrid vector with 
luciferase reporter gene 
regulated by CAG promoter 
Use as negative control to showed the 
stability of CAG promoter in the 
context of HSV-1 amplicon viral 
vector 
(n) pHCAG-L2EOP 
HSV/EBV hybrid vector co-
expresses luciferase and 
EBNA-1 regulated by CAG 
promoter and contains oriP 
sequences of EBV 
Hybrid vector that not only prolongs 
the stability but also increases the 
expression level of transgene in HCC 
tumors in vivo 
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Table A.3 Comparison of α-1-antitrypsin (hAAT) promoter with other liver-specific 
promoters in mouse liver. 
 
Other liver specific 
promoter 
Compared to 









maintain 80% of 
week 1 expression 
level at 40 weeks 
compared to 48% in 
alb promoter 





1.1 to 1.7-fold higher 
in hAAT promoter 
compared to ADH6 
promoter 
nil (Gehrke et al., 2003) 
Apolipoprotein A-I 
(apo A-I) promoter 
3.7-fold higher in 
hAAT promoter 
compared to apo A-I 
promoter (both with 
4×ApoE enhancer) 
Stable up to 35 days 
for both promoters  
(~3-fold higher in 
hAAT promoter 
compared to apo A-I 
promoter at day 35) 
(Van Linthout et al., 
2002a) 
Apolipoprotein C-II 
(apo C-II) promoter 
2.3-fold higher in 
hAAT promoter 
compared to apo C-




stable up to 35 days 
for both promoters  
(~3-fold higher in 
hAAT promoter 
compared to apo C-
II promoter at day 
35) 





About 10-fold higher 
in hAAT promoter 
compared to hpx 
promoter 
hAAT promoter 
stable up to 50 days 
compared to 2 weeks 
in hpx promoter 




Table A.4 Effect of ApoE enhancer in various promoters. 
 
Fold increase in gene expression with ApoE 
enhancer(s)  Promoter 






SV40 promoter in 
mouse liver) 





in mouse liver) 
nil 
9.8-fold 
(average from 0 
until 35 days) 
35-fold 
(average from 0 
until 35 days) 
(Van Linthout 
et al., 2002a) 
nil nil 
10-fold (day 6) 
6.8-fold (day 10) 
6.1-fold (day 14) 
5.4-fold (day 21) 
6.0-fold (day 35) 

















in mouse liver) 
nil 
15-fold 
(average from 0 
until 35 days) 
30-fold 
(average from 0 
until 35 days) 
(Van Linthout 
et al., 2002a) 
Apolipoprotein 




in mouse liver) 
nil 
5-fold 
(average from 0 
until 35 days) 
8.2-fold 
(average from 0 
until 35 days) 
(Van Linthout 




in mouse liver) 
No significant 
increase (day 3) 
1.4-fold (day 6) 
2.2-fold (day 
10) 
3.1-fold (day 3) 
1.6-fold (day 6) 
2.4-fold (day 
10) 
8.9-fold (day 3) 
2.7-fold (day 6) 
2.9-fold (day 10) 
1.7-fold (day 14) 
(De Geest et 
al., 2000) 
 
 
 
